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Motive
John was bom in 1949. He has Down’s syndrome. At the age o f 14 he was admitted to an 
institution for mentally handicapped. He lived there with 12 other boys. Initially he attended 
a school for mentally handicapped children. At an older age he started to work in a sheltered 
workshop. He enjoyed his job and got along very well with his colleagues. At the age o f 30, 
in 1980, a survey on hepatitis B was initiated at his institution because occasional cases of 
hepatitis B had been observed. It appeared that John was a carrier o f the hepatitis B virus. 
Everybody was astounded because John had never been diagnosed with hepatitis B before. 
The study revealed that 10% o f all inhabitants were carrier o f the hepatitis B virus and 
another 50% had had an infection with hepatitis B at some point earlier in their lives. 
Twenty percent o f all persons with Down’s syndrome appeared to be carriers o f the 
hepatitis B virus.
John’s family was told that he was a carrier o f the hepatitis B virus. They were informed 
about the illness, the dangers for transmission and how to prevent infections. John’s blood 
was considered especially infectious. It was strongly advised to avoid any contact with 
John’s blood, to take very good care o f his minor wounds and to make sure that he used his 
own toothbrush and shaving gear. A few years previous John’s mother had died from an 
acute hepatitis B infection. No one had ever suspected that she could have been infected by 
John. Now the family revealed, however, that his mother frequently sucked Johns wounds. 
John was doing very well for a few years. He was a real bon-vivant. He had many friends at 
work and in the institution. He was also an active member o f the drum band. He hardly had 
any symptoms from the hepatitis B carriership. His blood was tested annually. His liver 
functions were usually within the normal or semi-normal range. However, in 1991 a blood 
test revealed that his liver was clearly functioning less well than usual. Shortly after this, his 
vital conditions began to deteriorate. He became tired, his appetite was poor and he 
developed an oedema resulting in a potbelly. He had to stop working. It appeared that John 
was suffering from a liver cirrhosis, which means that his liver was scarred and shrivelled as 
a result from the chronic hepatitis B. This cirrhosis is not curable. In the following months 
he developed more and more complaints and complications. Finally, John lapsed into a 
coma and haemorrhages occurred in his abdomen and intestines. He died peacefully in the 
spring of 1992 at the age of 43.

Chapter 1
General introduction

Background
Hepatitis is an inflammation o f the liver. Hepatitis may be caused by viruses, chemicals, 
drugs or alcohol. Six different hepatotrophic viruses have been identified until today: the 
hepatitis A virus (HAV), the hepatitis B virus (HBV), the hepatitis C virus (HCV), the 
hepatitis D virus (HDV), the hepatitis E virus (HEV) and the hepatitis G virus (HGV). All 
these viruses, except HGV, may cause a viral hepatitis infection, o f which the clinical 
symptoms, if  present, are rather similar: fatigue, anorexia, gastrointestinal complaints, 
jaundice and liver enlargement. Hepatitis B, C and D may evolve into chronic hepatitis, 
cirrhosis o f the liver and hepatocellular carcinoma.
About 300 million people world-wide are carriers o f the hepatitis B virus and about 1 
million people die annually due to sequelae o f hepatitis B. A lot o f research has been 
performed to elucidate the molecular biology o f the hepatitis B virus and the pathogenesis 
o f hepatitis B. The knowledge derived from these studies has led to successful development 
o f a vaccine and to treatment sometimes capable o f eradicating chronic infection.
Historical notes
Viral hepatitis, in the past also known as epidemic jaundice, has been recognised since 
ancient times {Van Ditzhuijsen,1988; Wismans,1989}. About 2500 years ago, Hippocrates 
described epidemic jaundice as an acute onset o f illness with fever, chills, headache and 
yellow urine. This might have been the first description o f hepatitis A. Outbreaks of 
jaundice were also mentioned in the Babylonian Talmud as early as the fifth century B.C. 
{Cockaine,1912}. In the eight century Pope Zacharias suggested that some forms of 
jaundice were infectious and advised to separate patients with jaundice in order to prevent 
spreading o f the disease. During the subsequent centuries, the idea o f an infectious nature of 
jaundice gained gradual acceptance. Originally, epidemic jaundice was thought to be 
transmitted either orally or by the airborne route. This concept changed by the observation 
o f the first classical parental transmission o f hepatitis in Bremen in 1883, when large scale 
vaccination o f shipyard workers with a smallpox vaccine, containing human lymph, resulted 
in an epidemic ofjaundice {Lurman,1885}. In 1939 the pathology o f epidemicjaundice was 
described by Findlay, who suggested viral infection as the cause o f the disease 
{Findlay,1939}. As a result o f transmission experiments in human volunteers in the 1940’s 
two types o f hepatitis with distinctively different incubation periods were recognised: an 
infectious type, since the seventies called hepatitis A, that was thought to be transmitted by 
faecal-oral route, and a serum-transmitted type, later called hepatitis B, that was thought to 
be transmitted by inoculation o f blood or blood products only and may progress to a carrier 
state {MacGallum,1972}.
The discovery o f the Australia antigen by later Nobel Prize winner Blumberg proved to be 
of historical significance for the knowledge about hepatitis B {Blumberg,1977}. In 1964
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Blumberg detected, while studying precipitating antibodies in people who had received 
many transfusions, in the serum o f a haemophiliac patient an antibody that reacted only with 
one out o f 24 sera. This serum originated from an Australian aboriginal and Blumberg 
termed the antigen the “Australia antigen” (AuAg) {Blumberg,1964}. Subsequently he 
showed that this antigen frequently occurred in the serum o f leukaemia patients, who had 
received many transfusions and shortly later in persons with Down’s syndrome, who have a 
high risk o f leukaemia {Blumberg 1966'. During the course o f a study a patient with 
Down’s syndrome who originally did not have the Australia antigen in his serum developed 
the Australia antigenemia. Further clinical and laboratory evaluation o f the patient revealed 
that he had simultaneously anicteric hepatitis which led to the association o f Australia 
antigen with hepatitis {Blumberg,1967}.The development of acute clinical hepatitis in a 
laboratory technician who was working with the isolation o f Australia antigen provided the 
essential link to the clinical illness {Blumberg,1967}. Prince confirmed these findings with 
the discovery o f the serum hepatitis associated antigen (SHAA) which turned out to be 
identical to the Australia antigen {Prince,1968}. Using the electronmicroscope Bayer 
demonstrated small spherical 22 nM particles and filamentous structures in sera with 
Australia antigen {Bayer,1968} and Dane showed that the Australia antigen was part of the 
“Dane particle”, a double layered 43 nM structure that later turned out to be the complete 
virus {Dane,1970}. Simple tests for the detection o f the Australia antigen or hepatitis 
associated antigen (HAA antigen or Hepatitis B surface antigen (HBsAg)) and the antibody 
to this antigen became available in 1969. Magnius discovered a new antigen and antibody 
system in 1972: the hepatitis B e antigen (HBeAg) and anti-HBe {Magnius,1972}. 
Krugman detected in 1974 the antibody against the hepatitis B core antigen (anti-HBc) 
{Krugman,1979}. The association o f DNA polymerase with human hepatitis B antigen was 
made by Kaplan {Kaplan,1973} and Robinson was the first who described HBV-DNA in 
cores o f the hepatitis B virus {Robinson,1974}. The close relationship between hepatitis B 
virus infection and hepatocellular carcinoma was established in the early seventies 
{Blumberg,1975}.
Hepatitis B vaccines were introduced in the early eighties {Szmuness,1980}. Two general 
types o f hepatitis B vaccine have been used widely. A plasma-derived vaccine prepared 
from plasma o f chronic carriers. The HBsAg in this plasma was inactivated either 
chemically or by heat, both combined with ultra-centrifugation as purification step. The 
availability o f the plasma derived vaccines was limited during the first years, partly because 
o f the risk o f HIV-infected plasma samples. This problem was resolved in 1986 by the 
introduction of the recombinant vaccines. Successful treatment o f chronic HBV carriers was 
first demonstrated in 1990 for the first time using alpha-interferon {Perillo,1990}.
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HBV and the mentally handicapped
Ward was the first to draw attention to the high incidence o f viral hepatitis among persons 
with a mental handicap {Ward,1958}. After Blumberg published his landmark paper 
indicating that persons with Down’s syndrome have a significantly higher prevalence o f the 
Australia antigen than the general population {Blumberg,1966,1967}, many investigators 
performed epidemiological studies in residential institutions for mentally handicapped 
individuals (see chapter 3). Most studies reported a high prevalence o f the Australia 
antigenemia in both American as well as in European institutions. Five to thirty percent o f 
the mentally handicapped residents appeared to be carrier o f the hepatitis B virus. 
Percentages up to 15% were observed in the Netherlands {Dankert,1973, Bruining,1974 '.  
Within the institutions the proportion o f HBV carriers among people with Down’s 
syndrome was always higher than in people without this syndrome. Employees working in 
these institutions had lower incidences o f persistent HBV infection than the residents (see 
chapter 3).
In the late sixties and early seventies institutions for mentally handicapped residents were 
considered to provide ideal conditions to study the epidemiology and biology o f viral 
hepatitis. The population at risk was large and representative for all ages, the incidence of 
reported viral hepatitis was unusually high and statistical associations and follow up studies 
could be pursued within a well defined environment {Szmuness,1970}. Although this 
research has contributed substantially to the knowledge about hepatitis B in general some 
studies can be ethically questioned. Krugman and his colleagues studied the properties of 
the hepatitis B virus in a residential institution for mentally handicapped in the USA. First 
they administered mentally handicapped children sera or stools contaminated with hepatitis 
virus either by oral or by parenteral routes. They could identify two distinct hepatitis agents, 
MS-1, which was associated with a short incubation time (infectious hepatitis or hepatitis A) 
and MS-2 (what was demonstrated to contain AuAg) which was associated with a longer 
incubation time (serum hepatitis or hepatitis B) {Krugman,1970}. In a follow-up study he 
injected mentally handicapped children with MS-2 infected serum. One group o f children 
was injected with non-heated serum. Half o f these children developed a clinical hepatitis B 
infection. The other group, who was injected with heated serum, did not contract the disease 
and did not develop Australia antigenemia. This study proved that heated serum provided 
protection against hepatitis B in humans {Krugman,1973}.
Since the mid-eighties the living conditions o f mentally handicapped persons have changed 
substantially. Mentally handicapped children are staying at home longer. Many large 
institutions have closed their doors or have been reduced in size. The hygienic 
circumstances in the institutions have improved considerably and last but not least the 
residents o f the institutions can be vaccinated since 1982. For all these reasons one could 
speculate that the incidence o f HBV infection in the residential institutions should be 
decreasing in the last decade.
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In the Netherlands the Dutch Health Council advised in 1983 to vaccinate all mentally 
handicapped persons living in residential institutions because o f the reported high 
prevalence o f HBV infection in those institutions {Health Council,1983'. This advise was 
partly neglected due to a combination o f factors: high costs o f the vaccine, misinterpretation 
o f the importance o f this issue and fear o f HIV infection by plasma derived vaccines. The 
advise to vaccinate all mentally handicapped persons living in residential institutions was 
reiterated in 1991 {GHIGV/GGZZ,1991}. Furthermore, it was advised that all residential 
institutions, group-homes and day-care centres should adapt a strict hygienic protocol. The 
employees o f residential institutions should be vaccinated, in case they were taking care of 
HBV carriers. In 1996 the Health Council o f the Netherlands published a new report titled ” 
Protection against hepatitis B”, in which the risk groups for hepatitis B are indicated. 
Results reported in this thesis have contributed to the recommendations in that report 
{Health Council,1996'.
Objectives of the thesis
Since 1970 a large number o f studies have been performed o f the epidemiology o f hepatitis 
B in mentally handicapped individuals, generally in institutionalised settings and 
occasionally in non-institutionalised settings. The observed prevalences o f these studies 
varied to a great extent. Because o f the improved possibilities to prevent and to treat 
hepatitis B it is important to have information about the relationship between hepatitis B 
and mental handicaps. Therefore, it is important to know in what way hepatitis B 
distinguishes between people with a mental handicap and other patients, especially with 
regard to environment, constitution, behaviour and prevention. Furthermore, it is important 
to develop a policy for the prevention o f hepatitis B in people with a mental handicap 
comparable to general measures for preventing hepatitis B. The distinguishing factors in 
mentally handicapped people for the risk o f contracting hepatitis B and the consequent 
policies are the main objectives o f this thesis.
Structure of the thesis
In chapter two a general description o f hepatitis B is presented, including the epidemiology, 
the transmission, the virology, the immunopathogenesis, the clinical, serological, and 
biochemical features, the serological diagnosis, the possibilities for treatment and 
prevention. Chapters three and four focus on the epidemiology o f hepatitis B in mentally 
handicapped individuals. Chapter three gives an historical overview o f the literature from 
1969 until 1999, chapter four presents several Dutch studies concerning the epidemiology 
o f hepatitis B in mentally handicapped individuals in different settings in the Netherlands. 
In chapter five a fifteen year follow up o f a hepatitis B epidemic/endemic in a Dutch
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residential institution for mainly male mentally handicapped persons will be described and 
discussed. It will describe the infection rate in the residents and the staff and the reasons for 
the rise or decline o f this rate as well as the follow up o f the hepatitis B carriers. Chapter 
six continues with a study o f the response to and the effectiveness o f hepatitis B vaccination 
in mentally handicapped individuals. Chapter seven describes the special aspects o f 
hepatitis B in Down’s syndrome.
Based on the conclusions in the general discussion, regarding the special aspects o f hepatitis 
B infection in mentally handicapped individuals, recommendations for a Dutch policy to 
prevent hepatitis B infection in mentally handicapped are presented.
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Chapter 2
Hepatitis B: 
a general description

Introduction
Hepatitis B is an inflammation o f the liver, caused by the hepatitis B virus (HBV). The 
immune attack o f the host against HBV causes the liver injury, mediated by a cellular 
response to the antigens o f HBV {Lee,1997}. Hepatitis B is a leading cause o f chronic 
hepatitis, hepatic cirrhosis and hepatocellular carcinoma. Global statistics show that 2 
billion people have evidence o f past or current HBV infection and about 300 million people 
are chronic carriers o f HBV. Twenty -five percent o f the chronic carriers -about 1 million 
people a year- will die o f primary liver cancer or cirrhosis. The hepatitis B virus causes 60% 
to 80% o f primary liver cancer in the world. Primary liver cancer is one of the three top 
causes o f cancer deaths in males in highly endemic areas {WHO homepage,1998'.
This chapter will give a review o f the epidemiology, transmission, virology, immunology, 
immune modulation, clinical features, serological and biochemical features, treatment and 
prevention of hepatitis B {Tiollais,1987; Van Hattum,1992; Lau,1993; Moradpour,1995; 
Roitt,1995; Health Council,1996; de Meyer,1997; Gitlin,1997; Lee,1997; Lemon,1997, 
Sherlock,1997; LCI,1998; Vroom,1999; Zaaijer,1999}.
Epidemiology
More than 5 percent o f the world population are chronic carriers o f HBV. The geographic 
distribution varies greatly throughout the world. One can distinguish three different kinds of 
areas: low endemic areas (< 1% HBV carriers), intermediate high endemic areas (2 -7 % 
HBV carriers) and high endemic areas (> 8% HBV carriers) (Table 2.1).
Table 2.1 HBV endemic areas and major transmission-routes
Low endemic Intermediate endemic High endemic
HBsAg prevalence < 1% 2-7% >8%
Anti-HBs prevalence 4-6% 20-55% 70-95%
Distribution North-Western Europe 
North America 
Australia/New Zealand
Eastern Europe 
Mediterranean Europe 
Middle East 
Russia 
Japan
Central and South 
America
South-East Asia 
China 
Africa 
Oceania
Main transmission routes sexual
parenteral
sexual
vertical
horizontal
vertical
horizontal
The Netherlands is considered a country with a low prevalence o f HBV infection. No exact 
numbers are available. It is estimated that 0.5% o f its inhabitants are carriers and 4% have 
had an infection in the past. This implies that about 4.5% o f the Dutch people have HBV-
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markers in the blood. Regional differences can be predicted. More “high risk” people such 
as immigrants from high risk countries, drugs addicts and prostitutes, live in the large cities 
in the western part o f the Netherlands. A study o f pregnant women in Amsterdam showed 
that ethnic minorities are more often HBV carriers than caucasian women. The prevalence 
o f the carrier state was comparable to that in the country o f origin and was similar to the 
numbers o f Table 2.1 {Grosheide,1993; Leentvaer,1993'. In the Netherlands the incidence 
o f HBV infection is not exactly known because o f under-reporting {Grosheide,1991}. The 
annual attack rate for HBV infection in Western Europe is estimated between 5 and 50 per 
100.000 {Roure,1995}.
Transmission
HBV can be detected in hepatocytes, in blood and blood products, in semen, vaginal 
secretions and in saliva. The human skin protects against hepatitis B infection. If  this natural 
barrier is interrupted the virus may enter the human body. Transmission o f HBV occurs 
through mucous membranes or skin defects.
HBV is transmitted vertically, parenterally or horizontally by sexual or other intimate 
contacts. Vertical transmission from mother to child usually takes place perinatally, but also 
in utero or postnatally. Parenteral transmission takes place by contact with infected blood, 
blood products or contaminated instruments. Sexual transmission occurs more frequently by 
homosexual than by heterosexual contacts. Virus transmission unrelated to recognised 
vertical, parenteral or sexual exposure is often termed horizontal transmission. Horizontal 
transmission is less efficient than parenteral or sexual transmission and usually leads to an 
anicteric hepatitis. Horizontal transmission occurs during prolonged intimate contacts for 
instance in households, pre-schools, day-care centres or institutions for mentally 
handicapped. Horizontal transmission is mediated via saliva, small wounds or joint use of 
toiletry or other objects {Davis,1989}. In high and moderately high endemic areas infection 
is mainly vertically transmitted from mother to child or horizontally from one child to 
another. In low endemic areas, people are infected sexually by unsafe sexual contact, 
parenterally by needle injuries (drug abuse) and by intimate contact with carriers in a 
community (family, school) {Davis 1989' (Table 2.1). Infection by transfusion with 
infected bloodproducts is nowadays very rare because o f screening all blooddonors.
Virology
The HBV belongs to a family o f closely related DNA viruses called hepadnaviruses: 
hepatotrophic DNA viruses. Other members o f this unique class o f hepadnaviruses are 
ground squirrel hepatitis virus (GSHV), tree squirrel hepatitis virus (TSHV), woodchuck 
hepatitis virus (WHV) and duck hepatitis virus (DHBV). These viruses are not pathogenic 
for humans. All the hepadnaviruses have similar hepatotropism and life cycles in their host
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cells. There is no congeniality between the HBV and the other human hepatotropic viruses 
like the hepatitis viruses A, C, D, E and G, which are RNA viruses.
The HBV consists o f an envelope and a nucleocapsid containing a circular double stranded 
DNA molecule and a DNA polymerase or reversetranscriptase (Figure 2.1). The envelope 
carries the hepatitis B surface antigen (HBsAg) and the capsid consists o f hepatitis B core 
antigen (HBcAg). A third protein that is produced is the hepatitis B e antigen (HBeAg). 
This is a small protein, excreted by infected cells into the bloodstream o f HBV infected 
patients. The HBeAg protein contains a part o f HBcAg. The presence is not essential for 
virus replication. It frequently disappears because o f specific mutations in the genome. It 
has been proposed that HBeAg plays a role in virus persistence but its function is still 
enigmatic (see below).
Figure 2.1 Structures of the Hepatitis B Virus: a) the complete virion (Dane-particle), 
HBsAg sphere, HBsAg tubule {Sherlock, 1997}; b) electronmicroscopy of whole 
virions, HBsAg spheres and HBsAg tubules in blood {Lee, 1997}
HBV follows an unorthodox route o f DNA replication via an RNA intermediate. A full 
length RNA strand, named pregenomic RNA is transcribed in genomic DNA by use o f a 
reverse transcriptase. In a subsequent step the RNA is broken down and a complementary 
DNA strand is synthesised to make the DNA double stranded {Ganem,1996}.The discovery 
o f this unorthodox way o f DNA replication appeared essential for the understanding o f the 
biology of HBV. Reverse transcription is an inaccurate process that allows a high mutation 
rate, similar to that observed in RNA viruses such as the human immunodeficiency virus 
(HIV). The most obvious explanation for this unusual way o f replicating is that the virus 
makes use of the high error rate to adapt the constraints opposed by the host, trying to 
circumvent elimination by the immune system {Carman,1993). In addition, the virus can 
readily gain drug resistance.
In serum of HBV infected patients particles o f a diameter o f 42 nm and 22 nm can be 
detected. The 42 nm particles are the complete HBV virions, also called the Dane particles.
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The presence o f complete infectious virions in the serum is indicative for active virus 
multiplication in the liver. The 22 nm spherical and filamentous particles do not have a core 
and represent the non-infectious envelopes and are always in 1000 fold excess compared to 
the Dane particles (Figure 2.1). The HBsAg, present in the 22 nm particles is highly 
immunogenic. Nevertheless it is thought that the particles play a role in circumventing 
immune attacks o f the virus, possibly by absorbing antibodies.
Immunology
The virus may enter the human body by mucous membranes or skin defects (needlesticks, 
wounds, abrasions). Non-specific immune mechanisms, natural killer cells, macrophages 
and soluble factors as interferons (mainly alpha and beta) try to protect the host against the 
infection. If  these non-specific mechanisms are insufficient, the infection continues and 
specific mechanisms are elicited. Specific lymphocytes, cytotoxic T-cells, helper T-cells 
and B-cells are activated and immunoglobulins are produced.
HBcAg peptide 18-27 
binding to  HLA-A2
Figure 2.2 Immune response in Hepatitis B and the relation between the binding of 
HBcAg and T-cell responses {Lee, 1997}
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The target o f the HBV is the hepatocyte, in which the replication of HBV takes place. 
Although much information about the molecular biology o f HBV has been gained during 
the last decades, little is known about the mechanism o f attachment and penetration o f the 
HBV particle into human hepatocytes. The HBsAg proteins play an important role in the 
recognition o f a specific receptor molecule on the surface o f human hepatocytes. HBV is 
not directly cytopathic, but it is the immune attack o f the host against HBV which causes 
damage o f the hepatocytes.
During the replication o f HBV in the hepatocyte, peptide fragments o f viral antigens, 
HBsAg, HBcAg and the DNA polymerase are presented by human leukocyte antigen (HLA) 
class I molecules on the surface o f the infected hepatocyte. These are recognised by 
cytotoxic T-lymphocytes (CD8+ T-cells), leading to direct killing o f the hepatocyte. This 
allows intracellular virus to enter the circulation. Circulating HBV-particles can be picked 
up by antigen presenting cells, mainly macrophages. The macrophages present viral protein 
fragments by HLA class II molecules on their surface. Helper T-cells (CD4+ T-cells) 
recognise these complexes, which leads to T-cell proliferation and cytokine synthesis and 
provides help for B-cell responses (Figure 2.2). Activated B-cells produce humoral 
antibodies to the different viral antigens: antibodies to hepatitis core antigen (anti-HBc), 
antibodies to hepatitis e antigen (anti-HBe) and antibodies to hepatitis B surface antigen 
(anti-HBs). These antibodies neutralise the released viruses and prevent reinfection. 
Complete recovery of hepatitis B involves a co-ordinated T-cell and antibody response.
The different immune responses in patients depend on several factors. The polymorphic 
nature o f HLA molecules and differences in T-cell responses among persons, lead to a 
highly variable binding affinity for presented HBV peptides. If  the recognition and 
activation are sufficient, the immune response will be complete. All infected cells are 
destroyed, viral replication is aborted and antibodies to HBsAg (anti-HBs) prevent the 
reinfection o f hepatocytes. If  the binding affinity o f the receptors is low and the immune 
response is inadequate, the infection continues. Relevant viral factors may also determine 
the course o f HBV infection. Viruses with mutations in the genome, may not be eliminated 
completely by the hosts immune system. This enables them to persist and to replicate at low 
levels.
Modulation of the immune system
The non-specific immune response or innate immune defence against HBV is mediated by 
several mechanisms. The induction o f interferon has a central position among this. It has 
been shown, however, that HBV can suppress selectively cellular responses to both 
interferon-alpha and interferon-gamma, thereby favouring its own growth {Foster,1991}. 
The suppressed response to interferon results, for example, in impaired up-regulation of 
class I HLA molecules on the hepatocytes, a process that is required for immune
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recognition by CD8+ cytotoxic T-cells. Impaired killing o f infected hepatocytes may 
promote persistent infection.
It has furthermore been shown that the production o f HBV antibodies is selectively 
suppressed in HBV carriers {Yamachi,1988} In search for an explanation it was found that 
HBV not only replicates in hepatocytes, but also in cells o f the immune system, such as B- 
lymphocytes. It was shown that HBV-specific B-lymhocytes are selectively infected with 
HBV. Their selective killing by cytotoxic T-cells results in an impaired antibody response 
against the virus (Baranaba,1990}. A similar mechanism explored in mice resulted in 
persistent infection (Planz,1996}.
As described above HBV infection results in a massive production o f HBsAg and HBeAg. 
HBeAg peptide partly cross-reacts with HBcAg sharing dominant T- cell epitopes. It has 
been speculated that these products impair immune defenses against the virus, particularly 
by absorbing ant-HBs, thus impeding with virus neutralisation, and by inducing tolerance 
towards these antigens (Zinkernagel,1997}.
Finally the high mutation rate o f the virus promotes selection for mutants that escape either 
from neutralisation by antibody or recognition by cytotoxic T-cells. Epitopes have been 
found that can still interact with the cytotoxic T-cell, but in some way induce non­
responsiveness in stead of T-cell activation {Bertoletti,1994).
Recapitulating, the virus has gained several tricks to circumvent immune surveillance in 
favour o f persistent infection. However, these capabilities are rather weak and success 
appears to depend equally on factors o f the virus and on factors o f the host, such as HLA, 
immune competence and additional factors that are still unknown. Good examples o f host 
conditions that favour HBV carriership are perinatal infection and Down’s syndrome. As 
discussed in chapter 7, immunological impairments in Down’s syndrome are rather subtle 
and establishment of carriership in Down’s syndrome is still not fully understood.
Clinical features
The incubation period for HBV ranges from 1 to 6 months. An acute infection with hepatitis 
B may result in very different clinical conditions, varying from an entirely asymptomatic 
illness to an icteric hepatitis (Figure 2.3)
An acute hepatitis may start with a prodromal phase with symptoms like weakness, loss o f 
appetite, nausea, vomiting, abdominal pain, fever and arthralgia. With increasing injury of 
the liver, this period may be followed by an icteric phase due to increased cholestasis. 
Symptoms like clay-colored stool, darkening o f the urine and jaundice will occur. The 
majority o f the adults with acute hepatitis make a full and total recovery after 2 to 4 weeks. 
Fulminant hepatitis that is caused by a hyper immunological response, has a mortality rate 
o f 80%, is a very rare complication o f acute hepatitis B. Risk factors for fulminant hepatitis 
are adult age, female gender, pregnancy and concomitant infections.
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The severity o f the liver cell injury reflects the intensity o f the immune response. The most 
intensive immune response, acute icteric hepatitis, is associated with the greatest likelihood 
o f viral clearance. When the immune response is immature, deficient or otherwise 
insufficient, the patient may have an acute infection without jaundice or even without any 
symptoms with a high chance for developing chronic hepatitis. This is the reason why 
ninety-five percent o f the infected neonates have an asymptomatic acute infection followed 
by persistent infection and HBV carriership. The chance o f developing a persistent infection 
decreases at becoming older. Only 5 to 10 % o f adults, especially men, develop a chronic 
infection. Other risk factors for developing chronic infection are Down’s syndrome and 
defects in the immune mechanisms. About 25% o f persistent infection may deteriorate and 
progress to severe cirrhosis or hepatocellular carcinoma. The remaining 75% patients with 
persistent HBV infection have no complaints and no symptoms. Ultimately they recover 
completely from their HBV infection.
Figure 2.3 Features after exposure to hepatitis B virus
Serological and biochemical features
The serological determinants o f hepatitis B infection are based on the presence o f HBV- 
markers in the blood (Table 2.2). The spectrum o f HBV-markers describes the status o f the 
HBV infection: acute, chronic or recovered. If  the patient remains HBsAg positive for over 
six months, the patient has become a HBV carrier.
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Table 2.2 Diagnostic determinants of HBV infection {Vroom, 1999}
Virus proteins HBsAg marker of infection
HbeAg marker of high infectivety
Virus antibodies anti-HBc marker of current or past infection
Ig-M anti-HBc marker of acute or chronic infection
anti-HBe marker of low infectivety
anti-HBs marker of immunity
Virus DNA HBV-DNA marker ofhigh infectivety
It is useful to look at the development o f HBV infections in different stages. All infected 
patients pass one o f these stages (Table 2.3). The first stage is characterised by immune 
tolerance. HBsAg, HBeAg and HBV-DNA are present. HBcAg cannot be determined and 
anti-HBc is not yet detectable. HBeAg and HBV-DNA indicate that the virus is replicating 
actively in the hepatocytes and the patient is very contagious. Active replication continues 
despite little or no elevation o f aminotransferases or symptoms o f illness. In healthy adults 
this period lasts for about 2 to 4 weeks. In others, like neonates or immune deficient 
patients, this period often lasts for decades.
Table 2.3 The four stages of hepatitis B infection {Lee, 1997}
HBV-markers Replicative phase Integrative phase
stage 1 stage 2 stage 3 stage 4
HBsAg positive positive positive negative
Anti-HBs negative negative negative positive
HBV-DNA strongly positive positive negative negative
Anti-HBc negative/positive positive positive positive
HBeAg positive positive negative negative
Anti-HBe negative negative positive positive
Aminotransferase normal elevated normal normal
In the second stage, the specific immune response starts and many hepatocytes are 
destroyed by the inflammatory process. Secretion o f HBeAg still occurs, but HBV-DNA 
levels drop gradually because o f a decline in the number o f infected cells. Anti-HBc is 
produced in this stage and remains so for he rest o f the patient’s life. The levels o f 
aminotransferases increase, due to destruction o f infected hepatocytes. In patients with a 
solid immune response, this is the period o f symptomatic illness, which lasts for three to 
four weeks. In patients with chronic disease this period may last for 10 years or more and 
may lead to cirrhosis or to carcinoma.
When the host is able to mount a sufficient immune response active viral replication ends 
and the third stage begins. In this stage HBV-DNA can only be detected by polymerase 
chain reaction (PCR), HBeAg is no longer present and anti-HBe becomes detectable. This
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seroconversion is clinically important, because it decreases the chance of developing 
hepatocellular carcinoma and liver cirrhosis and it increases the chance o f full recovery. 
The aminotransferase levels become normal. In acute hepatitis this stage ends within 6 
months after onset o f the infection. In chronic hepatitis, especially in asymptomatic chronic 
carriers this stage may persist for several years, presumably due to the integration o f the 
viral gene into the hepatocyte genome o f the host.
Most patients sooner or later become negative for HBsAg and positive for antibody to HBs, 
marking the fourth stage, the immune stage. HBV-DNA can no longer be detected by any 
means. The patient is unlikely to be reinfected or to have a reactivation o f the HBV 
infection. However, it occurs frequently that patients, who have become negative for 
HBsAg and positive for anti-HBs, may have persistent low levels o f viral DNA in their 
blood indicating that the virus is not cleared completely {Reherman,1996}.In these cases 
hepatitis B infection can reactivate at any time. The longitudinal follow up o f the HBV- 
markers in acute and chronic hepatitis B is shown in the Figure 2.4.A and 2.4.B
symptoms
r  total anti-HE-core
t
l 2 3 4 5 6 7
infection months years
Figure 2.4.A The longitudinal follow up of the HBV markers in acute Hepatitis B {Zaaijer, 
1999}
anti-HE-core
i 2 3 4 5 6 7
I infection months y e a r s -------m-
Figure 2.4.B The longitudinal follow up of the HBV markers in chronic Hepatitis B {Zaaijer, 
1999}
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Anti-HBc is a very useful HBV-marker in distinguishing acute hepatitis from a chronic 
hepatitis, a totally recovered patient and a vaccinated person. It is therefore very often used 
for screening. In the beginning o f an HBV-infection, the anti-HBc will be an 
immunoglobulin o f the M-type. Later on it will be converted into an immunoglobulin o f the 
G-type. A person completely recovered from an HBV infection secretes anti-HBc (IgG) and 
anti-HBs. Anti-HBc (IgG) in absence o f HBsAg or anti-HBs may have several meanings: a) 
the patient is convalescing, HBsAg is not detectable anymore and anti-HBs is not detectable 
yet; this stage is also called “the window stage”; b) the result o f the test is false positive; c) 
the patient has not fully recovered o f acute hepatitis or has developed chronic hepatitis, the 
patient is still infectious while HBsAg is not detectable anymore; d) a lack o f anti-HBs 
response after previous hepatitis B infection; e) the patient has recovered such a long time 
ago that anti-HBs is not detectable anymore {Vrijmoeth, 1997'. When a person is 
vaccinated the serum level o f anti-HBs may be elevated in absence o f anti-HBc.
Treatment
Acute hepatitis B does not require specific treatment because more than 90% o f adults will 
clear their infection spontaneously. Symptomatic treatment o f the nausea, anorexia and 
vomiting may relieve the symptoms. In some cases o f a fulminant hepatitis a liver transplant 
is the only effective treatment.
For chronic HBV infection interferon-alfa was the only approved treatment until recently. 
Interferons have immunostimulatory and antiviral effects. Interferon-alpha induces the 
display o f HLA class I molecules on hepatocythe membranes thus promoting lysis by CD8+ 
cytotoxic T-lymphocythes. Furthermore interferon-alpha inhibit directly viral protein 
synthesis. The goal o f interferon therapy is eradication o f the virus with the clearance of 
hepatocythes replicating virus and leading to a remission o f the liver disease. Interferon 
therapy is successful only in patients with active immune responses (positive for HBsAg, 
HBeAg and HBV-DNA). Interferon therapy causes many side effects, such as fever, chills, 
headache, fatigue etc. Treatment is successful in 40% o f the patients. Interferon therapy is 
least effective in chronic HBV infection derived from infections at birth or in early 
childhood, presumably due to immune tolerance.
New antiviral medicines, as lamividine, that has been approved for HIV therapy, are being 
tested in large clinical trials at this moment. Lamividine, an oral nucleoside antagonist, is a 
specific transcriptase inhibitor and inhibits viral DNA replication. Twenty percent 
seroconversion rates to anti-HBe within one year has been reported recently in HBeAg 
positive patients, what is similar to interferon therapy. However lamividine was better 
tolerated than interferon because o f a lower incidence o f adverse events {Lai,1998; 
Dusheiko,1999'.
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Prevention
In view o f the serious public and individual health implications caused by HBV infection 
much effort has put in prevention o f hepatitis B. Prevention o f hepatitis B has several 
purposes: to prevent the morbidity and occasional mortality associated with acute HBV 
infection, to reduce the occurrence of chronic liver disease and hepatocellular carcinoma 
and to decrease the spread o f hepatitis B by reducing the number o f HBV carriers.
General safeguards are very important for the prevention o f hepatitis B. These include 
continuing precautions when dealing with blood, body secretions or blood products and the 
practice o f safe sex. After an accident with a chance of HBV transmission it is possible to 
prevent infection by injecting specific antibodies (hepatitis B immunoglobuline, HBIG) 
within 48 hours, followed by vaccination.
Hepatitis B vaccines are among the safest vaccines available. Mild injection-site reactions 
occur in up to 22 percent o f immunised persons, but fever and other systemic symptoms are 
uncommon. There is no harm for immunising pregnant women. The recommended series of 
three intramuscular doses o f hepatitis B vaccine induces a protective antibody level (i.e. 
anti-HBs concentrations ( >10 IU/l) in over 90% o f healthy adults and in over 95% of 
infants and adolescents {Szmuness,1980; Szmuness,1981; Zajac,1986; Andre,1989}. The 
anti-HBs response is reduced in persons over 40 years or otherwise immunocomprised 
{Wood,1993; Clements,1994}. Approximately 50% o f the people who do not develop 
antibodies after a three dose series will do so after one to three additional doses 
{Hadler,1986}. The antibody level decreases slowly and in a predictable way over the years 
{Jilg,1984}.
Well designed clinical trials have demonstrated the efficacy o f both plasma-derived and 
recombinant vaccines. Immunisation reduced the incidence o f hepatitis B up to 90-95 % in 
cohorts o f homosexual men {Coutinho,1983; Hadler,1986}, in health care workers 
frequently exposed to blood {Szmuness,1982), in children born to HBsAg positive mothers 
{Grosheide,1993} and in those who are living in areas with a high prevalence o f HBV 
infection {Wainwright,1989; Whittle,1995}. Immunisation also reduces the incidence of 
hepatocellular carcinoma in children {Chang,1997}.
Symptomatic hepatitis is very rare in immunised persons who have had an antibody 
response o f 10 IU/litre or higher. Some may have developed antibodies to hepatitis B core 
antigen (anti-HBc) that are indicative of HBV infection, but there is usually no evidence of 
disease {Szmuness,1981; Hadler,1986}. Follow up studies o f immunised infants indicate 
continued protection against the disease for years {Coursaget,1986; Stevens, 1992}. The 
long term protection, provided by immunisation, permits previously immunised persons, 
who have developed an antibody response >10 IU/L after prime vaccination, to mount 
protective memory antibody responses after exposure to a booster {Wismans,1989; West 
1994}. The long term effectiveness o f hepatitis B vaccine, even in those who have lost 
detectable anti-HBs, obviates routine monitoring o f antibodies and the administration of late 
booster doses.
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Since 1983 the World Health Organisation has endorsed the inclusion o f hepatitis B vaccine 
in routine childhood immunisation programs, world-wide.
In the Netherlands, the Health Council recommended in 1983 to immunise all persons at 
risk {Health Council,1983'. In 1996 a committee, assigned by the Health Council, 
evaluated the implementation o f the Health Council’s 1983 advice. The committee’s 
conclusion was that immunisation o f some risk groups had failed because o f insufficient 
funding and lack o f well-defined responsibility for the enforcement. A well-implemented 
immunisation policy directed at the established high risk groups and some groups with 
evidently increased risk, could limit considerably the incidence o f hepatitis B in the 
Netherlands. The committee considered that the Netherlands should take steps to launch a 
general program of immunisation for hepatitis B {Health Council,1996'.
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Chapter 3
Epidemiology of hepatitis B 
in the mentally handicapped: 
an overview of the 
literature

Introduction
In 1966 Blumberg showed that persons with Down’s syndrome had a significantly higher 
prevalence o f Australia antigen compared to the general population {Blumberg,1966}. 
Blumberg {Blumberg,1967} and Sutnick {Sutnick,1968} also reported a high frequency of 
Australia antigen in persons with Down’s syndrome in large institutions and a much lower 
frequency o f the Australia antigen in persons without this syndrome in the same institutions. 
Furthermore, Sutnick noticed a low frequency o f the Australia antigen in people with 
Down’s syndrome in small institutions. He did not observe any cases with Australia antigen 
in new-born and non-institutionalised people with Down’s syndrome. Therefore, he 
suggested two important factors in operation: an environmental factor, probably an 
infectious agent present in (large) institutions, and a host factor which renders persons with 
Down’s syndrome more susceptible to the same infectious agent compared to other 
residents, living in the same environment {Sutnick,1968}. Shortly later Australia antigen 
appeared to be connected with a hepatitis virus {Prince,1968; Dane,1970}. The 
nomenclature o f the Australia antigen changed in hepatitis associated antigen (HAA) and 
was replaced by the current nomenclature o f hepatitis B surface antigen (HBsAg) in the 
seventies. Extensive studies on the distribution o f Australia antigen were performed in and 
outside residential institutions for the mentally handicapped. The studies did not focus only 
on people with Down’s syndrome, including other mentally handicapped residents as well. 
The living and daytime conditions for people with a mental handicap have changed 
substantially since the first observations o f high prevalences o f hepatitis B virus (HBV) 
infections in the residential institutions. In the western countries, people with a mental 
handicap were usually nursed out o f the family home until 30 years ago. Most (large) 
institutions were founded in the first half o f this century. Mentally handicapped persons of 
all ages were admitted to these institutions, including very young children. People were 
living in very close contact to each other and they hardly had any activities outside the 
institution. The hygienic circumstances were often poor. The peak o f the institutionalisation 
o f the mentally handicapped population was in the sixties. The appropriateness of 
institutionalisation and segregation started to be questioned increasingly in the seventies. 
This resulted in a gradual transformation o f the care system from institutions towards the 
communities. One o f the visible aspects o f this reform is the change o f housing for persons 
with a mental handicap during the last decades. Large institutions are closing all over the 
world. Nowadays mentally handicapped children stay home more often and for longer 
periods o f time or they go to a foster home. A considerable number o f mentally 
handicapped adults are living in regular houses within the community. During daytime they 
go to school, to work, to sheltered workshops or to special day-care centres, often within the 
community. Some countries, like the Scandinavian countries, USA, UK and Italy, have 
closed almost all their institutions. Other countries, like the Netherlands still maintain some 
institutions, but the average size o f living units has decreased and the units are being more 
equally distributed throughout an area. Meanwhile the hygienic care in institutions is much
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more individualised, thanks to better knowledge about the spread o f various infectious 
diseases.
This chapter gives an overview o f the literature from 1967 until 1999. It describes the 
prevalence o f hepatitis B in people with a mental handicap throughout the years in different 
settings and different countries around the world. It also presents the influence of 
(changing) living conditions on the prevalence o f the HBV among people with a mental 
handicap.
Methods
Articles in English or with at least a summary in English have been included in this review 
provided that the included study topics were the mentally handicapped or Down’s syndrome 
and the presence o f hepatitis B. Articles were identified by a thorough literature search 
using various strategies. This included a computer search (MEDLINE) for the period 1967­
1999 using as a key word: hepatitis B, combined with one o f the key words: mental 
handicap and/or Down’s syndrome. In addition, references given in relevant publications 
were examined. No abstracts or proceedings were included. The following items were 
evaluated: year o f publication and first author; country o f the study population; living 
conditions and sizes o f these facilities (non-residential; small institutions: 25-250 residents; 
medium-sized institutions: 250-500 residents; large institutions: 500-1000 residents; mega­
sized institutions: more than 1000 residents), daytime spending conditions (school, sheltered 
workshop, day-care centre); number o f mentally handicapped persons studied with age 
indication and gender; percentages o f mentally handicapped persons (ever) HBV infected 
(HBV marker positive: anti-HBc positive/ HBsAg plus anti-HBs positive), percentages of 
HBV carriers (HBsAg positive) and percentages o f HBeAg positive carriers in the general 
study population; similar HBV marker specific numbers o f persons with and without 
Down’s syndrome; other relevant findings considered as significant risk factors for HBV, 
figures for staff and finally if  mentioned, the prevalences o f antibodies against the hepatitis 
A virus (anti-HAV) and the hepatitis C virus (anti-HCV) in mentally handicapped.
When applicable, the prevalence rates or percentages of persons studied with HBV-markers 
were abstracted or calculated. Among those percentages the median value o f the 
percentages is presented for all study populations, and then for specific groups. Regarding 
the relation between Down’s syndrome and HBV marker positivity the numbers o f persons 
from the selected studies were summarised into 2x2 tables, and odds ratios with 95% 
confidence intervals estimated.
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Table 3.1. Findings of studies selected from literature 1967-1996 on mentally handicapped and hepatitis B.
Year o f  publication 
& First author
Menially handicapped Menially handicapped Down’s syndrome/not DS
living* da> timet n gender HBV HBsAg HbeAg HBsAg HBcAg
Other Staff
risk --------
facU
n HBV HBsAg
tested range/ 
mean age
nVf
%
markers 
% pos
% poi %  pos. o f  
HBsAg
tested markers
% pos
% pos % pos o f
1113 sAg
tested marker
s
% pos
%  pos
1967 Blumbcrg, USA C4 € 151 0-60 100/0 15.3 75/76 25.3/5.3 h
1967 Mclartin Finland c3 c 7-46 69/31 32 9.4
1968 Sutnick USA a d.y all 34 0
1968 Sutnick USA cl c >6 33 3.0
1968 Sutnick USA 64 C 498 >6 18.5 310/188 27.7/3.2 a b 114 0
1970 ICrugnian USA c4 C 621 < 3 6 19-5 147/474 25.8/17.5 b
1970 Sztnurvess USA c4 c 268 > 5 52/48 26 1 134/134 35.1/17.2 a b e d
1970 Vierruci Italy a X all 32 3.1
1970 Vierucci Italy c3 c 77 all 32,0 53/24 32.0//0
1971 Goodman USA c4 c 1077 15 (m> 57/43 18,3 185/892 57.1/10.2 a c
1971 Nordenfell Sweden c3 c 597 all 74/26 6.0 28/414 10.7/5.1 668 0
1971 Skinhoj Danmark cl c 97 >20 20/80 4.1 18/79 11.1/2.5
1971 Skinhaj Danmark c3 c 148 8-67 54/46 16.9 74/74 31.1/2.7 a b  c
1971 Szmuncss USA c4 c 392 all 47/53 14.0 196/196 20.4/7.7 a b e d
1972 Dictzman USA c4 c 1104 all 55/49 7.9 105/999 23/6 a b
1972 Kerris Australia a X all 110 0
1972 Fens Australia c3 c 349 >5 19-2 )82/167 31.9/5.4
1972 1 lol linger USA c4 c 66 22 (in) 50/50 56.1 24.2 33/33 54.5/57.6 36.4/12.1 be
1972 Szmuness IJSA c4 c 268 >5 52/48 67.5 26.1 134/134 65.7/69.4 35.1/17.2 a b e d 176 23.9 3.5
1972 Szmuness USA c4 c 615 all 47/53 62.8 104 196/416 54 .1 /67.5 19.4/6.3 a b e d
1973 Dankert Netherlands c3 c 626 21 (m ) 55/45 12.8 6.4 76/550 27.7ft 0-7 26.4/3.6 a b e d 350 1.7 0.8
1974 Braining Netherlands c2 c 309 all 61/39 52.fi 14.6 95/214 63.2/48.1 315 /7 .0
1974 Tevaluolo Fini c3 c 615 all 62/38 3.5 54/479 10-3/2.6 a 468 0
1975 Perry Canada C4 c 364 all 74/26 17.8 155/209 34,8/5.3 a c d
1976 Boughton Australia Cl c 194 all 72-1 1 3 9 101/83 86/59 26.7/5
1976 Madden USA c4 c 227 all 50/50 61,2 12.8 46 98/129 60/64 20/7 a d 45 35.6 2.2
1976 Tiku USA c4 c 794 all 52.9 9,3 322 21.3 1.8
1977 Chaudliary Canada c4 c 190 all 50/50 78 16 95/95 76/81 38/4 b e d
1977 Mura Italy c2 c 346 8.7 4/342 0/8.7 257 5.4
1977 Szmuncss USA C4 c
1978 Kingham UK c2 c 340 54.1 7.6 46 36/304 22/6 b c d f 268 22 1.5
1978 Lehmann Australia c3 c
1979 McMillan USA c3 € 82 5-19 58/42 65.9 40.2 41/41 82.9/48.8 63,4/17.1 no
1979 McMillan USA c3 c 202 5*24 60/40 67.8 31.7 101/101 84.1/51.4 45.5/17.«
Mentally 
hamli cap tied
anti- anli- 
HAV HCV 
(%) (n)
75.1
74.7
<1
00
Table i. i continued
Year o f publication Country Conditions Mentally handicapped Mentally
&  First author
living* daytime t n
tested
age 
range-' 
mean age
gender
rri'T
%
III1V
marker
%  pus
1982 t ’ancio-Bello USA e3 c 212 6-24 71/29 20.2
1982 Williamson Australia c3 c 976 81.2
1983 Droggini Italy c l c 62 $-59 0/100 66 ’
1983 William* USA a/c4 d 252 5-1« 39.6
1984 Clarke UK c X 10-70
1984 Clarke UK c2 c 392 43.7 85/15
1984 Clarke UK cl 235 42.9 88/12
1984 Clarke UK c2 488 41.8 24/76
1984 Clarke UK c3 505 42.5 58/42
1984 Clarke UK c l 183 54.7 93/7
1084 Clarke UK c2 298 57.0 91/9
1984 Clarke UK c l e 138 60.2 9/91
1984 1 leytink Netherlands c4 e 160 33-63 66 .S
1984 l.ohiya USA c4 e 1254 0-65 58/42
1984 Perillo USA a/cl d 79 14,1 2.3
1985 Renner Austria a defg 231 4-42 61/39 16.0
1985 Rcinicrs Belgium C x c 11-43
1985 Wagemans Netherlands c3 c 677 2-88 0/100 28.5
1986 Holt NZL c 2 c 436 6-87 52/48 24.8
1986 Perillo USA c I edefg 91 5-60 80.3
1986 Perillo USA c 2 c 395 5-85 34
19K7 Dicks USA a alt
1987 Dicks USA Cl c 95 ah
1987 Dicks USA Cl C 67 all
1987 Dicks USA c2 c 378 all
1987 Dicks USA c2 c 310 all
1987 Dicks USA c3 c 700 all
19ft7 Dicks USA c3 c 586 all
1987 Follel UK c4 c
1987 Remis Canada a b  c d 505 4-25 53/47 34.2
1988 Jayartam UK c X ccg
1988 Schuckink K Netherlands c4 c 1026 all 59/41 32-5
1988 V Ditzhuy&en Netherlands c2 c 493 0-60 100/0 62.1
1988 Vr Dilzhuysen Netherlands c3 c 667 0-70 32/68 36.6
1989 French Hong Kong c2 e 284 0-20 47/53 50.4
handicapped Dow n’s syndrome/not OS Other
risk 
fact t
IIUsAg IfbeAg n IIBV HBsAg HBeAg n HBV HBsAg
% pos % pos o f  
HBsAg
tested markers
% pos
% pcs % pos o f  
H lisAg
tested marker
.s
% pos
% pos
5.6 41.6
14.9 175/901 94.8/78.2 40.8/9.3 a b
.16 15/47 86/57 53/4.2 23 56 4,3
7-1
561/1678 9.5/4.0 57/22
c
a b
122 8.2 0.8
12.5 46
5 1 82
5.f 24
5.1 23
3.3 17
1.0 33
1.4 0
18.1 10 87/73 74.7/57.7 25.2/9.6 13.6/0 a
12.2 . 106 /1148 43.3/9.3
10 55 1.8 0
8.2 68.4 125/106  
92/67«
20/11.3 12.8/2.8
32.6/7.2
68.7/66 6  
53.4/30.0
5.8 104/573 51-0/24.4 15.4/4.0 b e d  f
3.2 28.5 38/398 31-6/24.1 13.2/2.3 60/11 H 439 5.9
20-9 47.3 11/80 72.7/81.3 27.7/20 f 92 16 2.1
4.5 67/328
37/0
55/24.3 16.4/2.1
3
f 294 8 0
6 4/91 50/4
9 3/64 33/8
5 18/360 33/4
2
S
14/296
41/659
7/2
22/8
11 23/563 39/10
893 3.7
7.3 74 150/355 52.7/16.] 21.3/1 4 a b e 162
97
14.4
6.2
1.2
0
3.1 0 97/929 34/32.4 10.3/2.3 0 a
10.3 39.2 117/376 70.9/59.5 22.2.6.6 c
6-2 35.7 129/129 45.0/38.0 10.8/3 1 a c d 676 7.0 0.3
14.8 8/276
Mentally
liamlicappcJ
anti- anti- 
IIAV HCV 
<%j (n )
Table 3.1 continued
Year o f  publication 
& First author
Country Conditions Mentally handicapped Mcntully handicapped D ow n’s syndrome/not DS O ther
risk
fact*
Staff Mentally
handicapped
am i- anü- 
HÀV HCV 
(%) . ( n )
living* daytime t n age 
tested range
mean age
gender
in'T
IIBV 
markers 
% pos
IIUsAg
% p o s
11 he A g 
%  pos o f  
HBsAg
n
tested
1IIÎV
markers
% p o s
IIUsAg
% p o s
IIHeAg 
% pos o f  
HBsAg
n
tested
IlliV
marker
s
%  pos
IIUsAg
%  pos
1989 Kee Nort Irel IJK c3 c 720 39.7 45 0.1 68/652 4.5 /4 .5
1 <>89 Livcngood USA c4 c 920 10
1989 Scanlon Ireland c2 c 249 3-76 41 9 56/193 96/73 23/6
1989 Thomson UK e J c 220 22-77 59/41 0.5 0 11/209 0 /0 5 0/0
1990 Ellis Canada a d 23'» 6-20 58/42 7.5 2.5 30.3 57/182 10.2/6.5 98 4.1 0
1990 MoLsa Finland c 3 ! 0 2-73 53/47 1 6 80 0
1991 Devuyst U clg lL IV a .c l c 41/122 87.8/19.6 61.0/18.0 a b
1991 Devuyst Uelgium a £ 4> 5-42 60/40 40-0 11.1 100
1991 Devuyst Belgium el e 1 IS 5-42 22/78 35.6 6.8 62.5
1991 Stchr-Green New /ealjrul cl c 114 30 52/48 61 37 d 129 11 0
1991 Iscrmann Germany c2 c 325 39.1 6.2
1991 Iscrmann Germany c J c t m 50 4.6
1991 Iscrmann Germany c4 c 1100 44.36 5.3
1991 I’ucschel USA ab defg 335 1-29 56/44 1.2 0.9 1 HO/155 L l/1 .3 0.6/1.3 no
1991 Vermeltfoort Netherlands c2 c 451 31 63/37 23.9 4.0 60/391 33.3/22.5 10/3.0
1992 Aruirajan UK c2 c 300 4-90 67/33 3 2 3 5.7 47 31/269 32.232.3 9 7 /5 .2
1992 Chaudhary Canada C4 c 246 89 17.4 128/136 91/76 27/6 0
1993 Devlin Ireland a defg 242 13-61 58/42 11 4 30 94/145 15/11 7 /i a b 70
1993 Di Ciommo Italy a h 70 1-19 54/46 4.2 0 19/51 44 11.3 2 .2 '
1993 Schoub South Africa Cl c 176 4-80 23 4 21/155 50/19 19/2 c d
1993 Schoub South Africa c l c 203 6-52 68 4 5/198 60/68 20/4 c  d
1993 Tone Italy c l c 57 17-71 0/100 61.4 14.0 13/44 69/59 54/2.2 1
1994 Cunningham UK c2 c 134 24-72 65/35 12,6 2.9 0 a d 75 1.3 0
1996 Cramp UK ac c 101 25-79 58/42 42.5 13.8 0
* Living conditions: t  Daytime conditions: I Other nsk (actors:
a) non-residential (home/foster home) c) residential facility (school, day carc ccntrc) a) male
b) grouphomes (<25 residents) d) school b) mean age
c) general institutions e) day carc center for children c) age o f  ad mission
1. small (25-250 residents) 0 shelterd workshop d) average years o f  residence2. medium (250-500 residents) g) daycare center adults e) previous intitulionali/ation
3. large (500-1000 residents) h) not or not known 0 degree o f  severity o f  the mental handicap
4. mega (>1000 residents)
Results
Ninety-three specific published population studies have been considered for inclusion in the 
systematic review. Far the most studies originated from developed countries where the 
prevalence o f hepatitis B is low (( 1% HBV carriers). Four studies were fulfilled in Italy 
(prevalence of HBV carriers 1-3%). Two studies were performed in high endemic countries 
(HBV carrier rate ( 8%): Hong Kong and South Africa. HBV vaccination programmes had 
not been implemented in any o f the study-populations. Half o f the articles were published 
before 1985. The reviewing results are shown in the somewhat draconian Table 3.1. From 
these studies the prevalence rate (%) o f HBV-markers, the prevalence rate o f HBsAg 
positive and the prevalence rate o f HBeAg positive carriers were determined in 50, 80 and
24 study-populations, respectively. The summarising results are presented in Table 3.2. 
Among the populations o f mentally handicapped persons the median prevalence rate of 
HBV marker positive was 42%, the median prevalence o f HBsAg positive 8%, from whom 
was 37% HBeAg positive.
Stratification o f the studies in Table 3.2 to period o f publication reveals a downward trend 
in prevalence rates from the period of 1967-1973 to the period o f 1989-1996, except for the 
HBeAg positivity. In the lowest panel o f Table 3.2 a stratification towards extent o f
Table 3.2 Studies for the prevalence rate of HBV-markers in populations of 
handicapped persons according to year of publication and extent of
Prevalence rate HBV - Prevalence rate HBsAg Prevalence rate HBeAg
marker positivity positvity positivity
No. o f studies 50 80 24
Lowest rate 0.5% 0% 0%
P 25 rate 24% 4% 24%
Median rate 42% 8% 37%
P 75 rate 61% 15% 47%
Highest rate 80% 40% 100%
No. o f Median HBV No. o f Median HBsAg No. of Median HBeAg
studies prevalence rate studies prevalence rate studies prevalence rate
Period of publication
1967-1973 4 59% 17 17% ... . . .
1974-1984 14 58% 24 10% 11 33%
1985-1988 10 34% 16 7% 7 39%
1989-1996 22 40%
"■V
mmC
N 6 39%
Extent o f residency
non-residential 5 11% 6 3% 4 49%
combinations 6 33% 6 7% 2 61%
small (25-249 res.) 8 64% 14 6% 5 47%
medium (250-499) 10 37% 15 5% 7 33%
large (500-999) 9 37% 17 6% 3 36%
mega (at least 1000) 10 62% 19 16% 3 10%
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living condition, i.e. number o f residents, is made. Roughly speaking, the non-residential 
mentally handicapped present the lowest median prevalence rate o f HBsAg, i.e. 3%. For the 
largest situations regarding the number of residents the rate turned out to be 16%. The 
prevalence rates o f HBsAg in the other categories o f institutions (small, medium-sized and 
large) were about the same (5, 6 and 5% respectively).
Stratification o f the data to Down’s syndrome status yielded a contrast o f 54% vs.38% in 
not Down as the median prevalence rate for all HBV marker positive. The median 
prevalence rate for HBsAg positive for Down’s syndrome and non-Down’s syndrome was 
25% and 6%, respectively. For HBeAg positive carriers the rates were 54% and 23%.
Table 3.3.A Association of persons with Down’s syndrome and HBV-marker positivity 
based on pooled information from studies on mentally handicapped
No. of
studies
No. of persons with 
DS & NDS
HBV-marker
positivity
Odds ratio 95% Cl
All population studies 34 2839 & 8733 1546 & 3325 1.94 1.79 -2.12
Non residential 3 276 & 433 45 & 40 1.91 1.22 - 3.00
Combinations 3 371 & 632 117 & 83 3.05 2.23 -4.16
Small (25-249) 6 166 & 607 131 & 331 3.12 2.11 -4.62
Medium (250-449) 7 464 & 2169 276 & 818 2.42 1.98 - 2.96
Large (500-999) 7 694 & 2947 420 & 1054 2.75 2.33 -3.25
Mega (at least 1000) 8 868 & 1945 557 & 999 1.70 1.44 -2.00
Table 3.3.B Association of persons with Down’s syndrome and HBsAg-marker positivity 
based on pooled information from studies on mentally handicapped
No. of
studies
No. of persons with 
DS & NDS
HBsAg-marker
positivity
Odds
ratio
95% Cl
All population studies 55 5194 & 18011 1279 & 892 4.96 4. 57 - 5 . 38
Non residential 2 219 & 251 23 & 4 7.25 2 . 83 - 18 . 52
Combinations 5 1024 & 2988 141 & 145 3.13 2 . 48-3. 96
Small (25-249) 9 191 & 841 55 & 36 7.15 4. 84- 10.57
Medium (250-449) 10 532 & 109 109 & 112 5.85 4. 57 - 7 . 49
Large (500-999) 13 1081 & 4675 318 & 116 5 89 5 . 02-6. 91
Mega (at least 1000) 16 2147 & 6127 633 & 479 4 93 4. 36-5 . 58
Table 3.3.C Association of persons with Down’s syndrome and HBeAg-marker positivity 
based on pooled information from studies on mentally handicapped
No. of
studies
No. of persons with 
DS & NDS
H BeA g marker 
positivity
Odds
ratio
95% Cl
All population studies 5 903 & 2933 490 & 687 3 88 3. 33 -4. 51
Non residential 1 125 & 106 86 & 71 1 09 0. 62 - 1. 89
Combinations 2 653 & 2356 369 & 572 4 05 3. 40 -4  .82
Medium (250-449) 1 38 & 398 23 &94 12 . 34 6. 70 -22 . 71
Mega (at least 1000) 1 87 & 73 12 &0 -- --
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Back-calculation o f the prevalence rates to absolute numbers in groups o f persons with 
Down’s syndrome and no Down’s syndrome yielded figures as presented in Tables 3.3 A, B 
and C. According to these calculations it appeared that among the more than 10,000 
mentally handicapped individuals the odds ratio o f HBV marker positivity for persons with 
Down’s syndrome vs. persons without Down’s syndrome is 1.94; 95% confidence interval 
(1.79-2.12). Thus HBV-markers are about two times more prevalent in persons with 
Down’s syndrome compared to the other mentally handicapped. Table 3.3.A shows a more 
or less homogeneous result across the institutions o f various size, although, we were not 
able to adjust for confounding factors, responsible for the statistical heterogenicity o f the 
odds ratios. Table 3.3.B regarding the presence o f HBsAg displayed a five times higher 
prevalence rate among individuals with Down’s syndrome in comparison to the other 
mentally handicapped: odds ratio 4.96 with (4.57-5.38 as 95% confidence interval. This 5- 
times larger risk seems to be the overall picture across the living conditions, showing 
Down’s syndrome forms a risk by itself.
For HBeAg positive carriers finally, a four-fold increase in case o f Down’s syndrome is 
observed in Table 3.3.C. The somewhat deviant odds ratio values for non- residential and 
medium sized institutions can be ascribed to small numbers.
Although based on a small number o f studies, the median prevalence rates for staff were 
11% for all HBV-markers and 1% for HBsAg.
A few studies presented results o f screening for HAV and HCV infection in the mentally 
handicapped. HAV prevalences were reported 5 times, 3 times from an institutional 
population. The HAV prevalence emerges between 70 and 75%, except for the 7 % in one 
non-residential study. Only one case o f HCV infection was reported.
Discussion
H B V  prevalence in residential institutions
This review of the literature shows that the prevalence o f HBV infections is higher in almost 
all residential institutions for mentally handicapped compared to the prevalence o f HBV in 
the local general population, which is low in far the most studies. HBV transmission follows 
a typical pattern in these institutions. Parenteral transmission is negligible. Sexual 
transmission o f HBV may occur by unsafe sexual contacts. Thus HBV is usually transmitted 
by intimate contact in institutions for mentally handicapped, which way o f transmission is 
usually termed horizontal transmi ssion . The source o f the virus may be either saliva or 
minuscule quantiti es o f blood. HBV transmi ssion occurs by mucous membranes or skin 
defects, as ulcers or abrasions, and may require a period o f prolonged exposure. Thi s 
manner o f HBV transmission i s less efficient and often leads to anicteric hepatiti s 
B{Davis,1989}.
The hi gh HBV transmi ssion rate within the environment o f the resi dential instituti ons can be 
explained by a combination o f the following factors:
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a) Behaviour, which may result in poor hygiene. Poor hygi enic behaviour, which facilitates 
hori zontal viral transmi ssion in people with a (profound or severe) mental handi cap consi sts 
o f one or more o f the following characteri stics: scratching or picking of sores; refusing of 
bandages; mouthing and sharing food and other utensils as toys; drooling; sharing of 
toothbrushes and shaving gear; automutilation; aggressive behaviour; biting, 
etc.{Bakal,1980; Cancio-Bello,1982}.
b) Frequent and prolonged close contacts with di fferent HBV carriers. Type and frequency 
o f contact between carri ers and others affect the HBV transmi ssion rate. Hazardous 
conditions for high HBV transmission are close contacts between resi dents o f different ages, 
constant changes in institution population as well as long duration o f institutionali sation 
{Szmuness,1970}.
c) High number o f residents who are at ri sk for chronic hepatiti s. Down’s syndrome and 
young chi ldren run a high risk o f becoming HBV carriers because o f an insuffici ent immune 
response. It was common in the past to institutionalise chi ldren at a very young age.
d) Unawareness o f HBV infection. Most institutions were not aware o f the enormous spread 
o f the di sease because the majority o f the HBV infecti ons were not diagnosed in the sixti es 
and seventi es. Many authors reported high numbers o f anicteric hepatitis B in institutions. 
Szmuness estimated the ratio between icteric/anicteric hepatitis in patients who 
subsequently became chronic HBV carri ers in an institution for mentally handicapped in 
1971 as 1:6 {Szmuness,1971}. One year later he demonstrated an icteric/ani cteri c rati o of 
1:26 in residents who converted to HBV-markers {Szmuness,1972}. Other investigators 
reported the same high rates for anicteric hepatiti s B {Boughton,1976}.
This revi ew suggest that the HBV prevalence in mega-sized institutions (more than 1000 
resi dents) i s much hi gher than in others In 1968 Sutnick already reported a higher 
prevalence o f hepatiti s B infection in a very large institution compared to a small institution 
and he suggested an easi er transmission o f the virus in large and crowded populations 
{Sutni ck,1968'. One can imagine that the above suggested factors were much more 
prominent in the old large institutions than in the modern and smaller ones. As a matter o f 
fact most o f these mega-sized institutions have been closed during the last decades. The 
median HBV prevalences in the other three categories o f institutions were about the same, 
while we were expecting gradual di fferences.
Furthermore the overview o f studi es shows a downward trend in prevalence rate o f HBV- 
markers from the period o f 1967-1973 to the period o f 1989-1996. The better awareness of 
the di sease might be the main reason for this observation, because no HBV vaccination 
programmes were started in the study-populations. Another sign for decreasing HBV 
transmissi on in resi dential institutions are lower reported inci dence rates. Very hi gh 
incidence rates have been reported in the past. Szmuness reported that 50% o f the newly
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admitted residents within a mega-sized residential institution turned out to be positive for 
HBV-markers within 2 years and 20% o f the infected ones became HBV carrier 
{Szmuness,1972}. Other investigators mentioned seroconversion rates of 80% for Down’s 
syndrome within 3 years {Boughton,1976}, and about 15 % in 1.5 year {Tiku,1976} and 
2.3% in one year (these thesis, chapter 5) for all mentally handicapped. A downward 
tendency for HBeAg positivity was expected, because o f the lower reported incidence rates, 
but could not be observed in this review. The reviewed studies showed that percentages of 
carriers, positive for HBeAg, varied from 9 to 82 %. These percentages were higher in 
Down’s syndrome than in other mentally handicapped (54% vs. 23%). HBeAg positive 
carriers in general are more contagious than HbeAg negative carriers (see chapter 2), 
because the presence o f HBeAg in the serum o f a patient indicates that the virus is 
replicating actively in the hepatocytes. Lohya demonstrated that HBeAg prevalence within 
one institution was significantly higher in residents with Down’s syndrome than in others, 
and higher in blacks than in whites {Lohya, 1986'. It has been suggested that institutions 
for mentally handicapped can be divided into those with a high percentage o f HBeAg 
positive carriers where HBV transmission is active and those with a low percentage of 
HBeAg carriers, where hepatitis B transmission has decreased to a low rate (Cossart,1977; 
Clarke,1984).
H BV prevalence o f  mentally handicapped individuals living at home 
Some studies were performed in mentally handicapped people living at home. The mean 
frequency rates o f HBV-markers in these non-institutionalised mentally handicapped were 
lower than in mentally handicapped residents o f general institutions (11% vs. 30% at least). 
The results o f these studies varied enormously. Some authors reported low HBV 
prevalences {Sutnick,1968; Ferris,1972; Pueshell,1991', some medium high HBV 
prevalences {Vierucci,1970; Ellis,1990; Devlin,1993' and others high prevalence rates 
{Renner,1985; Cramp,1996). These variations can be explained by the kind o f contacts 
during daytime. During daytime, the home-living mentally handicapped individuals often 
had close contacts to other, institutionalised, de-institutionalised or never institutionalised, 
mentally handicapped persons within schools, day-care centres or sheltered workshops.
H BV prevalence in schools fo r  the mentally handicapped
Several HBV prevalence studies have been performed in special schools established for 
mentally handicapped children {Sutnick,1968; Bakal,1980; Williams,1983; Perillo,1984; 
Remis,1987; Ellis,1990'. In all studies students living at home as well as institutionalised or 
deinstitutionalised students attended these schools together. Some investigators showed an 
increased risk for students and/or teachers when one or more classmates were HBV carrier 
{Perillo, 1984; Breuer,1985; Remis,1987 ' ,  whereas others did not {Bakal,1980; 
W illiams,1983'.
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Individual riskfactors
The overview shows clearly that persons with Down’s syndrome are at risk for hepatitis B. 
They have a twofold increased risk for HBV infection, a fivefold increased risk for chronic 
hepatitis B and a fourfold increase for persisting HBeAg (Table 3.3).
Many studies have been performed regarding other individual risk factors for higher HBV 
transmission in residential institutions. A significantly higher prevalence o f all HBV- 
markers in residential institutions has often been reported in males compared to females, in 
residents who are institutionalised longer compared to those who are institutionalised 
shorter and in residents who are profound or severely handicapped compared to residents 
who are moderately or mildly handicapped (Table 3.1). This last risk factor was only 
proved by three investigators (Kingham,1978; Wagemans,1985; Perillo,1986). The 
prevalence rate o f HBV carriers in institutions was significantly higher in males compared 
to females, in children compared to adults, in residents admitted to an institution at young 
age compared to those admitted at older age. The reported higher HBV carrier rates in 
individuals with Down’s syndrome, male, children and residents admitted at an early age 
can be explained by immunological factors. Persons with Down’s syndrome, males and 
children are more susceptible to chronic HBV infection {see chapter 2 and chapter 7). The 
higher prevalence rate o f HBV-markers in long institutionalised individuals can be 
explained by a prolonged exposure to the virus and the higher prevalence rate in more 
handicapped individuals by poorer hygienic behaviour. Only one study examined the 
determinants for transmission o f hepatitis B in mentally in a mixed population o f home 
living and deinstitutionalised handicapped school children. Spending the day in a classroom 
with a carrier was a significant risk factor {Breuer,1985'.
H B V  prevalence in fam ily members o f  the mentally handicapped
Two investigators have reported high prevalences o f HBV-markers in relatives o f mentally 
handicapped HBV carriers. Devlin reported a HBV marker prevalence o f 22% in first 
degree family members o f HBV marker positive mentally handicapped individuals, who 
lived at home {Devlin,1993'. Van Damme calculated that relatives o f institutionalised 
mentally handicapped HBV carriers have been infected 6-7 times more likely than relatives 
of mentally handicapped, who were not carriers{Van Damme,1995'. He concluded that the 
risk o f horizontal transmission o f HBV among relatives o f institutionalised mentally 
handicapped is considerable, even if  family contact is reduced to weekend and holiday 
activities.
H BV prevalence in sta ff
Close contacts, facilitating transmission o f infectious diseases as HBV, occur frequently 
between mentally handicapped individuals and staff. These contacts are generally 
considered an integral part o f the daily care. In 27 studies among employees o f residential 
institutions or schools for mentally handicapped the prevalence o f HBV carriers varied from 
0 to 5.4%, and the prevalence o f all HBV-markers from 1.7% to 56% (Table 3.1).
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Only one study described a seroconversion rate in staff members that was almost equal to 
the conversion rate in the mentally handicapped {Tiku,1976; Breuer,1985', whereas others 
did not notice any evidence o f increased HBV transmission{Dankert,1973; Follet,1987; 
Ellis,1999; StehrGreen,1991'. Although in most studies the HBV prevalence among health 
care taking employees o f institutions for mentally handicapped was somewhat elevated 
compared with the local population, the prevalence was never as high as the prevalence in 
the residents {Szmuness,1972; Kingham,1978'. In other staff, like administration, the 
prevalence was similar to that o f the general population {Mura,1977; Kingham,1978'. 
Kingham showed that the HBV carrier rate in employees was related to the duration of 
employment within the institution and the age o f the children who they were taking care of 
{Kingham,1978'. Breuer reported that possible risk determinants for a hepatitis B infection 
among staff members in a school for mentally students were male, age and ethnicity 
{Breuer,1985'. Although never reported, HBV infected health care workers may transmit 
HBV to mentally handicapped, as it is observed in several clinical settings {Ristinen,1998'.
Hepatitis A and C in the mentally handicapped
Some studies have evaluated the prevalence o f hepatitis A and hepatitis C in mentally 
handicapped individuals. Hepatitis A differs much from hepatitis B. The only resemblance’s 
are the hepatropism and the hyperendemicity in populations with poor hygiene. The 
transmission routes varies a lot. Hepatitis A virus (HAV) is mainly transmitted by the fecal- 
oral route, while transmission o f HBV occurs by a vertical, parenteral, horizontal and sexual 
route. Hepatitis A virus is very contagious and spreads very easily. The chance o f an 
epidemic is high when an index case has been located once. The spread o f hepatitis B is 
much slower, like a bottleneck, in the beginning o f an endemic or epidemic. Reasons for 
this difference are the longer incubation time for hepatitis B (1 to 6 months) compared to 
hepatitis A (2-6 weeks) and the different transmission route. Matthew described a major 
epidemic o f hepatitis A in an institution for mentally handicapped. The overall institutional 
attack rate was estimated at 15.7%. In severely handicapped residents the attack rate was 
much higher (57%) compared to less handicapped persons. The attack rate for residents 
with Down’s syndrome was similar to the attack rate for other handicapped. Males and in 
females were affected equally. The clinical to subclinical ratio was approximately 2:1. Only 
one employee developed clinical hepatitis A. {Matthew 1973, Madden 1976'. Other studies 
in residential institutions for mentally handicapped individuals showed a high prevalence of 
past hepatitis A as well {Szmuness,1977; Lehman,1978; W illiamson,1982'. Prevalences up 
to 75% have been reported. Devlin showed an increased prevalence for hepatitis A as well 
as for hepatitis B in a non-institutionalised mentally handicapped population 
{Devlin,1993'. In contrast, Renner observed a high risk for HBV infection, but no 
increased risk for hepatitis A in a non institutionalised mentally handicapped population. He 
suggested there was a better hygienic care in mentally handicapped persons living with their 
families {Renner,1985'.
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Two studies have showed a higher susceptibility for HAV infections in Down’s syndrome 
{Lehman,1978; W illiamson,1982'. It is not known whether this difference is caused by 
behavioural or by immunological factors.
Hepatitis C is frequently associated with hepatitis B because both hepatitis C and hepatitis 
B, are a major cause o f chronic hepatitis and share several routes o f transmission. Some 
investigators performed combined studies o f HBV and HCV infections in residential 
institutions for mentally handicapped {Chaudhary,1992; Torre,1993; Cunningham, 1994; 
Cramp,1996'. All studies showed a high prevalence o f HBV infection and an absent or 
infrequent low prevalence o f HCV infection. These discrepancies between HBV and HCV 
infection in residential institutions might be explained by a difference in transmission and/or 
virulence and/or susceptibility between both viruses. Parenteral transmission o f hepatitis C 
virus (HCV) is well documented and considered as the most important route o f transmission 
in case o f hepatitis C. Perinatal transmission has been described. Sexual transmission is still 
controversial, but is probably not a course o f transmission {LCI,1999; Health Council, 1996; 
Health Council,1997; Vroom,1999). Horizontal transmission which is highly responsible for 
most HBV infections among mentally handicapped in institutions, may be less important for 
transmission o f HCV, due to lower contagion o f HCV. Persons with Down’s syndrome, who 
are very susceptible to HBV infection, have not shown to be at risk o f HCV infection until 
now {Chaudhary,1992; Torre,1993; Cunningham,1994; Cramp,1996'.
Conclusion
From this literature survey concerning hepatitis B in mentally handicapped individuals it 
can be concluded that the prevalence o f hepatitis B is usually intermediately high (2-7% 
HBV carriers) or high (>8% HBV carriers) in residential institutions for the mentally 
handicapped. In mentally handicapped individuals living at home, the prevalence of 
hepatitis B is generally lower. Transmission o f hepatitis B may occur in schools and day­
care centres. The HBV prevalences in institutions incline to decrease during the years. 
Reasons for this decline are the changing living conditions for the mentally handicapped 
people within the institutions. In addition, the knowledge o f the disease has much improved. 
Depending on the presence o f HBeAg one can distinguish institutions with active hepatitis 
B and those where hepatitis B is almost eliminated. Mentally handicapped individuals who 
run a higher risk for hepatitis B infections are persons with Down’s syndrome, males, 
persons who are very young at time o f admission to an institution and who had been 
admitted for a long time. The risk for catching hepatitis B is 2 times higher in persons with 
Down’s syndrome compared to other mentally handicapped, the risk for developing chronic 
HBV infection is 5 times higher in Down’s syndrome. Family members and care-taking 
personal o f mentally handicapped HBV carriers are at risk for HBV infection as well.
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Chapter 4
Epidemiology of hepatitis B 
in the mentally handicapped
in
the Netherlands

Introduction
The Netherlands is a country with a low prevalence o f hepatitis B infection. It is estimated 
that 0.5% o f the population is a carrier o f the hepatitis B virus (HBV) and 4% has ever had 
an infection {Health Council,1996}. In the Netherlands only people at risk participate in a 
vaccination program for hepatitis B. Therefore it is important to know if, when and which 
people are at risk for HBV infection.
The first study on the prevalence o f hepatitis B in a Dutch residential institution for people 
with a mental handicap was presented in 1973 {Dankert,1973}. Several studies followed 
{Bruining, 1974; Wagemans, 1985; Van Ditzhuysen, 1988; Schuckink-Kool, 1988; 
Vermeltfoort, 1991'. All studies showed a high risk for HBV infection in these institutions. 
Distinct individual risk factors were Down’s syndrome, male gender, low age at admission 
and prolonged duration o f institutionalisation. The results o f these studies were similar to 
those from many studies in the USA and Europe, which have been published in the same 
period (see chapter 3, Table 3.1). In 1982 the NVAZ (Netherlands Association for 
Physicians Working for Mentally Handicapped Persons) distributed a questionnaire about 
the HBV prevalence to all residential institutions for mentally handicapped for the first 
time. About 30% o f the residential institutions responded to the questionnaire. It appeared 
that 5.3% o f the reported 8,517 mentally handicapped residents was carrier o f HBV. In the 
18 responding institutions the percentages o f HBV carriers varied from 0 to 13.8% 
{NVAZ,1982'. In 1983 the Netherlands Health Council advised general residential 
institutions for the mentally handicapped to vaccinate all residents against hepatitis B 
because o f the frequently reported high prevalences o f HBV infection in those institutions 
{Health Council, 1983'. A second questionnaire in 1989 showed that this advice was partly 
neglected. One third o f the 56 institutions, which responded the questionnaire at that time, 
vaccinated all residents, one third only the residents at risk and one third did not carry out 
any hepatitis B vaccination program at all{Gruyters,1990'. The reasons for neglecting this 
advice were the high costs o f the vaccines, the questions o f some doctors about the 
necessity o f HBV vaccination for institutionalised mentally handicapped persons and the 
fear o f HIV transmission by plasma derived vaccines at that time. In 1991 the advice to 
vaccinate all mentally handicapped persons living in institutions was reiterated by the 
Health Inspection o f the Netherlands {GHIGV/GGZZ,1991'. A third questionnaire was 
sent in 1993 to all Dutch residential and non-residential organisations providing care for 
mentally handicapped individuals to re-evaluate the hepatitis B prevention policy. This 
questionnaire generated substantial information about hepatitis B infection and prevention 
in the Dutch residential institutions. However, it became clear that hardly any data about 
hepatitis B were available on mentally handicapped persons who live outside the residential 
institutions. Therefore, the Netherlands Inspection o f Health was not able to give any 
advice on hepatitis B prevention concerning mentally handicapped persons living at home
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or in small scale facilities such as group-homes and concerning those who attend special 
daytime facilities for mentally handicapped such as schools, day-care centres or sheltered 
workshops. Only a few studies, outside the Netherlands, evaluated this issue, but no firm 
conclusions could be drawn (see chapter 3: Sutnick,1968; Ferris,1972; Bakal,1980; 
Williams,1983; Perillo,1984; Renner,1985; Remis,1987; Ellis,1990; Pueshell,1991; 
Devlin,1993;). In 1994 the Health Inspection of the Netherlands initiated HBV prevalence 
studies outside the general residential institutions. The results o f these studies are presented 
in this chapter. The prevalence o f HBV in Dutch mentally handicapped individuals is 
correlated to environmental factors and individual risk factors. Data were obtained from the 
questionnaire in 1993 and a serological examination in 1994.
Methods
About 100,000 people in the Netherlands have a mental handicap which requires special 
care. The facilities for living and daytime activities are different and depend mainly on the 
degree o f the handicap. General descriptions o f the living conditions and daytime facilities 
o f the mentally handicapped in the Netherlands are given in Table 4.1 and 4.2. Part o f them 
were studied in 1993 and 1994.
Questionnaire and serological examination
In 1993 a questionnaire was sent to all physicians, working in organisations, providing care 
for people with a mental handicap. The questionnaire contained questions about the size of 
the centre; characteristics o f the centre like distribution o f gender, age, incidence o f Down’s 
syndrome, degree o f mental handicap and about the results o f HBV screening and 
vaccination programs for residents and staff. Only centres with all their residents screened 
were included in the study.
A serological examination of HBV-markers was performed in 1994 in people who were 
living at home, in group-homes or in institutions for mild mentally handicapped youngsters 
or people attending day-care centres or sheltered workshops. It was concluded that a 
research pool o f about 1,500 people would be sufficient to get accurate information of the 
HBV prevalence in the group o f about 70,000 non-institutionalised mentally handicapped 
people in the Netherlands. Only persons older than 10 years o f age participated in the study. 
Five organisations providing care for persons with a mental handicap, in different areas in 
the Netherlands, participated in the study: two organisations, consisting o f group-homes and 
day-care centres: WODAGG (now part o f Vizier) in Noord-Brabant and NOVO in 
Groningen; one organisation with only day-care centres: AGO in Amsterdam; one sheltered 
workshop: INTOS in Gennep (Limburg); and one institution for people with a mild 
mentally handicap: Groot Emaus in Ermelo (Gelderland). On behalf o f the board of 
directors, informed consent was asked for all 2,025 clients or their legal representatives.
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Table 4.1 Different living conditions for people with a mental handicap in 
Netherlands
Home or fosterhom e
About 50,000 people with a mental handicap live independent, at home with their family or in foster-homes 
(1997:48,800).
Residential institutions.
Institutions specially established for mentally handicapped people. In these institutions people are living in 
groups with about 6 - 1 2  residents. Several groups together are housed in one building. The buildings are 
situated together on a segregated terrain. There are many central facilities as kitchen, laundry, swimming pool, 
manege, playground, dentistry, doctor’s office, hairdresser, day-care centre, etc.
Residential institutions can be divided into
General institutions (119), where people with all degrees o f mental handicap and all ages live together, 
including many people with Down’s syndrome. The number o f residents varies from 150 to 1200. About 30,000 
people with a mental handicap are housed in general institutions (1997: 32,112).
Special institutions (11). 9 Institutions for abo ut 1,200 people with a mental handicap combined with a 
severe visual, motoric, or auditive handicap (1997:1,227) and 2 institutions for about 900 people with epilepsy, 
from whom are many mentally handicapped too. The number o f residents with Down’s syndrome is mostly low 
in the special institutions, because attendant handicaps in Down’s syndrome are usually not so severe, that 
admission in a special institutions is indicated.
Institutions (22) for people with a mild mentally handicap with 2,000 places (1997 : 2,126). Most residents are 
adolescents and have behaviour disorders. Hardly any persons with Down’s syndrome live in these institutions.
Observation institution (1) for 120 mentally handicapped children with behaviour problems.
Group-homes
Group-homes are houses for 2-24 people with a mental handicap. The houses are situated within the community. 
Central facilities don’t consist. Residents work in sheltered workshops or visit special day-care centres. About 
17,000 people (1997: 16,701) live in 601 houses. Many ofthem  have Down’s syndrome.
Short stay houses (29) where about 350 people (1997:346) with a mental handicap stay for only a few months.
Sources:
VGN/Associated organisations for the Care for the handicapped in the Netherlands; Annual report 1997 
NZI/National Hospital Institute; Financial Statistic 1997
Table 4.2 Different daytime facilities for people with a mental handicap in the 
Netherlands
D ay-care centers
Within the community; most attendants live at home or in a group-home
109 Day-care centres for about 4,000 children with a mental handicap (1997:4209)
242 Day-care centres for about 12,000 adult people with a mental handicap (1997:11.901)
Residential day-care centres on the terrain’s of the institutions. The attendants of these centres are mostly 
residents of the institutions, but nowadays also people living at home or in a group-home attend residential day­
care centres.
Sheltered, workshops
People with a handicap can obtainjobs in one of the 101 sheltered workshops. About 28,000 people with a 
mental handicap have find ajob in such workshops. Often they work together with other disabled.
Schools
Special schools (444) for mild and moderate mentally handicapped children, from 5 until 20 years of age.
About 30,000 children attend these schools (1997: 7,375 moderate mentally handicapped students and 23,613 
mildly handicapped students)
Sources:
VGN/Associated organisations for the Care for the handicapped in the Netherlands; Annual report 1997 
N.O.S.W/Netherlands Organisation for Sheltered Workshops; Annual report 1997 
“Primair onderwijs in cijfers”. Ministry of Education 1997.
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From the persons who consented to participate, blood samples were taken and examined for 
HBV-markers. Blood samples were taken in the group-home, the institution, the day-care 
centre or the sheltered workshop. All blood samples were tested for antibodies against 
hepatitis core antigen (anti-HBc). Anti-HBc positive samples were tested for hepatitis B 
surface antigen (HBsAg) and antibodies against hepatitis B surface antigen (anti-HBs). In 
the HBsAg positive blood samples hepatitis B e antigen (HBeAg) and antibodies against 
hepatitis B e antigen (anti-HBe) were also assessed. All tests were performed in the 
Department o f Virology o f the University Hospital in Nijmegen. The Abbot IMX test was 
used.
In addition to the serological testing also a written questionnaire regarding (previous) living 
and daytime conditions, age, gender, cause o f mental handicap, degree o f mental handicap, 
history o f institutionalisation and country o f birth was sent to each participant. The 
questionnaire contained also questions about whether a person had ever been in contact with 
HBV in the past, had ever had a blood transfusion or had been treated with blood products 
and whether this person had had sexual contacts. Because these questions were hardly 
answered these items could not be incorporated in the data analyses. In most cases a staff 
member, but sometimes the parents or other family members filled out the questions. 
General information such as the size o f the group, distribution o f gender and age, number of 
persons having Down’s syndrome and distribution regarding degree o f handicap, was 
obtained from all participating facilities.
Results
Questionnaire based H B V  prevalence in general institutions fo r  the mentally handicapped 
in the Netherlands
Thirty-two general institutions (33%) o f all general institutions in the Netherlands answered 
the 1993 questionnaire completely. Data were collected from 14,698 people with a mental 
handicap, almost 50% o f all residents o f the Dutch institutions. Blood tests had been taken 
between 1980 and 1993. The results are summarised in Table 4.3. O f the investigated 
population 55% was male and 16% had Down’s syndrome. On average 28.8% o f the 
residents had HBV-markers and 3.8% were HBV carriers. In the 5 small institutions (<250 
residents) 11.4% o f the residents had HBV-markers and 2.2% was HBV carrier. The 
average prevalences were 28 and 4.2% respectively in the 14 medium sized institutions 
(250-500 residents). Positive HBV serology was detected in 31.5% o f the residents o f the 
13 large institutions where 3.8 % was HBV carrier. The percentages o f Down’s syndrome 
residents were about the same in the small, medium sized and large institutions, so were the 
percentages o f males. A low prevalence of HBV carriers (d  1%) was found in 5 institutions 
(three small ones, one medium sized and one large institution). Intermediate high 
prevalences (between 2% and 7% carriers) were found in 23 institutions and high 
prevalences ( t  8% HBV carriers) in 4 institutions (2 medium and 2 large ones).
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Table 4.3 HBV prevalence in people with a mental handicap living in different facilities in the Netherlands: results of the 1993 
questionnaire and the 1994 serological examination
Living conditions Number facilities/ 
Number residents 
in the Netherlands 
approximately
Number of 
responding 
facilities
Size of
responding
facilities
Number 
of persons 
tested
Down’s
syndrome
(%)
Daytime 
conditions *
Age
range
m/f (%) HBV
markers (%) 
range
HBsAg
(%)
range
Group-homes*** 600/17,000 30 3-38 5)1 13 dfg 10-45 54/46 5.5 0.6
General institutions* * 120/30,000 32 150-1,000 14,698 16 cdefg all 55/45 28.8 3.8
small * * 5 150-250 994 17.8 cdefg all 55/45 11.4
0.8-19
2.2
0-4
medium  * * 14 250-500 5,404 18.3 cdefg all 52/48 28.0
1.8-86
4.2
0.8-12
large ** 13 500-1,000 8,300 14.5 cdefg all 58/42 31.5
7-60
3.8
0.7-11
Special 
institutions **
11/2,000 3 60-450 942 1.2 cdefg all 56/44 7.1 0.4
Institution for 
mild mentally 
handicapped***
22/2,000 1 24S 219 0 dfg 14-22 75/20 1 0.5
* Daytime conditions:
c) residential facility (school* day-care centre)
d) school
e) day-care centre for children
f) sheltered workshop
g) day-care centre adults
h) not or not known
** Results from a questionnaire
* * *  Results from the serological testing
L/n
Questionnaire based H B V prevalence in special institutions fo r  the mentally handicapped 
in the Netherlands
Three o f the nine special institutions answered the 1993 questionnaire completely. One 
institution was specialised in epilepsy, one in visual handicaps and one in hearing 
handicaps. Data were obtained from 942 residents. The percentage o f the investigated 
residents with Down’s syndrome was 1.2% and 56% were male. It appeared that 7.1% of 
all investigated residents o f the special institutions had positive HBV-markers, and 0.4% 
were HBV carriers (Table 4.3).
Serological examination
Legal representatives o f 1,351 mentally handicapped persons, belonging to the 5 
participating organisations, consented for participation in this study. Some o f the 
participants lived in one o f the participating group-homes and attended during daytime one 
of the participating day-care centres or the sheltered workshop. The characteristics o f the 
studied population and of the included living and day-care facilities are shown in Table 4.4. 
The characteristics o f the total study population were the following: 58% was male, 16% 
had Down’s syndrome. Most were moderately (52%) or mildly handicapped (40%), 5% 
were or had been institutionalised in the past and 9% originated from a country with an 
intermediate high or high prevalence of HBV. The results o f serological testing were as 
follows. O f the 1,351 persons examined, 1,283 (95%) showed no HBV-markers at all and 
68 were anti-HBc positive (5%) (Table 4.4). Twelve of the 68 anti-HBc positive persons 
(0.9%) were also HBsAg positive, which means that they were carrier. Three HBV carriers 
were probably very contagious because they showed HBeAg. Fifty-three persons were 
positive for anti-HBs. Three anti-HBc positive persons did not show HBsAg or anti-HBs. 
Two o f them were infected in the past, because anti-HBe could be detected. In one person 
anti-HBc was the only HBV marker.
Information on the living conditions was available for 1,315 participants. Six hundred and 
sixty-eight persons lived in a group-home. Most o f them (511) lived in one o f the 
participating group-homes, the remaining 157 lived in other group-homes, scattered all over 
the different regions. Two hundred and nineteen individuals lived in an institution for mild 
mentally handicapped and 15 persons in a general institution. From the 415 persons, living 
at home (independent, with their family or in a foster home) 6.8% showed HBV-markers 
and 0.7% was HBV-carrier.
O f the 1,351 tested mentally handicapped persons, 1,269 went during daytime to facilities in 
the community: 771 to a day-care centre for adults and 768 o f them to one o f the 
participating day-care centres; 281 persons were working in a sheltered workshop and 146 
children visited a special school. The 146 school children, all between 10 and 20 years old, 
attended different schools. They lived in the participating institution for mildly handicapped 
young people or in one o f the participating group-homes for youngsters. Three o f all school 
children (2%) showed anti-HBc, and 2 (1.4%) appeared to be HBV
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carriers. From 281 participants it was known that they worked in a sheltered workshop, 68 
in the participating workshop (Table 4.4). The other 173 living in one o f the participating 
group-homes, worked in different workshops scattered throughout the regions. Seventeen 
(6.1%) o f all tested labourers showed HBV-markers and 4 (1.4%) were HBV carriers.
Table 4.4 Characteristics of the 1994 serological tested
Whole
study
group
Group-
homes
Institution for 
mildly 
mentally 
handicapped
Day-care
centre
Sheltered workshop 
non-institutionalised 
labourers/ 
(institutionalised 
labourers *)
Number studied facilities 30 1 21 1
Number persons 2,025 787 248 1,219 96 (173)
Number tested persons 1,351 511 ** 219 768 ** 68 ** (173)
Mean age 33 16/45 18 36 36 (38)
m /f (%) 58/42 54/46 75/25 48/52 91/9 (92/8)
Down’s syndrome (%) 18 13 0 28 6 (21)
Degree o f mental handicap:
profound/severe (%) 8 6 0 13 0 (0)
moderate (%) 52 53 0 73 34 (89)
mild (%) 40 41 100 14 66 (11)
(Ever) institutionalised (%) 5 n.a. 1 n.a 12 (100)
Country o f  origin: n.a n.a n.a n.a n.a
low prevalence (%) 91
intermediate prevalence (%) 7
high prevalence (%) 2
Anti-HBc positive (%) 5 3.7 0.9 5.7 16.2 (58.3)
HBsAg positive (%) 0.9 0.6 0.5 0.8 4.4 (7.5)
* Institutionalised labourers were tested for HBV-markers before
** From the 511 tested persons living in a group-home, 200 attended also one o f the included day-care centres 
and 15 worked in the included sheltered workshop 
n.a: not available
H B V  prevalence in group-homes fo r  the mentally handicapped
Thirty group-homes, 5% o f all group-homes in the Netherlands, participated in this study. 
Two homes were established for children and adolescents, the others for adults. Sixty- five 
percent (511) o f the residents o f the participating group-homes had given consent. The 
mean age in the group-homes for youngsters was 16 years, in the other group-homes it was 
45 years. The percentage o f males was 53. Thirteen percent had Down’s syndrome. The 
degree o f the mental handicap was moderate in 53% or mild in 41%. In 19 persons (3.7%) 
HBV-markers were detected, 3 persons appeared to be carrier o f HBV. The carriers lived in 
different houses. (Table 4.3 and more details in Table 4.4).
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HBVprevalence in an institutionfor the mildly mentally handicapped 
The institution for mildly handicapped young people consisted o f 13 living units, 7 close 
together on one terrain, 3 in the nearby village and 3 in other parts o f the country. Eighty- 
eight percent (219) o f all residents participated in the serological survey. The mean age was 
18 years; 74% were male. All were mildly handicapped. Nobody had Down’s syndrome. 
Two persons had HBV-markers, one o f them was an HBV carrier (Table 4.3 and more 
details in Table 4.4).
H B V  prevalence in day-care centres fo r  the mentally handicapped
Twenty-one day-care centres for mentally handicapped adults, 10% o f all that particular 
type o f centre in the Netherlands, participated in this study. The day care-centres provided 
care for 1,219 people. Informed consent was given for 768 o f them (63%). The mean age of 
the participants was 36 years; 48% were male, 28% had Down’s syndrome. The degree of 
the mental handicap was severe in 13%, moderate in 73% and mild in 14% o f the 
participants. Forty-four (5.7%) showed HBV-markers, 6 persons (0.8%) were HBV carriers 
(Table 4.4).
H B V  prevalence in a sheltered workshop fo r  the mentally handicapped 
One sheltered workshop participated in this study. It provided work for 269 labourers with a 
mental handicap. Most o f them, 173 (64%) lived in a nearby residential institution where 
they were tested for HBV-markers before. It was known that 101 o f them (58.3%) had 
HBV-markers and 13 (7.5%) were HBV carrier. The other 96 labourers lived at home or in 
a group-home. Sixty-eight (64%) consented in participation. Their mean age was 36 years, 
91% were male, 6% had Down’s syndrome, 34% were moderately handicapped, 66% 
severe. Eleven labourers (16.2%) showed HBV-markers, 3 (4.4%) o f them were HBV 
carriers (Table 4.4).
Contributing risk factors o f  H BV infection
With the outcomes o f the serological examination, performed in 1994, it was possible to 
analyse the relationship between HBV-markers and population characteristics. Table 4.5 
shows the potential contributing risk factors for HBV infection. Persons were classified as 
infected by HBV when they were anti-HBc positive, whether or not cured. It appeared that 
persons who were anti-HBc positive were more often male, had Down’s syndrome more 
often, had a more severe degree of mental retardation, were more often (ever) 
institutionalised and originated more often from a country with a high prevalence of 
hepatitis B. The same applied for those positive for HBsAg, except that none o f the HBsAg 
carriers had ever been institutionalised.
Table 4.6 shows the results o f a multivariate logistic regression analysis for the determinants 
o f a higher risk o f hepatitis B transmission in the total study population. Persons o f age 30­
49 years had a significantly higher risk o f hepatitis B transmission than
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Table 4.5 Differences in characteristics for infected and non-infected contributors 
in a non-institutionalised study population, univariately tested.
HBsAg positive Anti-HBc positive Not infected 
n=12 n=68 n=1283
Mean age (sd) 33.8 34.6 34.3
Gender
m ale 8 67% 45 67% 722 56%
female 4 33% 23 33%  561 44%
D ow n’s syndrome
no 7 58% 49 72% 1074 84%
yes 5 42% 19 28% 209 16%
Degree o f retardation
severe/profound 3 25% 11 16% 101 8%
m oderate 5 42% 40 59% 664 52%
m ild 4 33% 17 25% 518 4%
Ever institutionalised
yes 0 0% 8 12% 50 4%
no 12 100% 60 88% 1233 96%
Country o f  birth
low prevalence 9 75% 55 81% 1148 89%
medium  prevalence 2 17% 10 15% 86 7%
high prevalence 1 8% 3 4% 18 1%
Table 4.6 Multivariate analyses of determinants of the risk of transmission of
(anti-HBc positive) within a non-institutionalised study
Determinant Odds ratio 95% Cl
Age
10-29 year 1 Reference category
30-39 year 3.5 1.7 - 7.1
40-49 year 3.0 .5
CO
> 5 0  year 0.8 .7
CNCO0
Gender
male 1.9 1.1 -3 .4
female 1 Reference category
Down’s syndrome
no 1 Reference category
yes 2.0 1 .0 -3 .7
Degree o f retardation
mild 1 Reference category
moderate 1.1 0.5 -2 .3
severe/profound 2.1 0.8 -5 .7
Ever institutionalised
no 1 Reference category
yes 4.0 1 .7 -9 .5
Country o f birth
low prevalence 1 Reference category
medium prevalence 5.4 2.3 -12 .6
high prevalence 5.4 1 .4-20 .7
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persons under age 30 (odds ratio30-39 =3.5 , 95% Cl: 1.7 - 7.1; OR40-49 =3.0, 95% Cl: 1.3 - 
2.7). Persons over age 50 had no elevated risk for hepatitis B transmission. It appeared that 
males had almost two times higher risk conditional on all other possible contributing 
determinants for HBV transmission (OR = 1.9; 95% CI: 1.1-3.4) and so did have persons 
with Down’s syndrome (OR = 2.0; 95% CI: 1.0-3.7). Persons who had ever lived in an 
institution had a 4 times higher risk o f HBV transmission (OR = 4.0; 95% CI: 1.7-7.9), and 
persons who were born in a country with a medium or high prevalence o f hepatitis B had an 
even 5.4 times higher risk o f HBV transmission (ORmedium= 5.4; 95% CI: 2.3-12.6; O R ig  = 
1.4-20.7).
Discussion
The results from the questionnaire distributed in 1993 shows an intermediately high 
prevalence o f HBV carriers among the mentally handicapped residents o f the Dutch 
residential institutions. In these institutions the average percentage o f HBV marker positive 
residents appeared to be 28.8%, the average percentage o f HBV carriers 3.8%. The 
prevalence o f HBV carriers is lower than the previously reported prevalence o f 5.3% in 
1982. Nevertheless, it cannot be concluded that the prevalence o f the HBV carrier rate is 
declined during this decade for the following reason. In 1982, mainly large institutions 
responded to the questionnaire and in 1993 the large institutions as well as the medium 
sized and small institutions responded. In small institutions with less than 250 residents the 
average percentage o f HBV carriers was 2.1%. In medium-sized institutions (between 250 
and 500 residents) and large institutions (more than 500 residents) the median percentages 
o f HBV carriers were 4.2% respectively 3.8%. Fifteen percent o f the institutions showed a 
low HBV prevalence (mostly small institutions), 75% an intermediate and 12% a high 
prevalence (medium and large institutions). The characteristics o f the residential population 
in the small, medium and large general institutions are about the same. Mentally 
handicapped people of all ages are resident with varying degrees o f mental handicap. There 
are more males than females and the percentage o f Down’s syndrome is usually between 15 
and 20%. The risk for HBV transmission in medium and large institutions seems to be 
somewhat higher than in small institutions.
In the special institutions the prevalence o f hepatitis B is similar to the general prevalence in 
the Netherlands. The difference in hepatitis B prevalence in special institutions compared 
with the general institutions might be due to differences in population characteristics, e.g. 
the percentage o f Down’s syndrome which is much lower in special institutions than in 
general institutions. The reason for this is that attendant handicaps in Down’s syndrome are 
usually not that severe, thus admission in a special institution is not warranted.
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In only one institution for mild the mentally handicapped was the HBV prevalence 
examined. Despite the presence o f many risk factors such as changing sexual contacts, drug 
abuse and coming from high endemic countries, the HBV prevalence appeared to be very 
low. One can imagine that mild mentally handicapped people can take rather good care of 
their own hygiene. Besides that, the time o f institutionalisation is rather short, usually less 
than 2 years and there are no persons with Down’s syndrome living in these institutions. 
Among the non-institutionalised mentally handicapped persons, i.e. those who live at home 
or in group-homes, the HBV prevalence was low. Three out o f 511 tested persons, living in 
30 group-homes appeared to be HBV carrier. The carriers were living in different houses. In 
all cases one or two house-mates o f these carriers showed antibodies against HBV.
The 21 participating day-care centres show an average HBV marker prevalence o f 5.4%. 
Six o f the 768 tested persons were HBV carrier. Three were attending the same day-care 
centre. Two o f them were HBeAg positive. Two other attendants showed antibodies against 
HBV. One o f the carriers belonged to a family with more HBV marker positives. The other 
infections might have been occured in the day-care centre, despite the fact that never was 
any clinical infection noticed. Hygienic conditions in the day-care centre could not be 
optimal because o f a population with many profoundly and severely handicapped persons, 
who show often poor hygienic behaviour (see chapter 3).
A remarkable fact was the slightly elevated percentage o f HBV marker positives in one of 
the participating organisations, Groningen: 7.1%. It appeared that 10 o f the 25 marker 
positives lived a few years earlier together in one group-home. HBV transmission had 
probably taken place within that group-home.
Sixty-four percent o f the mentally handicapped labourers in the participating sheltered 
workshop lived in an institution, where HBV was highly endemic (Sint Augustinus- 
stichting, see chapter 5). Fifty-four percent o f them were HBV marker positive. The 
serologic tests o f the non-institutionalised labourers showed a percentage o f 16.2% HBV 
marker positives, 3 o f them were HBV carriers. Reasons for the high transmission in the 
sheltered workshop might be prolonged interpersonal contacts, including (homo)sexual 
contacts, between institutionalised and non-institutionalised labourers.
The above mentioned facts suggest that there is a risk for HBV transmission when mentally 
handicapped have activities, live or work together with HBV carriers. A risk for 
transmission in non-residential facilities for mentally handicapped was earlier 
reported{Williams,1980; Perillo,1984; Breuer,1985; Remis,1987}
Another purpose o f this study was to get insight into the contributing factors that potentially 
elevate the risk o f transmission o f hepatitis B for mentally handicapped people. Studies on 
institutionalised mentally handicapped persons have determined that Down’s syndrome, 
male gender, age, young age at admission and prolonged duration o f institutionalisation are 
risk factors for HBV infection (chapter 3). Having Down’s syndrome was a constantly 
found risk factor, also outside residential institutions (Sutnick,1968; Ferris,1972; 
Bakal,1980; Perillo,1984; Breuer,1985; Renner,1985;
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Ellis,1990; Devlin,1993). In this study persons with Down’s syndrome had a two times 
higher risk for HBV infection, the same risk as we calculated from an international review 
(chapter 3). Furthermore we found that males were more often marker-positive than 
females, which is in agreement with other studies in residential institutions (chapter 3), with 
a longitudinal study in a non-institutionalised population {Breuer,1985}and with a 
prevalence study in the general Dutch population{Grosheide,1991}. Age and degree of 
retardation were in this study also associated with marker-positivity. Age was confirmed in 
other non-institutionalised studies investigating these determinants (Devlin;1993'. The fact 
that only persons between the age o f 30 and 50 years had a higher risk o f HBV-transmission 
can probably be explained by the fact that they have had a longer chance to be infected 
during their life. Furthermore it is an age-group which is sexually active. It appears evident 
that people having a more severe degree of mental retardation are more likely to have been 
institutionalised at some point in their lives. Therefore, the suggested, but statistically not 
significantly, higher risk in these people can be (partly) due to the fact that they have a 
history o f institutionalisation. Furthermore, country o f birth was strongly associated with 
high prevalence o f hepatitis B markers. Having a history o f institutionalisation appeared to 
be one o f the strongest determinants contributing to the higher risk o f hepatitis B infection 
in non-institutionalised mentally handicapped. Others also linked HBV infection in schools 
to earlier institutionalisation {Bakal,1980; Williams,1983; Remis,1987'. Persons who were 
born in a country with medium or high prevalence o f hepatitis B were 5.4 times more often 
HBV marker positive then those who were born in a country with a low prevalence of 
hepatitis B. In the Netherlands it was already known that HBV infection occurs more often 
in certain sections o f the population (Grosheide,1991; Leentvaar-Kuypers,1993).
Finally it was a correct decision to study only individuals older than 10 years o f age. It 
appeared namely that the overall HBV prevalence outside the residential institutions was 
not elevated in mentally handicapped persons older than 10 year so one can expect that the 
prevalence is not higher in younger ones.
Conclusion
From this study it can be concluded that in the Netherlands the risk o f hepatitis B for 
mentally handicapped persons living in general institutions is still substantial. In mentally 
handicapped individuals who live at home or in houses in the community the risk for HBV 
infection is about the same as that o f the Dutch population. Individual risk factors for HBV 
infection are Down’s syndrome, age, male gender, ethnicity and previous 
institutionalisation.
When non-institutionalised mentally handicapped people live, work or share activities with 
other mentally handicapped, who are HBV carriers, there is a risk for transmission.
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It is highly recommend to vaccinate mentally handicapped individuals who live in general 
institutions and all those who live together with HBV carriers outside the institutions. In 
day-care centres, schools or sheltered workshops vaccination is recommended if  one can 
expect that HBV carriers have close contact with attendants who show poor hygienic 
behaviour.
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Chapter 5
Hepatitis B in a residential 
institution for the mentally 
handicapped
Parts o f this chapter have been published in:
van Ditzhuijsen TJ, de Witte-van der Schoot PPM, van Loon AM, Rijntjes PJ, Yap SH. 
Hepatitis B virus infection in an institution for the mentally retarded. Am J Epidemiol 1988; 
128: 629-38.
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Introduction
Residents o f institutions for the mentally handicapped have a high prevalence o f past or 
present hepatitis B virus (HBV) infection and therefore HBV infection has long been 
considered as an almost inevitable, health hazard in those institutions (chapter 3). 
Institutions for mentally handicapped were even regarded by some investigators as an 
excellent model for epidemiological studies o f hepatitis B infection {Szmuness, 1971}.
The formerly Sint Augustinus-stichting (now part o f Vizier in Gennep), used to be a general 
residential institution for about 500, mainly male, mentally handicapped residents in the 
Netherlands. During the seventies, acute clinical hepatitis B infection occurred once or 
twice a year in the handicapped residents o f the institution. By sporadic screening, for 
instance when people were admitted to a hospital, unsuspected persons appeared to be 
carrier o f HBV. Occasionally employees developed acute hepatitis B. Knowledge o f the 
spread o f the infection seemed very important to control HBV transmission in this 
institution. Serological studies o f HBV infection were started in 1980. In 1984 a hepatitis B 
vaccination program was initiated to prevent further transmission. The vaccination response 
and long term immunogenicity o f the vaccinees in the Sint Augustinus-stichting is been 
reported in chapter 6 o f this thesis.
This study describes the epidemiology o f acute and chronic HBV infection in an institution 
for mainly male handicapped persons in the Netherlands during a period o f 15 years. It 
describes the influence o f knowledge o f the serological HBV-markers, hygienic regulations 
and HBV vaccination on the transmission o f HBV. Special interest is focused on age related 
variables as age, age at admission and duration o f institutionalisation and on Down’s 
syndrome.
Methods
Population
In the middle of 1980 the population o f the institution consisted o f 493 males. Down’s 
syndrome was established in 117 residents (23.7%). The residents ranged in age from 8 to 
65 years and 50% were aged between 25 and 35 years. The degree o f the mental handicap 
was profound in 20% o f the residents, severe in 30%, moderate in 40% and light in 10%. 
Most residents lived in units consisting o f 10 to 12 persons. Three to 6 units were housed in 
one building. The number o f employees was 421.
The population changed a little after 1980. At the end o f 1995 the population consisted of 
502m ales and 7 females. Compared to 1980, about 20% o f the population in 1995 had 
changed because o f new admissions (93), deaths (30) and discharges (47). The average age 
had increased 10 years since 1980 because most residents continued to live within the 
institution. The prevalences o f Down’s syndrome and the degrees o f the mental handicap
67
did not change during that period. In 1995 the number o f employees had increased to 688. 
This increase was partly caused by higher financial resources and partly by more part time 
employees.
Before 1980 the awareness o f the high transmission o f HBV in the institution was absent 
and the hygienic control was low. Toothbrushes and shavers were shared regularly. Because 
quite a few mentally handicapped refuse bandages, wounds of carriers were not always 
covered. Unsafe (homo)sexual activities occurred.
Serological testing
In 1980 serum specimens have been collected from all residents, 493 mentally handicapped 
males. The specimens were examined for HBsAg, anti-HBc and anti-HBs. HBsAg positive 
samples were further examined for the presence o f HBeAg and anti-HBe. These serological 
HBV-markers were determined by commercial radioimmunoassays or enzyme-linked 
immunosorbent assays (Abbott IMX). All specimens were coded and stored. Most o f those 
specimens were retested in 1986 for the presence o f hepatitis B virus DNA 
In 1983 the survey was extended to the known HBV carriers, to all residents who in 1980 
had no serological signs o f past HBV infection, to newly admitted persons and to the 
employees. The known HBsAg positive sera were tested for HBsAg and when still positive 
also for HBeAg and anti-HBe or when became HBsAg negative for anti-HBs. All other sera 
were tested for anti-HBc. Anti-HBc positive sera were tested for anti-HBs and HBsAg. 
After 1983 the chronic HBV carriers were tested annually for HBsAg, HBeAg, anti-HBe, 
anti-HBs and as assessment for the liver function for alanine amininotransferase (ALAT). 
Newly admitted people were tested for anti-HBc on admission. All tests were performed in 
the Department o f Virology o f the University Hospital in Nijmegen.
Hepatitis B virus DNA hybridisation & Statistical analysis
The detection o f HBV-DNA by means o f a molecular hybridisation technique in this 
population has been described by Van Ditzhuysen in 1988 {Van Ditzhuysen, 1988'.
For the statistical comparison of the prevalence of serologic data between groups, we used 
the Mantel-Haenszel chi-square test {Mantel, 1959'. Differences in age, duration of 
residency and age at residency were tested by means o f the unpaired Wilcoxon test.
Results
Prevalence o f  hepatitis B serologic markers in mentally handicapped residents 
The distribution o f serologic markers o f HBV infection in the 493 male residents is shown 
in Table 5.1. In 1980, 306 (62.1%) o f the 493 residents were positive for one or more HBV- 
markers and showed therefore serologic evidence o f past or current HBV infection. Fifty- 
one (16.7 % o f these 306 residents or 10.3% o f all residents) were positive for HBsAg. 
Twenty HBV carriers (39.2%) were HBeAg positive. Anti-HBc is, as shown in
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Table 5.1, a suitable marker for the detection o f past or present HBV infection because in 
more than 98% the presence o f HBsAg or anti-HBs is associated with the presence o f anti- 
HBc. After the screening in 1980, we decided to use anti-HBc as test marker for HBV 
infection in the future.
Table 5.1 Distribution of HBV-markers in 493 mentally male handicapped residents in 
1980
HBsAg + HBsAg + HBsAg - HBsAg -
Anti-HBs - Anti-HBs + Anti-HBs + Anti-HBs -
Anti-HBc positive (a) 50 (b)l (c) 247 (d) 3
Anti-HBc negative 0 0 (e) 5 (f) 187
(a): HBV carriers: 50
(b): HBV carrier, developing antibodies: 1;
at retesting in 1983: HBsAg neg, anti-HBs pos
(c): past infection: 247
(d): anti-HBc sole marker: 3
at retesting in 1983: one had still anti-HBc as sole marker
one became anti-HBs positive (past infection) 
one became anti HBc negative (false positive in 1980)
(e): anti-HBs sole marker: 5 (suits normally to vaccinated people, probably false positive) 
at retesting in 1983: all appeared to be anti-HBs negative
(f): never infected: 187
Hepatitis B serologic markers in age related factors
As shown in Table 5.2.A, the prevalence o f HBV-markers increased with age up to 30 years 
and decreased afterwards. The percentage o f HBV carriers under the HBV marker positives 
seemed to decrease after 20 years until the age o f 35. These differences were not 
statistically significant.
With regard to age on admission into the institution, the highest prevalence o f HBV- 
markers was observed in those residents who had been admitted at ages 11-15 years. 
However, the proportion o f HBsAg positive subjects in this age group with any HBV 
marker was similar to that o f other age groups (Table 5.2.B). Statistically significant 
differences were only recognised between the prevalence o f any hepatitis B serologic 
markers in the age groups 0-10 and 11-15 years (%2-score = 5.33, df=1) and in de age 
groups 11-15 and>  15 years (%2-score = 20.75, df=1).
Table 5.2.C shows that the prevalence o f HBV-markers was nearly steady up to 10 years of 
institutionalisation, after which a sharp rise occurred. Prevalence o f HBsAg appeared to be 
independent o f the duration o f residency.
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Table 5.2.A Distribution of hepatitis B serologic markers in 493 mentally handicapped
male residents by age
Age(years) Testedresidents positivefor anyHBV HBsAgpositive
„ marker
n % n % with any 
HBV marker
% of all tested sera
0-15 38 4 10.5 1 25.0 2.6
16-20 61 37 60.7 9 24.3 14.8
21-25 113 75 66.4 13 17.3 11.5
26-30 150 114 76.0 16 14.0 10.6
31-35 96 61 63.5 8 13.1 8.3
>35 35 15 15 4 26.7 11.4
Total 493 306 62.0 51 16.7 10.3
Table 5.2.B Distribution of hepatitis B serologic markers in 493 mentally handicapped 
male residents by age at entry
Ageatentry Testedresidents PositiveforanyHBV HBsAgpositive
(years) n marker
n % n % with any 
HBV marker
% of all tested sera
0-10 140 84 60.0 15 17 9 10 7
11-15 226 162 71.7 27 16 7 11 9
> 15 127 60 47.2 9 15 0 7 1
Total 493 306 62.0 51 16 7 10 3
Table 5.2.C Distribution of hepatitis B serologic markers in 493 male handicapped 
residents and duration of residency
Duration of
residency
(years)
Tested
residents
n
Positive for any HBV 
marker
HBsAg positive
n % n % with any 
HBV marker
% of all tested sera
0-5 77 26 33 8 5 19 2 6 4
6-10 89 30 33 7 4 13 3 4 4
11-15 180 145 80 6 24 16 6 13 3
> 15 147 105 71 4 18 17 1 12 2
Total 493 306 62 . 0 51 16 7 10 3
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Table 5.3.A Prevalence of hepatitis B serologic markers by age at entry and Down’s
syndrome versus other mentally handicapped residents
Age at entry (years) Tested
residents
Positive for any HBV 
marker
HBsAg positive
n n % n % with any 
HBV marker
% of all tested 
sera
0-10
Down 34 23 67 7 8 34 8 23 5
Other 36 22 61 1 1 4 5 2 7
11-15
Down 55 45 81 8 15 33 3 27 3
Other 54 39 72 2 5 12 8 9 3
> 15
Down 28 15 53 6 3 20 0 10 7
Other 27 12 44 4 3 25 0 11 1
Total
Down 117 83 70 9 26 31 3 22 2
Other 117 73 62 4 9 12 3 7 7
Table 5.3.B Prevalence ofhepatitis B serologic markers by duration of residency in 
Down’s syndrome versus other mentally handicapped residents
Duration of 
residency (years)
Tested
residents
Positive for any HBV 
maker
HBsAg positive
n n % n % with any 
HBV marker
% of all tested 
sera
0-5
Down 19 8 42 1 2 25 0 10 5
Other 22 7 31 8 1 14 3 4 5
6-10
Down 22 8 36 4 2 25 0 9 1
Other 19 7 36 8 1 14 3 5 3
11-15
Down 40 36 90 0 13 36 1 32 5
Other 37 29 78 4 4 13 8 10 8
16-20
Down 36 31 86 1 9 29 0 25 0
Other 39 30 76 9 3 10 0 7 7
Total
Down 117 83 70 9 26 31 3 22 2
Other 117 73 62 .4 9 12 3 7 7
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Prevalence o f  hepatitis B markers in D ow n’s syndrome
The prevalence of hepatitis B markers in 117 residents with Down’s syndrome was 
compared with that in 117 residents with other forms o f mental handicap by stratification on 
age at entry and duration o f residency (Tables 5.3.A and 5.3.B). Serological evidence for 
exposure to HBV was observed in 70.9 % o f persons with Down’s syndrome and in 62.4% 
o f other mentally handicapped persons. This difference is not statistically significant. 
However, HBsAg carriers status was more prevalent in Down’s syndrome than in other 
residents (31.3% versus 12.3%; p<0.02). The frequency o f one or more HBV-markers in 
each group o f age at entry or duration o f entry was approximately the same for both 
categories o f residents. Nevertheless, prevalence o f HBsAg was significantly higher in 
Down’s syndrome residents than in residents with other causes o f mental handicap when 
they were admitted before the age o f ten years (Table 5.3.A: 3 times higher; %2-score=9.64, 
p<0.003). With regard to length o f residency persons with Down’s syndrome were shown to 
have a higher prevalence o f HBsAg positivity than others in all categories (Table 5.3.B: 3 
times higher; %2-score=5.60, p<0.01).
Hepatitis B virus DNA status in mentally handicapped residents
HBV-DNA was tested in the serum samples o f 490 residents collected in 1980. HBV-DNA 
was found exclusively in HBsAg positive specimens. The total number o f HBsAg positive 
specimens tested for HBV-DNA was 49. Nineteen HBsAg carriers showed HBeAg and 30 
were anti-HBe positive. Twelve o f the 19 HBsAg/HbeAg positive carriers had detectable 
HBV-DNA in serum, whereas HBV-DNA was undetectable in the remaining 7 
HBsAg/HBeAg positive carriers and in the 30 HBsAg/anti-HBe positive carriers.
Nine o f the 12 residents positive for HBV-DNA had Down’s syndrome (37.5% o f 24 
HBsAg positive Down’s syndrome residents), while three o f de HBV-DNA positive carriers 
had other forms o f mental retardation (12 % o f 25 HBsAg positive residents with other 
forms o f mental retardation). The difference in HBV-DNA positivity among HBsAg 
positive Down’s syndrome residents and other mentally handicapped residents appeared to 
be statistically significant (%2-score = 4.218, d f = 1, p<0.05). It is interesting to note that
83.3 % o f HBV-DNA positive persons had been admitted to this institution at ages 11-15 
years, although those who entered at these ages accounted for only 45.8% o f total residents. 
The mean duration o f residency o f HBeAg positive /HBV-DNA positive residents was 
shorter than that o f HBeAg positive/HBV-DNA negative residents (11 versus 19 years); the 
mean age o f HBeAg positive/HBV-DNA positive residents was lower than that o f HBeAg. 
positive/HBV-DNA negative residents (24.5 versus 30 years). These differences were not 
statistically significant (unpaired Wilcoxon test).
Incidence o f  hepatitis B in mentally handicapped residents
After the results o f the serologic screening in 1980 became available, hygienic measures 
were tightened, especially concerning the care o f HBV carriers. During the following 3 
years only one person developed clinical hepatitis B. One hundred seventy-seven persons of
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the group o f 187 HBV marker negative residents (as determined in 1980) were tested for 
anti-HBc in 1983. Twelve o f them had become anti-HBc positive. This means an annual 
attack rate for HBV infection o f 2.3%. Three persons showed anti-HBc as sole marker, 6 
were also positive for anti-HBs, 3 appeared to be HBV carrier (HBsAg positive, HBeAg 
negative).
Table 5.4 Longitudinal follow up of the HBV carriers within a residential institution for 
the mentally handicapped
Year Number
of
residents
HBV carriers 
(n)/percentage of all 
residents
HBe Ag 
positive 
carriers (n)/ 
percentage of 
all carriers
Carriers
newly
infected
Carriers
newly
admitted
Carriers
sero-
converted
Carriers
discharg
ed
Carriers
died
1980 491 Total 51 104 20 39 2
Down 26 16 61 5
Other 25 4 16
1983 516 Total 52 10 1 11 21 2 +3 -1 -1
Down 24 8 33 3 -1 -1
Other 28 3 10 7 +3
1986 513 Total 50 9 7 10 20 + 1 -3
Down 25 10 40 +1
Other 25 1 4 -3
1989 506 Total 46 9 1 5 10 9 -3 -1
Down 25 5 20
Other 21 0 0 -3 -1
1992 506 Total 40 7 9 7 17 5 -4 -1 -1
Down 23 7 30 4 -1 -1
Other 17 0 0 -4
1995 509 Total 42 8 3 4 9 5 +2
Down 25 4 16 +2
Other 17 0 0
Longitudinal follow  up o f  the H B V  carriers
Between 1980 and 1983 one HBsAg positive resident, with Down’s syndrome, died due to 
liver failure. In 1983 specimens from 50 HBsAg residents, positive in 1980 were examined 
for HBsAg, HBeAg and anti-Hbe. Only one HBV carrier (HBe-negative in 1980) showed 
seroconversion to anti-HBs in 1983. After 1983 all HBV carriers were tested every year for 
HBV-markers and ALAT. Table 5.4. shows the three-annually results o f the tests. The 
percentage o f HBV carriers decreased during the fifteen years o f the study slowly from 10.4 
to 8.3%; the percentage o f HBeAg positive carriers from 39.2 to 9.5%. HBeAg positivity 
decreased in Down residents from 61.5 to 16%, in the other residents from 16 to 0%. The 
sera o f 10 HBV carriers, seroconverted to anti-HBs. None o f them had Down’s syndrome.
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Since 1983 three carriers were newly admitted. Three carriers (two with Down’s syndrome) 
developed cirrhosis o f the liver. Two o f them have died.
Longitudinal follow  up o f  those with anti-HBc as sole marker
In 1980 sera o f 3 residents showed anti-HBc as sole HBV marker. At retesting in 1983 one 
o f these residents had become negative for any HBV marker, one showed anti-HBs as well 
and one had still anti-HBc as sole marker. The serum o f this last person was tested annually. 
Finally in 1992 he showed anti-HBs. In 1983, 3 sera which were negative for HBV-markers 
when tested in 1980, showed anti-HBc as sole marker. At retesting in 1986, two o f these 
residents appeared to be negative for any HBV marker and one showed anti-HBs as well. 
Four persons who showed anti-HBc as well as doubtful anti-HBs in 1980, showed anti-HBc 
as a sole marker in 1983. In 1986 they all had become positive for anti-HBs again.
Longitudinal follow  up o f  he H B V  marker negative residents
All 205 residents negative for HBV-markers in 1983 have been vaccinated against hepatitis 
B. Their longitudinal follow up is been reported in chapter 6 o f this thesis. The annual 
attack rate decreased to 0.1% because only 2 vaccinated residents converted to anti-HBc 
within the 6 following years.
Prevalence o f  hepatitis B markers in employees
Most o f the employees, 429 out o f 499, took part o f a serological study to anti-HBc in 1983. 
Twenty-three (5.3%) were positive for anti-HBc. Eighteen showed anti-HBs as well, 5 had 
anti-HBc as sole marker. No one appeared to be HBV carrier. All HBV marker positive 
employees were carers of the residents.
Discussion
This study demonstrates that HBV infection in de Sint Augustinus-stichting was highly 
endemic around 1980 and before. The first screening in 1980 for HBV-markers showed that 
more than 62% o f the mentally handicapped residents o f this institution had serological 
evidence o f past or current HBV infection. The percentage o f HBV carriers in this 
institution was 10.1%. This implies that 16.7% o f those infected with hepatitis B had 
become a chronic carrier. Thirty-nine percent of the carriers showed HBe-Ag as well and 
could be regarded as very infectious. HBV-DNA was detected in 63.2% o f HBe-Ag positive 
serum specimens. HBV-DNA was exclusively found in HBeAg/HBsAg positive carriers 
{Van Ditzhuijsen,1988}. The detected prevalences o f HBV-markers are very high 
compared with an estimated prevalence o f about 4 % past infection and 0.5% HBV carriers 
in the Dutch population {Health Council,1996}. The prevalences were similar to 
contemporary reported prevalences o f 6 to 40% HBV carriers in medium sized and large 
general institutions for mentally handicapped in the USA and in Europe {Blumberg,1967;
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Melartin,1967; Sutnick,1968; Krugman,1970; Vierruci,1970; Goodman,1971; Nordenfelt, 
1971; Skinhoj,1971; Ferris,1972; Hollinger,1972; Szmuness,1972; Dankert,1973; Bruining, 
1974; Tiku,1976; Chaudhary,1977; Kingham,1978; MacMillan,79; chapter 3}. Compared 
to the prevalences o f other Dutch institutions in the early eighties the prevalence, observed 
in the Sint Augustinus-stichting was rather high. A questionnaire taken in 1982 reported 
percentages from 0 to 13.8% HBV carriers in Dutch institutions for mentally handicapped, 
with an average percentage o f 5.3% {NVAZ,1983; chapter 4 '.
The percentages o f HBV-marker positive residents in this study increased to the age of 
about 30 and decreased slowly afterwards. Other investigators reported the same tendency 
{Hollinger,1972; Szmuness,1972; Wagemans,1985; Devlin,1993'. At older age the period 
of possible exposition to HBV is longer and the chance to become HBV marker positive 
increases. At the other hand we observed a remarkable fall in HBV marker positivity after 
the age of 35 years. It might be possible that at the time the endemic started, probably 10 to 
15 years before, these persons where not that young anymore and therefore less susceptible 
for HBV infection. A reduction in HBsAg carrier rate with increasing age is both described 
in the general population {Szmuness,1975' as well as in institutions for mentally 
handicapped {Sutnick,1968; Krugman,1970; Szmuness,1970; Szmuness,1972; Skinhoj, 
1972; Clarke,1984; Wagemans,1985; Lohyia,1986; Devuyst,1993). This fall can be 
explained by the higher risk o f children to develop a chronic HBV infection and by a 
tendency o f the chronic carriers to recover ultimately (chapter 2). This study shows, as 
many other studies did, that the prevalence o f HBV-markers is higher in persons who are 
admitted at younger ages and who are admitted for a longer period {Krugman,1970; 
Szmuness,1972; Dankert,1973; Chaudhary,1976; Wagemans,1985; Schoub,1993'. The 
explanation for this is that the younger someone is, and the longer someone stays in an 
endemic environment, the chance increases is to become infected with HBV, usually 
horizontally but also sexually. In this study the highest HBV marker prevalence rate was 
observed in the children who were admitted when they were between 11 and 15 years old, 
not when they were younger at admission. Children admitted at younger age in the Sint 
Auginstinus-stichting were mostly between 7 and 10 at entree. They might need some time 
for infection. Another reason for the higher prevalence in those admitted between the age of 
11 and 15 years might be the fact that most o f these children had lived in a nearby 
institution before, where hepatitis B was also endemic. They had to move when they had 
become 12 years old, because that other institution was established for young children and 
females only.
In this institution, where HBV infection appeared to be highly endemic, we demonstrated 
that Down’s syndrome residents (overall) slightly more often had HBV-markers than other 
mentally handicapped residents (70.1 and 59.6% respectively), although the differences are 
not significant statistically. This deviates from the in chapter 3 o f this thesis calculated 2 
times more prevalence o f HBV infections in Down’s syndrome. In addition, Down’s 
syndrome residents had a significantly higher (31.7%) prevalence o f HBsAg than other 
mentally handicapped residents (11.2%) and more often had markers indicative o f active
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viral replication. HBeAg could be detected in: 61.5% for Down’s syndrome versus 16.0% 
for other mentally handicapped persons and HBV- DNA in 37.5% for Down’s syndrome 
versus 12.0% for other mentally handicapped persons. These findings are consistent with 
most studies presented in chapter 3. The HBsAg carrier status in Down’s syndrome 
residents aged 0-10 years on admission was found to be significantly higher than in the 
other categories. This finding indicates that Down’s syndrome residents at young age are 
more susceptible to HBV carriership than other mentally handicapped people. Persons with 
Down’s syndrome were also significantly more HBsAg positive than others regarding the 
length o f institutionalisation. This means that the carrier status in Down’s syndrome persists 
longer compared with other mentally handicapped. Because the environmental conditions 
were identical for both categories this observation can only be explained by impaired 
immune responses to the HBV in people with Down’s syndrome.
The risk for HBV-marker negative residents o f acquiring serologic evidence o f hepatitis B 
infection from 1980 to 1983 was 2.3 per cent per year (12 o f 177 residents within 3 years). 
This is much higher than an estimated annual attack rate o f less than 0.05% for a Northern 
Western European population {Roure,1995}. Only one o f these 12 had developed a clinical 
hepatitis B, the others had not shown any clinical sign o f HBV infection. This resembles to 
the icteric/anicteric infection rate o f 1/26 mentioned by Szmuness {Szmuness, 1972}. No 
one o f the newly admitted residents between 1980 and 1983 showed HBV-markers.
From 1980 to 1995 the percentage o f HBV carriers decreased from 10.4% to 8.3%. 
Meanwhile the HBV infection had almost burnt out because the percentage o f HBeAg 
positive carriers decreased from 61.5% to 16% in Down’s syndrome and from 39.2% to 0% 
in other mentally handicapped. Seroconversion to anti-HBs was much less in Down’s 
syndrome carriers (3.8%) than in others (40%). Between 1980 and 1983 three residents 
became HBV carrier. After the vaccination program was started in 1984 none o f the 
residents became HBV carrier anymore. New carriers were detected only ad admission. 
Hepatic cirrhosis was diagnosed in 4 patients, three of them died.
O f the 10 persons who showed anti-HBc as sole marker at any time, three appeared to be 
negative after retesting and were probably false positive before, 4 had become in a stage of 
late recovery, 2 were probably recovering or had recovered from an acute or chronic 
infection because they showed anti-HBs at the next screening. One person developed anti 
HBs 10 years later. He might either have been infectious all that time or he was not able to 
develop antibodies. Vrijmoeth claims that persons, who show anti-HBc as sole marker in 
their serum repeatedly, should be investigated for HBV-DNA on HBV carriership and if 
negative to be vaccinated because they are probably in a situation that they cannot develop 
antibodies {Vrijmoeth,1997}.
HBV-markers could be detected in 5.3% o f the employees. No one appeared to be HBV 
carrier. HBV-markers were only detected in staff who were involved in the daily care o f the 
residents, not in others like administration or management. This suggests that in this 
institution transmission o f HBV occurred between the residents and their carers.
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Conclusion
A screening in 1980 revealed that the Sint Augustinus-stichting (now part o f Vizier, 
Gennep) appeared to be an institution with a high endemic rate o f hepatitis B infection. A 
combination o f constitutional determinants, behaviour conditions and a lack o f knowledge 
about the disease has caused this situation. First the relatively high percentage (23) of 
persons with Down’s syndrome. Down’s syndrome forms a risk factor by itself. They have a 
high risk to develop a chronic hepatitis B and to become a HBV carrier for a long time. It 
was noticed that seroconversion to anti-HBe, and subsequently to anti-HBs takes more time 
in persons with Down’s syndrome than in other mentally handicapped, infected with HBV. 
Secondly all residents were male, who also have a higher risk for chronic hepatitis. 
Furthermore, before1980 many mentally handicapped were admitted to the institution at 
young age. High risk conditions which facilitated HBV infection within this highly endemic 
situation were the poor hygienic behaviour o f many mentally handicapped residents, 
including unprotected (homo) sexual activities. Hygienic regulations reduced the incidence 
o f icteric hepatitis B from one or two patients a year before 1980 to one patient in 3 years 
between 1980 and 1983. The icteric/anicteric rate for HBV infection appeared to be 1/11 
during that 3 year period. In contrast to the period before 1980, no clinical infections in 
personnel were noticed anymore. After a vaccination program, for all HBV-marker negative 
mentally handicapped residents and care-taking staff was started in 1983, the annual attack 
rate for HBV infection in the mentally handicapped residents has decreased from 2.3% 
between 1980 and 1983 to 0.1% between 1983 and1995. Meanwhile the percentage of 
HBeAg positive carriers has decreased from 39.2% in1980 to 9.5% in 1995. It can be 
concluded that the hepatitis B endemic in the Sint Augustinus-stichting has become under 
control, partly through better hygienic regulations, but mainly after implementation o f a 
successful vaccination programme.
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Chapter 6
Hepatitis B vaccination in 
the mentally handicapped: 
response, long-term 
immunogenicity and efficacy

Introduction
Hepatitis B virus (HBV) infections are a significant health risk for persons with a mental 
handicap living in residential institutions. Numerous surveys have documented the relatively 
high risk o f HBV transmission in this population, as described in chapters 3, 4 and 5 o f this 
thesis. This phenomenon is mainly caused by two factors: the high number o f residents with 
Down’s syndrome and the insufficient hygienic conditions in those institutions. Persons 
with Down’s syndrome have defects in their immune system, leading to a high chance for 
asymptomatic hepatitis and persisting HBV infection. This facilitates the spread o f the 
disease, especially in circumstances o f insufficient personal hygiene. Insufficient hygiene is 
inevitable to some extent due to hazardous behavioural characteristics and frequent close 
interpersonal contacts (chapter 3).
Studies on active immunisation against hepatitis B were initiated by Krugman et al. in 1970 
in an institution for mentally handicapped people where hepatitis B infection was highly 
endemic {Krugman,1970; Krugman,1971'. They inoculated mentally handicapped persons 
with heated and unheated diluted carrier serum. Those who received the unheated serum 
developed clinical hepatitis B in contrast to those who received the heated serum. However, 
this latter group developed high titres o f antibodies against HBV.
In 1982 a plasma derived vaccine and in 1986 a recombinant vaccine came available, which 
made active immunisation possible. Hepatitis B vaccines are among the safest vaccines 
available. The recommended series o f three intramuscular doses o f hepatitis B vaccine 
induces a protective antibody titre (i.e. anti-HBs concentrations t  10 IU/l) in over 90% of 
healthy adults and in over 95% o f infants and adolescents {Szmuness,1980; 
Szmuness,1981; Zajac,1986; Andre,1989'. The anti-HBs response is reduced in persons 
over 40 years or otherwise immuno-compromised {Stevens,1984; Wood,1993; 
Clements,1994}. Approximately 50% o f the people who do not develop antibodies after a 
three dose series will do so after one to three additional doses {Coutinho,1983; 
Hadler,1986'.The antibody titre decreases slowly and in a predictable way over the years 
{Jilg,1984}. Well designed clinical trials have demonstrated the efficacy o f both plasma- 
derived and recombinant vaccines. Immunisation reduced the incidence o f hepatitis B by 
90-95 % in cohorts o f homosexual men {Hadler,1986}, of health care workers frequently 
exposed to blood {Szmuness,1982}, o f children born to HBsAg positive mothers 
{Grosheide,1993} and o f those who are living in areas with a high prevalence o f HBV 
infection {Wainwright,1989; W hittle,1995'. Immunisation also reduced the incidence of 
hepatocellular carcinoma in children {Chang,1997}. Symptomatic hepatitis is very rare in 
immunised persons who have ever had an antibody response o f 10 IU/l or higher, although 
there is a loss o f detectable antibody in up to 50 percent o f these persons 5 to 10 years after 
immunisation. Some may develop antibodies to hepatitis B core antigen (anti-HBc) which is 
indicative o f HBV infection, but usually there is no evidence o f disease {Szmuness,1981; 
Hadler,1986'. Follow up studies o f immunised infants indicate continued protection
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against the disease for years {Coursaget,1986; Stevens,1992'. The long term protection, 
provided by immunisation permits previously immunised persons to mount protective 
memory antibody responses after exposure to a booster {Jilg,1988; Wismans,1989; 
W est,1994'. Thus the long term effectiveness o f hepatitis B vaccine, even in those who 
have lost detectable anti-HBs, obviates routine monitoring o f anti-HBs titres and the 
administration o f late booster doses.
Several studies have reported on the response to hepatitis B vaccine in institutionalised 
mentally handicapped persons with or without Down’s syndrome. Early studies, concerning 
small numbers o f mentally handicapped residents and health care workers, showed that the 
immune response o f mentally handicapped persons with and without Down’s syndrome was 
inferior to the response seen in healthy controls (76% vs. 94%, and 90% vs.100%) 
{Wahl,1983; Heijtink,1984}. Some consecutive studies showed a lower response rate for 
persons having Down’s syndrome {Cooper,1986; Van Damme,1990; Scull 1996'. The way 
o f administering the vaccine may have played a role {Cooper,1986'. Other studies reported 
that persons with Down’s syndrome respond like normal volunteers o f a similar age group 
{Triosi,1985; Green,1988; Vajro,1992'. Mentally handicapped without Down’s syndrome 
appeared to have normal immune responses compared to healthy subjects {Torre,1984; 
Heijtink,1988; Van Damme,1990; W est,1990'. Furthermore, it was found that the 
proportion o f mentally handicapped persons remaining at a protective titre declined as a 
function of the initial antibody titre {Van Damme,1990; W est,1990'.
In this chapter we shall analyse the factors which affect the vaccination response and the 
maintenance of immunity in male mentally handicapped. Special interest is focused on age 
and Down’s syndrome. It is important to know whether the long-term immunogenicity and 
efficacy differs from the vaccination response as known from the general population, so that 
future vaccination policies can be set up accordingly.
Methods
Population
The former Sint Augustinus-stichting (now part o f Vizier, Gennep), used to be a residential 
institution for about 500, mainly male mentally handicapped persons o f whom 25% had 
Down’s syndrome. Until 1980, the extent o f the occurrence o f HBV infections in this 
institution was unknown. A few HBV infections were diagnosed every year, but 
asymptomatic infections remained unrecognised in those times. In 1980 the institution 
started serological screening for hepatitis B among the residents in order to get more insight 
in this issue. The presence o f HBV-markers in blood gives an indication o f the existence of 
present or past HBV infection (chapter 2). It appeared that about 10% o f the inhabitants 
were carrier o f HBV and about 51% had ever been infected with HBV{Van 
Ditzhuijsen,1988; chapter 5 '.
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In 1983 all seronegative inhabitants were screened once again for hepatitis B. Twelve 
persons who were negative for HBV-markers in 1980 showed seroconversion in 1983. This 
indicates an annual attack rate o f 2.3% within the Sint Augustinus-stichting. Furthermore, 
the number o f hepatitis B carriers was so high that the risk for transmission o f hepatitis B 
was constantly exalted (chapter 5). Hence it was decided to vaccinate all mentally 
handicapped, who were seronegative for HBV-markers at that time. The major objective for 
this decision was that hepatitis B infections still occurred, in spite o f the better hygienic 
supervision.
Vaccination strategy
All seronegative mentally handicapped (205 out o f 516 residents: 197 males and 8 females) 
were vaccinated with a triple dose o f H.B.Vax (20 pg) intramuscular in the upper leg in 
April, May and October 1984. After this primo-vaccination a screening examination was 
conducted in May 1985, thirteen months after primo-vaccination. In the serum o f the 
vaccinated inhabitants the vaccination response was determined by measuring the anti-HBs 
level, quantitatively up till 120 IU/l. Above this level the marking ‘positive’ was given, 
because it is was at that time a very labour-intensive test, and thus very costly to determine 
quantitatively.
If  this screening examination revealed that a person had built up little or no vaccination 
response (anti-HBs titre <10 IU/l ), a booster vaccination with C.L.B. vaccine (3 pg) was 
given in August 1985. In September 1985 the response was measured again. If  the response 
was still lower or equal to 10 IU/l, another booster vaccination with H.B.Vax (20 pg) was 
administered.
Considering the potential fall o f antibodies in time, all vaccinated persons were screened for 
anti-HBs again in July 1989, five years after primo-vaccination in order to determine 
changes in titre level. This time titre levels up to 160 IU/l were determined quantitatively. 
When the titre was lower then 100 IU/l a single booster was given in August 1989 to those 
who did repond in 1985. The results o f this boostering were examined in October 1989.
In July 1989 also the anti-HBc levels were measured in the sera o f all vaccinated persons in 
order to investigate the eventual occurrence o f a HBV infection. Positive anti-HBc levels 
are indicative o f a HBV infection since hepatitis B vaccination does not result in 
development o f antibodies against HBc. All sera were tested in the virology department of 
the University hospital in Nijmegen, the Netherlands, using the Abbot IMX test for anti- 
HBs, anti-HBc and in some cases for HBsAg.
Data-analysis
The vaccination response in the group o f vaccinated people was analysed based on the anti- 
HBs titre. The observed levels were divided in three strata: <  10 IU/l (non-responders), 10­
100 IU/l (moderate responders), and >100 IU/l (good responders).
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Factors such as Down’s syndrome and age which may influence the vaccination response, 
were included in this study. Gender could not be studied as a possible influencing factor 
because of the small number o f women in the population.
In a logistic regression model, in which the titre level was dichotomised at 10 IU/l, the 
relationship between Down’s syndrome and the vaccination response was examined 
independently o f age. Also the changes in titre levels were analysed multivariately, i.e. by 
age and Down’s syndrome.
Results
O f 205 persons vaccinated in 1984, 194 had a complete follow-up. Two persons deceased 
before they were able to receive their final booster-vaccination in August 1989. Because 
they were classified as non-responders until July 1989 they were included in the analyses 
after all. Two other residents moved before they received their booster-vaccination in 
August 1989, for which they were eligible. These two were also included in the analyses. 
The other 7 cases who were lost to follow-up could not be included in the analyses. 
Therefore, the analyses were conducted on 198 persons.
Because it was hypothesised that Down’s syndrome may influence the vaccination response, 
in which age and gender could also play a role, the vaccinees are classified according to 
these determinants at time o f the primo-vaccination (Table 6.1). People with Down’s 
syndrome were often younger than the other mentally handicapped (mean age 23.6 years vs.
29.4 years).
Table 6.1 Gender and age characteristics of the vaccinees before primo-vaccination in 
people with and without Down’s syndrome
Down’s syndrome (n=45) No Down’s syndrome (n=153)
n % n %
Gender
male 40 89% 152 99%
female 5 11% 1 1%
Age (years)
d 15 13 29% 18 12%
16-20 11 24% 16 11%
21-25 3 7% 23 15%
26-30 5 11% 29 19%
30-35 5 11% 30 20%
> 36 8 18% 37 24%
Mean age (years) 23.6 SD=11. 4 29 4 SD=10. 8
From Figure 6.1 it can be derived that initially (May 1985) 87% responded sufficiently to 
vaccination as manifested by a value higher than 10 IU/l. There was no significant 
difference in initial response between people with Down’s syndrome compared to other 
mentally handicapped.
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The initially non-responders received a booster in August 1985. People with Down’s 
syndrome remained more often non-responder after boostering than those with other causes 
for their mental handicap (70% vs. 50%). That difference was statistically not significant 
because o f the small numbers. Those who had still an insufficient response in September 
1985 were boostered for a second time. Two persons, one with Downs syndrome, converted 
to a moderate response as yet.
After 5 years (July 1989), almost all, initially non-responders, again had a titre < 1 0  lU/l. 
There was no difference between people having Down’s syndrome and those who do not 
have this syndrome (Figure 6.2).
Figure 6.3 shows that only 15% o f those who had an initially moderate response (11-100 
lU/l) had a titre o f more than 10 lU/l after 5 years. Persons having Down’s syndrome 
appeared to maintain the antibody titre more often at a sufficient level. However, these data 
are based on very small numbers (n=5 with DS vs. n=16 without DS). More than 60% of 
those with an initial response o f more than 100 lU/l remained at a level > 100. About 90% 
o f these people still had a level o f more than 10 lU/l after 5 years (Figure 6.3). There was 
no difference in antibody decrease between persons having Down’s syndrome and other 
mentally handicapped during that period.
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Figure 6.1 Antibody responses in the total study population (n=198). Initial response 
(May 1985), response after boostering the non-responders (October 1985), response 
after 5 years (July 1989) and response after final boostering (October 1989)
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Figure 6.2 Antibody-development for those with an initial response of d 10 IU/l
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Figure 6.3 Antibody-development after 5 years for those who had an initially (May 
1985) good (>100 IU/l) or moderate (11-100 IU/l) response according to Down’s 
syndrome
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Figure 6.4 Antibody levels after primo-vaccination
100%
80%
60%
40%
20%
0%
10
12
13
12
12
17
14
14
□<=10 IU/1 
□11-100 IU/1 
□>100 IU/1
<V>° <v>° <v>° <v>° <v>° <v>°
-v-0  -v -0  -v-0  -v-0  -v-0  -v -0
yrs <=15 yrs 15-19 yrs 20-24 yrs 25-29 yrs 30-34 yrs > = 35
Figure 6.5 Antibody levels 5 years after vaccination for those with a initial antibody 
level > 10 IU/L
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The results presented in Figure 6.3 indicate that persons who have an initially moderate 
response (11-100 IU/l) are more likely to have a declining level than persons who have an 
initially good response (85% vs. 35%: Fisher exact test 2-tail; p<0.0001). After adjustment 
for the group with moderate and good response, there was no difference in long term 
development between people having Down’s syndrome and other mentally handicapped. 
Figure 6.1 shows about 70% o f all tested vaccinees still have a sufficient level (>10 IU/l) in 
July 1989, 5 years after primo vaccination. All persons having less than 100 IU/l at that 
moment were boostered once more. After this booster the vast majority o f the vaccinated 
persons had sufficient antibody levels. Ninety percent had a titre more than 100 IU/L 
afterwards. The response after this booster (October 1989) was not different for persons 
having Down’s syndrome and those with other causes o f mental handicap.
About 10% o f the vaccinees were still non-responders in October 1989. In 7% o f those any 
response to vaccination or boostering was absent throughout the entire five years. Six o f the 
17 non-responders had Down’s syndrome. Therefore, there was no significant difference in 
the percentage o f non-response between persons with Down’s syndrome and other mentally 
handicapped. Also the finally achieved protection level (October 1989), as shown in Figure 
6.1, seemed not different for persons with Down’s syndrome compared to other mentally 
handicapped (%2=1.04; df=2; p=0.85).
Figure 6.4 shows that up to the age o f 30 years the initial response is rather good in most 
persons. However, beyond that age the initial response is lower. Figure 6.5 displays the age 
distribution for those who had a protective level in both screening rounds in 1985 and 1989. 
People vaccinated at a younger age have a better initial response and are more likely to 
maintain that protective titre over the years. Furthermore, it appeared that the mean age of 
non-responders (34.8 years) was significantly higher than the age o f those who react 
satisfactorily on vaccination (27.1 years); Wilcoxon test; p<0.005.
Table 6.2. Multivariate analyses for the influence of Down’s syndrome and age on the 
anti-Hbs levels (insufficiently protected (d10 IU/l) vs. sufficiently protected (>10 IU/l))
c3 1985 (n = 198) October 1985 (n = 26)
OR 95% Cl OR 95% Cl
Down’s syndrome 
Age in years
3.04
1.04
1.08-8.57
1.00-1.09
3.23
1.05
0.35-30.0
0.92-1.20
July 1989 (n = 198) October 1989 (n = 26)
OR 95% Cl OR 95% Cl
Down’s syndrome 1.83 0.77-4.32 * *
Age in years 1.06 1.02-1.10 0.89 0.86-1.38
* One of the cells contains the value zero. OR is odds ratio
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In Table 6.2 the simultaneous analysis for Down’s syndrome and age are presented. Age 
was included in the model as a continuous variable, i.e. in years. An unprotective level (< 
10 IU/l) was reached after primo vaccination three times more often if  Down’s syndrome 
was present, independently o f age. After a booster vaccination this difference persists, 
although it was no longer statistically significant, probably due to the small numbers (n = 
26).
Because age influences the influence o f Down’s syndrome on the antibody level, the 
difference in development over the years is analysed conditionally on age. These analyses 
were conducted for those who had an initial response o f more than 10 IU/l. After 5 years the 
antibody level o f these persons was measured again. The level had developed to 
insufficiently if  in 1989 that person had a level <  10 IU/l. These analyses were also 
performed when a level was set at 100 IU/l, i.e. the antibody level o f a person had declined 
from more than 100 IU/l to less than 100 IU/l after 5 years (Tables 6.3.A and 6.3.B).
It appeared that the development was not different for persons having Down’s syndrome 
than for other mentally handicapped. It made no difference which cut-off point was chosen, 
or whether boostered persons were included in the study or not. Furthermore, in the 
multivariate analysis age still influenced the development. Older persons were more likely 
to have a decreasing level over time.
Table 6.3.A Difference in antibody response between May 1985 and July 1989 for non- 
boostered persons, multivariately analysed
Protective titre >10 IU/l (n=172) Protective titre >100 IU/l (n 151)
OR 95% CI OR 95% CI
Down’s syndrome 1.58 0.53-2.03 1.04 0.41-2.63
Age in years 1.06 1.02-1.11 1.07 1.02-1.12
Table 6.3.B Difference in antibody response between May 1985 and July 1989 for the in 
1985 boostered persons, multivariately analysed
Protective titre >10 IU/l (n=183) Protective titre >100 IU/l (n= 157)
OR 95% CI OR 95% CI
Down’s syndrome 1.38 0.50-3.82 0.99 0.40-2.44
Age in years 1.06 1.02-1.10 1.07 1.03-1.12
In July 1989 all vaccinees were not only tested for HBsAg, but also for anti-HBc, which is a 
sign for a natural infection with HBV. Two persons were positive for this marker, but had 
no signs o f a clinical infection. After retesting the serum o f 1983 it appeared that one person 
was already positive for anti-HBc at that time. The other person, with an antibody level 
<100 IU/l in 1989, became positive after vaccination. This implies an annual attack rate for 
HBV infection of 0.05% in the vaccinees.
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Discussion
The results o f this study suggest that age played an important role in the response and 
development o f the hepatitis B antibodies after vaccination. After 30 years o f age the initial 
response and the long term immunogenicity (after 5 years) appeared to be much lower than 
before the age o f 30 years. This is in agreement with other studies performed in persons 
both with and without a mental handicap {Hadler,1986; Wainwright,1989; W est,1990'. The 
lower response in older persons might be due to poorer immunological response. It might be 
also possible that occult chronic HBV carriers influence the lack o f response 
{Cooper,1986}. Furthermore, older persons have a statistically significant higher chance to 
develop an antibody level less than 10 IU/L after 5 years.
It appeared that, after adjustment for age, persons with Down’s syndrome have less change 
to develop sufficient initial response to vaccination than those with a mental handicap due 
to other causes. This difference must be due to differences in immune responses. Fifty 
percent o f the initial non-responders showed protective levels as yet after a fourth or fifth 
doses o f the HBV vaccine. Boostering after primo-vaccination showed broadly the same 
antibody responses in persons having Down’s syndrome and those having a mental 
handicap due to other causes. It is unclear if  the manner o f injection has played a role in the 
immune response too. In general, subcutaneous injections in the fatty tissue results in lower 
antibody responses compared to intramuscular injections. Injection in the buttock, and 
maybe also in the upper leg causes more often a subcutaneous deposit o f the vaccine, 
especially in fat persons. Hence it is advised to vaccinate people in the upper arm, were the 
mass o f fat is mostly very low {Galama,1985}.
After five years the initial responses had declined in the population study. Only 14% of 
those having an initial antibody response between 10 and 100 IU/l, and 88% o f those having 
an initial level >100 IU/l , remained at sufficiently high levels o f more than 10 IU/l. The 
development in time was not different for persons having Down’s syndrome. Other studies 
showed very divergent percentages o f declining levels over time. In healthy people 
antibodies decreased to <10 IU/l in 23% o f all vaccinated people. All vaccinees with a 
primo-response between 10 and 100 IU/l declined to a level less than 10 IU/l {Jilg,1984}. 
In a study among homosexuals 42% had an antibody level < 1 0  IU/l after 5 years. In that 
study also all men with a moderate prime response (<50 IU/l) declined to very low 
values{Hadler,1986'. Furthermore, in Eskimos 19% had undetectable or very low levels 
after 5 years {Wainwright,1989}. In a study among mentally handicapped 24% had an 
antibody response less than 10 IU/l after 4 years {West,1990}.
The results from these studies in combination with the results presented here suggest that 
mentally handicapped persons have no different long term antibody-development compared 
to other, healthy, people. In fact, this study shows that after a decreased level all persons 
reacted very well to a booster injection including those with Down’s syndrome 5 years after 
primo-vaccination. This means they have mounted sufficient memory antibody responses to
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new infections. Revaccination will not be necessary because the immune system o f those 
who had a sufficient primo-response will react properly to an eventual contamination with 
HBV {Wismans,1993}. Thus, if  persons with Down’s syndrome are vaccinated and reached 
a sufficiently high titre, they need not be treated differently from other people vaccinated for 
hepatitis B.
The influence o f gender on the vaccination response could not be assessed in this study 
because the small number o f females in this population.
From 1983 to 1989, only two persons became infected with HBV: one just before primo­
vaccination, one after vaccination. In the years before vaccination was started, 12 persons 
seroconverted within three years, yielding an annual attack rate o f 2.3%. After the 
vaccination programme was started this attack rate decreased to 0.05 % in the vaccinees.
Conclusion
This study showed that people having Down’s syndrome have a significantly higher chance 
o f an insufficient antibody response after primo-vaccination against hepatitis B. This lower 
initial response was covered up in this study because persons with Down’s syndrome are 
often younger than other mentally handicapped in the Sint Augustinus-stichting. At a 
younger age a better primo response is obtained. The poorer response o f the hepatitis B 
vaccination as persons grow older appeared to be more pronounced in persons with Down’s 
syndrome than in other mentally handicapped, probably due to weaker cellular 
immunological responses in Down’s syndrome, followed by less production o f antibodies. 
Nevertheless, after those persons with Down’s syndrome reached a protective titre, no 
differences between persons with Down’s syndrome and other mentally handicapped could 
be observed in the long term titre development. Therefore, it is unnecessary to have a 
different vaccination strategy for persons having Down’s syndrome.
Non-responders to vaccination for hepatitis B will have to be monitored closely as long as 
there is a danger for infections. In case o f a possible infection, like a needlestick injury, they 
need passive immunisation with specific immunoglobulins. However, because o f the 
decreasing infectious pressure obtained by vaccination, the prevalence o f hepatitis B will 
decrease as well as the prevalence o f contagious chronic carriers within these types of 
institutions.
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Chapter 7
Host defence and hepat it is 
B in Down's syndrome

Introduction
It is generally accepted that individuals with Down’s syndrome exhibit an increased 
frequency o f infections, particularly infections o f the respiratory tract {Siegel,1948; 
Oster,1975}. Frequencies o f infectious diseases were reported 12 times {Oster,1975} and
50 times more often {Levin,1987} among children with Down’s syndrome compared with 
matched non-Down’s syndrome populations. Infections o f the respiratory tract, infections of 
the ears, infections o f the skin and chronic hepatitis B have been observed significantly 
more frequently in Down’s syndrome {Lang,1991}. Also some non-infectious diseases, 
associated with possible immunological dysfunction have been noticed much more in 
Down’s syndrome, such as leukaemia and hypothyroidism. The presumed deficiency o f the 
immune system that is part o f Down’s syndrome made Burgio conclude that “Down’s 
syndrome is a model o f immunodeficiency” {Burgio,1983}.
This chapter reviews the present knowledge o f defects in defence mechanisms against 
infectious diseases in general as well as in Down’s syndrome. We try to give an explanation 
for the high susceptibility for infections in Down’s syndrome and for hepatitis B 
particularly.
Host defences in general
Table 7.1 outlines the general principles o f host defence mechanisms against infectious 
agents (Van der Meer,1994}. The skin and mucous membranes, including their secretory 
and motility function, form the first barrier against infectious agents. This barrier may be 
disturbed by congenital abnormalities and a variety o f acquired lesions, e.g. physical or 
chemical. When the first barrier is broken and micro-organisms enter the body, the host 
reacts with non-specific immune responses the so-called innate immunity. Natural killer 
cells (NK-cells), phagocytes and soluble factors, e.g. cytokines - such as interleukines (IL), 
interferons (IFN), tumor necrosis factor (TNF)- are released. If  the innate immunity is 
insufficient and the infection continues specific immune responses are elicited. Specific T­
and B-lymphocytes are activated and immunoglobulins (Ig) produced, leading to 
elimination o f the micro-organism and prevention o f re-infection.
Defects in humoral and in cellular defences lead to increased susceptibility to micro­
organisms in patients and lead to recurrent infections. Derangement’s o f humoral defence 
are deficiencies o f the complement system and that o f the immunoglobulins. Deficiencies in 
the complement-system should be divided into those o f the early factors o f the classic route, 
those o f the alternative pathway leading to infections with capsulated bacteria and those of 
the late factors C6 through C9, leading to an increased susceptibility to Neisseria infections 
(such as the pneumococci, the meningococci and Haemophilus influenzae). Deficiencies of 
the immunoglobulins can be divided into a general deficiency or agammaglobulinaemi and 
selective deficiencies of the subclasses, such as a IgA deficiency.
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Agammaglobulinaemi leads to infections o f the respiratory tract, the ears and throat and the 
gastrointestinal tract. The most important deficiencies o f the a-specific cellular responses 
are qualitative and quantitative defects o f the phagocytes, leading to bacterial and fungal 
infections. Deficiencies in the cellular immunity are due to defects of the T-lymphocytes, to 
defects o f cytokines and other signalling molecules between lymphocytes and macrophages 
and to defects o f the macrophages. Cytokines, crucial in the interaction between 
lymphocytes and macrophages, are interleukines (e.g. IL-2, Il-6, IL-12) and interferon­
gamma. Defects in the cellular immunity may occasionally lead to deficiencies in humoral 
immunity because T-lymphocytes activate antibody producing B lymphocytes. Defects in 
the cellular immunity lead to infections caused by viruses (e.g. herpes simplex virus, 
varicella, and cytomegalovirus), bacteria (e.g. lysteria, salmonella, mycobacteria), fungi 
(e.g. cryptococci and pneumocystis carinii) and protoza (e.g. toxoplasma gondii).
In spite o f the suggested existence o f immunodeficiency in Down’s syndrome, the spectrum 
o f infections, frequently observed in Down’s syndrome i.e., pneumonia, otitis media and 
hepatitis B, does not fit easily in the defects in host defence discussed above.
Table 7.1 Host defences against infectious agents {Van der Meer. 1994'
Non specific Specific adaptive memory
First defence skin
mucous membranes
immunoglobulins
Humoral defence complement
cytokines, s . a. interferons
immunoglobulins
Cellular defence phagocytes T-lymphocytes
neutrophilic granulocytes 
eosinonphilic granulocytes 
moncytes
NK cells
macrophages
Features in Down’s syndrome
The following - infectious and non-infectious - diseases, often associated with possible 
immunological dysfunction, have been observed more frequently in Down’s syndrome.
Infections o f  the upper respiratory tract
These includes infections o f the ear, the nose and throat and pneumonia {Heide,1990}.
This kind o f infection is common in patients with defects in humoral defence, e.g. 
agammaglobulinemi. However defects in the humoral defences leads to more and other 
infectious diseases, such as gastro-intestinal infections and bronchitis, thanjust infections of 
the upper respiratory tract and the skin (see next). Infections o f the gastro-intestinal tract 
and bronchitis have not been reported to happen more often in Down’s syndrome.
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Infections o f  the skin
The often noticed bacterial and fungal infections o f the skin, the nails and the conjunctivas 
in Down’s syndrome {Heide,1990}, are observed frequently in patients with (qualitative 
and/or quantitative) defects o f the phagocytes. These defects are not likely in Down’s 
syndrome because the infections in Down’s syndrome are usually milder compared to those 
in patients with phagocyte defects.
Hepatitis B
Many studies, including those reported in this thesis (chapter 3, 4 and 5) have shown that 
people with Down’s syndrome are at risk for Hepatitis B. From a large literature survey, 
reviewing 93 study-populations and 10,000 mentally handicapped, we calculated that 
hepatitis B virus (HBV)-markers were about two times more prevalent in persons with 
Down’s syndrome compared to the other mentally handicapped (chapter 3). This difference 
could not be observed in all study populations. Some authors concluded that persons with 
and without Down’s syndrome are equally exposed and equally infected with HBV within 
the same environment, but that persons with Down’s syndrome are more likely to become 
HBV carrier. Other investigators showed a higher prevalence of any HBV marker in 
Down’s syndrome and they concluded that persons with Down’s syndrome are more 
susceptible for HBV infection anyhow. However, a higher prevalence for chronic hepatitis 
B in Down’s syndrome compared to other mentally handicapped was reported by almost all 
authors reviewed in chapter 3. We calculated a 5-fold risk for chronic hepatitis B in Down’s 
syndrome.
Table 7.2 demonstrates 11 sample based studies, including our own empirical studies 
(chapter 4 and 5). Six studies were performed in mentally handicapped living in general 
institutions and two studies in mentally handicapped living at home. There were three 
combination studies. One study was performed in mentally handicapped living at home as 
well as in a group-home and two studies were performed in mentally handicapped 
individuals living at home and in a general institution. In seven studies {Szmuness,1972; 
Chaudhary,1977; Renner,1985; van Ditzhuijsen,1988; Peuschel,1991; Devlin,1993; de 
W itte,1995' the overall HBV infection rate in persons with Down’s syndrome was, 
univariately analysed, equal or not significantly higher as in persons without Down’s 
syndrome, living in the same environment. Nevertheless the eleven studies together 
demonstrate a 2-fold higher prevalence o f (past and present) HBV infections in Down’s 
syndrome (pooled odds ratio 2.3 with (1.9-2.8) as 95% confidence interval). All, except two 
studies (Peuschel,1991; de Witte,1995) show, again univariately analysed, significantly 
higher percentages o f HBV carriers in Down’s syndrome. Together they reveal a 
prevalence o f almost 5 times higher in Down’s syndrome (pooled odds ratio for HBV: 4.6 
with (3.5-6.1) as 95% confidence interval).
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Viral diseases such as hepatitis B are common features in persons with defects in the 
cellular immunity. However in case o f serious defects in the cellular immunity a wide scale 
o f viral, bacterial, fungal and protozoal infections occurs may be expected, which is not 
known in Down’s syndrome.
Tabel 7.2 Hepatitis B in mentally handicapped with Down’s syndrome (DS) or without 
Down’s syndrome (NDS)
Year
of
public
ation
First
author
Number
of
DS/NDS
Age Living
conditions
HBs Ag 
(%)
DS/NDS
Odds ratio + 
(95% Cl)
HBV-
markers 
pos (%) 
DS NDS
Odds ratio + 
(95% Cl)
1972 Szmuness 134/134 >5 institute 35.1/17.2 2.6 (1.4-5.0) 65.7 69.4 0.8 (0.5-1.5)
1977 Chaudhary 95/95 all institute 38 4 14.7 (6.0-36.0) 76/81 0.7 (0.4-1.5)
1984 Heytink 87 73 33-63 institute 25.2 9.6 3.2 (1.5-6.9) 74.7 57.5 2.2 (1.2-4.0)
1985 Renner 125/106 4-42 home 12.8 2.8 5.1 (1.5-17.2) 20.0/11.3 2.0 (0.9-4.3)
1985 Wagemans 104/573 2-88 institute 15.4/4.0 4.4(1.5-12.7) 51.0/24.4 3.2 (1.8-5.8)
1988 Ditzhuysen 117/117 0-60 institute 22.2 7.7 3.4 (1.5-7.9) 70.9 62.4 1.5 (0.8-2.6)
1989 Scanlon 56/193 3-76 institute 23 6 4.7 (1.9-11.4) 96 73 8.9 (3.4-23.1)
1991 Devuyst 41 122 5-42 inst/ home 61.0/18.0 7.1 (3.8-13.3) 87.7 19.6 29.3 (14.7-58.1)
1991 Pueschel 180/155 1-29 inst/ home 0.5 1.3 0.4 (0.02-9.0) 1.1 1.3 0.8 (0.1-10.3)
1993 Devlin 94 145 13-61 home 7 1 7.5 (1.2-46.1) 15 11 1.4 (0.6-3.3)
1995 De Witte 228/1123 10- gr.home/home 2.2 0.6 3.7 (0.3-54.6) 8.3 4.4 2.0 (0.6-6.4)
Pooled 4.6 (3.5-6.1) Pooled 2.3 (1.9-2.8)
OR*: OR*:
• Pooled odds ratio according to Mantel Haensel procedure over 11 studies
Quoted from Van Schrojenstein Lantman-de Valk’s study: “Comorbidity in people with Down’s syndrome 
(1996)” plus empirical studies from this thesis
Leukaemia
The risk for leukaemia especially in young children is increased. Increases 10 to 20 fold 
over that in the general population have been reported {Robinson,1992}. Leukaemia in 
Down’s syndrome comprises two types mainly: Acute myeloid leukaemia {AML} almost 
exclusively in children < 4 years and acute lymphatic leukaemia (ALL) in older children 
{Hayes,1997}.
Acute myeloid leukaemia (AML) in very young children with Down’s syndrome is 
nowadays associated with chromosomal dysfunction and not with immunological disorders 
{Lange,1998}. Acute lymphatic leukaemia (ALL) in older children may be associated with 
immunological disturbances, probably caused by unknown viral infects.
Autoimmune diseases
Furthermore, there is an increased occurrence o f some autoimmune diseases such as 
hypothyroidism and alopecia in Down’s syndrome {Lang,1991}. Hypothyroidism occurs 
98
about 5 times more in Down’s syndrome {Van Schrojenstein Lantman,1996}. The risk for 
developing hypothyroidism increases after the age o f 35 years. The most common 
serological feature in hypothyroidism in Down’s syndrome is the presence o f circulating 
anti-thyroid antibodies, which are likely abnormal B-cell. This phenomenon is attributed to 
aging, since the incidence o f antibody against the thyroid shows a gradual increase in the 
elderly {Cuadrado,1996}.
Alzheim er’s disease
Although hardly ever considered as an immunolgical disorder in itself, we mention 
Alzheimer’s disease, because o f supposed relations between the brain and the immune 
system, such as origination from the same embryonic layer. Persons with Down’s syndrome 
have a high risk for Alzheimer’s disease. Symptoms o f dementia in living people with 
Down’s syndrome are mainly seen in subjects aged 50 years and over {Zigman,1987}. 
However, most adults with Down’s syndrome develop neuropathologic features of 
Alzheimer’s disease, such as amyloid plaques, already at the age o f 35.
Contributing factors for increased infections in Down’s 
syndrome
Because the increased risk for infections in persons with Down’s syndrome cannot be 
explained by major immunological defects in their specific or non specific immune defence 
mechanisms, other non- immunological as well as minor immunological factors may play a 
role. We will consider various facts and factors, which can contribute to the high 
susceptibility for infections in Down’s syndrome and try to relate these to the known 
mechanism for defences against infectious agents discussed above.
Behaviour
It is often suggested that persons with Down’s syndrome contract infections easily, because 
they frequently have close physical contacts with other people. There is some strong 
impression that the majority o f the individuals with Down’s syndrome have an affectionate 
nature, however, the variation in both normal and abnormal behaviours are considerable 
{Cunningham, 1982'.
Environment
Environmental factors, such as living and daytime conditions may influence the risk for 
transmission o f micro-organisms too. Although institutionalisation o f young children with 
Down’s syndrome is largely a thing o f the past, still many individuals with Down’s 
syndrome, children and adults, are grouped together, during a long time, with other mentally 
handicapped individuals, showing poor hygienic behaviours. This promotes interpersonal 
transmission.
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First defence
The first line o f defence may be compromised in Down’s syndrome by congenital disorders. 
Congenital abnormalities lead often to physical and functional defects in the defence against 
infectious diseases and facilitate micro-organisms to enter the body quite easily. 
Abnormalities such as underdevelopment o f the skull, hypotonia and congenital heart 
disease are probably relevant to the increased rate o f infections in the upper respiratory 
tract. Dry skin, which chaps easily, presumably plays a role in infections o f the skin and the 
nails and infections with HBV.
Innate immunity
Deficiencies in non-specific immune responses such as NK-cell function and cytokine 
production have been reported in Down’s syndrome occasionally {Burgio,1983; Lang,1991; 
Cuadrado,1996}
Humoral and cellular immunity
A variety o f abnormalities in humoral and cellular immune responses o f persons with 
Down’s syndrome have been described. Among these: reduction in circulating T-cells, 
increased levels o f T-suppresser cells, decreased number o f T-helper cells (CD4+ T-cells), 
increased number o f cytotoxic T-cells (CD8+T-cells), inverted ratio CD4+/ CD8+ T-cells, 
decreased T-cell function, reduced T-cell proliferation, abnormalities o f T-cell development 
in foetal thymus, histological abnormalities in the postnatal thymus, markedly reduced B- 
cells numbers, defective B-cell function with depressed synthesis o f immunoglobulins and 
reduced IgM and IgG levels {Burgio,1983; Lang,1991; Cuadrado,1996'.
Overexpression o f '21 chromosome genes
Overexpression o f genes may lead to overproduction and disturbed function o f gene 
products.
The 21 chromosomes bear genes which influence among others the immune system and the 
aging process. Molecular research in the genes o f chromosome 21 revealed that the genes 
for interferon-alpha receptor, interferon-beta receptor {Fournier,1985}and for AF 1 
(assesory factor 1), a co-factor for interferon-gamma receptor {Hemmi,1992}, are located 
on chromosome 21. Chromosome 21 also encodes the gene for CD18, one o f the cofactors 
for TNF (tumor necrosis factor), another immunomodulatory cytokine.
Important genes too on chromosome 21 are those for amyloid precursors 
{Wisniewski,1985} and others related to premature aging {Cuadrado,1996}. Furthermore 
genes responsible for acute myeloid leukaemia have been located on chromosome 21 too 
{St.Clair,1987}.
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Hypothesises on the cause of the immune deficiencies 
in Down’s syndrome
Different hypothesises can be set up to explain the multiple observed immune defects in 
Down’s syndrome. There is an increasing evidence that Down’s syndrome is a gene dosage 
disease. Overexpression o f genes may lead to overproduction o f gene products, resulting in 
functional defects o f more or less body cells, dependent on the extent o f overexpression 
and overproduction. Overexpression o f specific 21 chromosome genes may lead to 
disorders in the processes o f immune responding and aging.
Interferons
Interferons take a central position in the innate immune defence. They have, after 
attachment to their receptors on cells (tissue cells, phagocytes and T-cells) antiviral and 
immunomodulatory (such as proliferation) effects {Roit,1995}. Overexpression o f the 
receptors for the interferons may cause an imbalance in the regulation o f these processes. 
Substantial dysregulation o f the antiviral effects is not likely, because susceptibility for virus 
diseases, other than hepatitis B, is considered to be normal. Nevertheless overexpression of 
the receptors might influence immunomodulatory processes in some way.
Decreased T-Cells
Murphy et al. showed decreased T-cell levels in the blood o f persons with Down’s 
syndrome. They observed anatomical and functional abnormalities in the thymus and the 
spleen. The abnormal maturation might be due to the overexpression o f two chromosome- 
21 gene products, CD18 and AF-1, leading to increased levels o f interferon-gamma and 
TNF. This overexpression may influence the developing o f the thymocytes in the thymus of 
persons with Down’s syndrome and leads to an insufficient and inefficient release of T-cells 
to the spleen and the blood. The deficiency in the spleen results in a decreased education of 
B-cells, followed by diminished antibody responses {Murphy 1995}.
Functional defects o f  T- cells
Scotese et al. reported normal T-cell numbers. However in contrast they showed a 
functional defect in half o f the persons with Down’s syndrome. The defect involved an 
early stage o f the signal transduction o f the T-cells, resulting in diminished proliferation 
after stimulation with anti-CD3. The defect takes place in an early stage o f the activation 
process and was not seen after stimulation with a mitogen. They suggested that the cause of 
the defect might be an overproduction o f one or more chromosome 21 genes products, such 
as those coding for interferon receptors and perhaps other relevant molecules 
{Scotese,1998}.
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$ g ing
Overexpression o f premature aging genes which have been located on chromosome 21 
might be responsible for early senescence o f persons with Down’s 
syndrome{Cuadrado,1996}. Early senescence plays a role in the development of 
Alzheimer’s disease and hypothyroidism, both occuring more frequently in Down’s 
syndrome from the age o f 35 years.
The immune system itself appears to be subject o f early senescence too. Hence, in Down’s 
syndrome early senescence may affect the function of the immune system. Some 
immunological alterations, such as a low number o f circulating B-cells, decrease o f CD4+ 
T-cells and increase o f CD8+ T-cells have been observed in adults with Down’s syndrome, 
but not in children. Further investigations revealed a reduction o f some subsets o f CD4+ T- 
cells. The same subset changes did occur in normal people, when growing older, but in 
Down’s syndrome these changes were accelerated and more pronounced{Cuadrado,1996}. 
Bertotto recently reported an increase o f specific subsets o f CD 4+ T-cells, 
i.e.CD3+/CD30+ T-cells, compared to healthy controls. The increase was strongly 
correlated to age in Down’s syndrome. Similarly, senescence may influence the structure of 
the thymus and the maturation o f T-cells within the thymus {Bertotto,1999}.
It remains controversial whether the multiple immunological disturbances observed in 
Down’s syndrome are due to primary immune deficiency or early senescence o f the immune 
system.
However, the majority o f the persons with Down’s syndrome do not show clear features of 
immunological disorders. On the other hand, many o f the immunological alterations are age 
related changes and can be included in the spectrum o f multiple signs o f early senescence 
characteristics in Down’s syndrome {Cuadrado 1996}. Further investigations to the effects 
o f gene doses and o f early senescence may highlight this question.
Hepatitis B and Down’s syndrome
Persons with Down’s syndrome are at risk for hepatitis B in the following way: they 
contract infection easily, develop asymptomatic primary infection and chronic hepatitis 
easily and do not complete the immune response. Furthermore they show a lower response 
to hepatitis B vaccination.
A combination o f behaviour factors (sometimes resulting in poor hygiene), environmental 
factors (such as prolonged interpersonal contacts), congenital abnormalities (dry skin for 
instance) and defects in innate immunity (e.g. an imbalanced production o f interferons) may 
contribute to a 2  times higher risk for acquisition o f HBV infection in Down’s syndrome.
We suggest that the high susceptibility for chronic hepatitis B is due to a combination of 
factors o f the host as well as factors o f the virus, because factors o f the host alone cannot
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explain the selective susceptibility for HBV in Down’s syndrome. Insufficient 
immunological response to the HBV infection, which might be caused by overexpression of 
21 chromosome genes, such as discussed above, can give HBV the time and the chance to 
modulate the immune system and to mutate and to circumvent immunesurveillance in favor 
o f persistent infection(chapter 2).
Studies, regarding the vaccination response o f persons with Down’s syndrome, 
demonstrated that persons with Down’s syndrome have a significantly higher chance of an 
insufficient antibody level after primo-vaccination against hepatitis B and that at a younger 
age a better prime response is obtained (chapter 6). In the general population the response 
to HBV vaccination is age-related. This effect is more pronounced in Down’s syndrome, 
possibly due to precocious senescence as argued above. When persons with Down’s 
syndrome reach a protective level, no difference between them and other mentally 
handicapped is found, indicating that their humoral immunity is sufficient.
Conclusion
Although the mechanism, whereby the supernumerary chromosome 21 contributes to the 
pathology o f Down’s syndrome remains elusive, there is an increasing belief that Down’s 
syndrome is a gene dosage disease. We have discussed that the higher chance for 
acquisition HBV infection in Down’s syndrome might be declared by an combination of 
behaviour, environmental, and constitutional factors, including defects in innate immunity. 
The extremely high risk for chronic carriership is probably due to a combination o f host 
factors, i.e insufficient immunologial responses, and factors o f the virus, such as mutation 
and modulation o f the immune system. The insufficient immunological response might be 
caused by an overexpression o f 21 chromosome genes, leading to a minor immune 
dysfunction and early senescence o f the immune system. This premature senescence is 
probably also responsible for a lower response to HBV vaccination in Down’s syndrome.
103

Chapter 8
Rat ionale for poli cy 
recommendations

Introduction
The risk for hepatitis B virus (HBV) infection in mentally handicapped individuals has been 
associated with large institutions and Down’s syndrome already since 1965. The aim of the 
study presented in this thesis was to point out the distinguishing factors of persons with a 
mental handicap in the Netherlands (about 100.000) when compared to the general Dutch 
population, in which the HBV prevalence is low (estimated percentages of 0.5 HBV carriers 
and of 4% past infections). The purpose of the analysis was to develop clear policy 
recommendations for the prevention of hepatitis B in mentally handicapped individuals in 
the Netherlands. We focused this study on environmental conditions, constitutional 
determinants behavioural factors and possibilities of prevention. Data were obtained from: 
1) a literature survey, running from 1967 until 1999, including 93 residential and non- 
residential population studies and reviewing about 10.000 mentally handicapped; 2) a 
questionnaire which was sent to all residential institutions for mentally handicapped in the 
Netherlands in 1993; 3) a serological examination among 1,351 non-institutionalised 
mentally handicapped in 1994; and 4) a epidemiological study from 1980 until 1995, within 
a Dutch medium sized (circa 500 residents) general institution where HBV infection was 
hyperendemic.
Environment
The literature survey showed that the risk for hepatitis B is strongly related to the 
environment of the mentally handicapped individuals. We calculated a mean prevalence of 
16% HBV carriers in mega institutions (> 1000 residents) and of about 5% HBV carriers in 
other residential institutions. In the non residential population studies the median prevalence 
rate of HBV carriers was 3%.
The living and working conditions of the Dutch mentally handicapped vary and depend 
usually on the degree of the mental handicap. People with a mental handicap live at home, 
in group-homes or in institutions. During the day they stay at home or at the institution, or 
they go to a crèche, a school, a day-care centre or a sheltered workshop. More mentally 
handicapped individuals have regularjobs nowadays.
Living conditions
The average prevalences of HBV marker positivity and HBV carriership in persons with a 
mental handicap, within different living conditions in the Netherlands were estimated from 
data obtained from the questionnaire as well as from data of the serological examination.
In general institutions, where residents with all degrees of mental handicap live together 
were on average 28.8% of the residents positive for HBV-markers and 3.8% were HBV 
carriers. Data obtained from the questionnaire were gathered from 30% of all residential
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institutions and from 14,698 mentally handicapped, almost 50% o f the institutionalised 
population. Sixteen percent o f them had Down’s syndrome. The prevalence o f HBV carriers 
varied from 0 to 12%. In more than 75% o f the institutions the prevalence o f HBV carriers 
was higher than 1%. In small institutions with less than 250 residents the average percentage 
of HBV carriers was 2.2, lower than that in medium-sized institutions (between 250 and 500 
residents) and large institutions (more than 500 residents) where the average percentages for 
HBV carriers were 4.2% and 3.8% respectively.
The same questionnaire was completed by 3 special institutions, where people are living 
with a mental handicap combined with another severe physical handicap (blindness, 
deafness, epilepsy, cerebral palsy) and where the number o f residents with Down’s 
syndrome is usually very low, because o f the uncommon combination Down’s syndrome 
and severe physical handicap. On average 0.4% o f the examined 942 mentally handicapped 
residents were HBV carriers and 5.7% appeared to have HBV-markers.
Sera o f all 219 residents o f the “largest” institute fo r  mild mentally handicapped young 
people in the Netherlands were examined for HBV-markers in 1994. The HBV marker 
prevalence in this group was 1% and 0.5% were HBV carriers. Nobody had Down’s 
syndrome.
The majority (65%) o f the residents o f 5% (31) off all Dutch group-homes, houses for 2-24 
mentally handicapped people, located within the community, were tested for HBV-markers. 
About 15% o f the residents had Down’s syndrome. The houses were situated in different 
regions o f the Netherlands. The HBV marker positivity was 3.7% in the 511 tested blood 
samples. Three persons (0.6%) were carriers for HBV. They lived in different houses and in 
different regions. Only one or two o f the housemates o f the carriers showed antibodies 
against HBV.
O f the participants in the same study, 415 mentally handicapped people lived at home. The 
percentage o f HBV-markers was 6.8% and 0.7% were HBV carriers. These people 
frequently contacted other mentally handicapped people because they all attended special 
day-care centres for mentally handicapped.
It can be concluded from these data that the average prevalence o f HBV infection in 
residents o f general institutions in the Netherlands is substantially higher than that estimated 
in the general population (3.8% versus 0.5% carriers, 28.8% versus 4.5% HBV marker 
positives) and that the HBV prevalence in the other living conditions, e.g. special 
institutions, institutions for mild mentally handicapped youngsters and group-homes, can be 
considered as low (less than 1% HBV carriers), close to that o f the Dutch population.
We discussed that the main reasons for the high transmission rate in the general institutions 
are the insufficient hygienic behaviour o f many people with a mental handicap, the high 
number o f residents who are at risk for hepatitis B, e.g. people with Down’s syndrome and 
the unawareness o f the issue during long time.
The literature search shows that there are institutions where transmission o f HBV was (very) 
active and institutions were HBV transmission was almost eliminated. In other institutions 
HBV transmission had been low all the time.
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Daytime conditions
The study in non-institutionalised mentally handicapped in 1994 did not only evaluate the 
living circumstances o f mentally handicapped persons, but also the daytime conditions. 
Twenty-one day-care centres fo r  adults in different regions in the Netherlands, where 
mentally handicapped people spent their days, carrying out different activities, were 
involved in this study. Sixty-three percent o f all the mentally handicapped attendees, 768 
persons, were tested for HBV. Twenty-eight percent had Down’s syndrome. From this 
group 5.7% were positive for HBV-markers, 6 persons were HBV carriers (0.8%). Three 
HBV carriers visited different day-care centres in one region. In that particular region the 
percentage o f persons with antibodies against HBV was also higher than in the other 
investigated regions. This could be attributed to a cluster o f 10 persons, who had lived 
together earlier in one group-home for children. All 3 other carriers visited the same day­
care centre. Two other visitors o f that centre had antibodies to HBV. One o f the carriers 
may have been infected perinatally, the other four likely in the day-care centre.
One sheltered workshop participated to the study. Half o f the mentally handicapped 
labourers were living in one general institution. It was known that 58% o f this group had 
HBV-markers and 8% were HBV carriers. The other half o f the mentally handicapped 
employees lived either in a group-home or at home. Fifty percent o f those living at home or 
in a group-home were tested for HBV-markers in 1994. Eleven (16%) were HBV marker 
positive, and 3 (4%) HBV carrier. This relatively high percentage can be explained from the 
fact that the non-institutionalised labourers had worked together with institutionalised 
labourers for many years. Some had intimate contacts, including sexual contacts.
We concluded that HBV infection in day-care centres is not very frequent, but in some 
special conditions HBV is transmitted rather easily, provided that one or more o f the fellow 
attendees is a HBV carrier. These special conditions are, long- standing, close contact and 
sharing materials with people who are not capable o f taking care o f their own hygiene such 
as young children or mentally handicapped persons with a severe or profound mental 
handicap.
Constitution
Different constitutional determinants are described in this thesis: Down’s syndrome, age, 
gender, degree o f mental handicap, country o f origin, institutionalisation at young age. We 
used data obtained from the literature search, the epidemiological study in the Dutch general 
institution and the serological examination in non-institutionalised mentally handicapped.
D ow n’s syndrome
Because o f the link between the Australia antigen and Down’s syndrome, described by 
Blumberg in 1968, researchers focused on people with Down’s syndrome from the
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beginning. Within institutions for mentally handicapped people, the proportion of HBV 
carriers among people with Down’s syndrome was usually higher compared to mentally 
handicapped people without this syndrome. The same phenomenon could be observed in the 
few studies performed in non-institutionalised mentally handicapped people. From the huge 
survey o f the literature, we calculated that among the circa 10,000 reviewed mentally 
handicapped individuals, people with Down’s syndrome have a 2-fold increased risk for 
acquisition o f HBV infection, a 5-fold increased risk for chronic HBV infection and a 4­
fold increased risk for persisting infectivity (HBeAg).
Data from the study performed within the general institution lead to the conclusion that 
residents with Down’s syndrome had slightly, but statistically not significant, more often 
HBV-markers than other mentally handicapped residents (70.9 and 62.4 % respectively). 
Furthermore Down’s syndrome residents had a significantly higher prevalence o f HBsAg 
(31.3%) than other mentally handicapped residents (12.3%) and HBV carriers with Down’s 
syndrome had more often and more prolonged markers indicative for active viral replication 
than other mentally handicapped (HBeAg: 61% vs. 16% and HBV-DNA: 37% vs. 12%).
The serological study, carried out in the non-institutionalised mentally handicapped, showed 
an overall percentage o f 5.2% HBV-markers, about equal to that of the Dutch population. 
Nevertheless, when multivariately analysed, the prevalence o f HBV-markers was two times 
higher in people with Down’s syndrome compared to mentally handicapped people without 
this syndrome.
People with Down’s syndrome are obviously at risk for HBV infection because o f a 
diminished defence against HBV infection. We have hypothesised that the susceptibility for 
HBV infection may be caused by an overproduction o f genes o f the 21 chromosome, 
leading to congenital abnormalities, minor primary immune defects and early senescence of 
the immune system, resulting in defects o f the innate and specific immunity. The extremely 
high risk for chronic carriership may be caused by a combination o f factors o f the host, i.e 
insufficient immunologial responses, and factors of the virus, such as mutation and 
modulation the immune system.
Age
We evaluated the relation between age and HBV infection from different points o f view: 
age at admission in a specific facility and age at the time o f the first HBV screening.
Very young children run a high risk for chronic hepatitis B, due to immature responding 
immune mechanisms. Young age at the time o f admission in a general institution was 
reported many times as a risk factor for chronic HBV infection in the literature search.
In the institutional study it could be observed that residents admitted at ages o f 11-15 years, 
had the highest prevalence o f HBV-markers. It had to be considered that most o f them had 
lived before in an institution where HBV was also endemic.
As people grow older and live longer in an environment with HBV carriers they have a 
higher chance o f having close contacts to HBV carriers and getting infected with HBV.
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In the institutional study the prevalence o f HBV-markers increased with age up to 30. 
Furthermore the study showed that the prevalence o f HBV-markers was nearly steady up to 
10 years o f institutionalisation after which a sharp rise occurred. In the non-institutionalised 
study HBV-markers were significantly more noticed in people between 30-50 years.
The same tendencies were observed in the literature search.
Gender
In the Dutch population the prevalence o f HBV-markers in males is significantly higher 
than in females. The literature study confirmed the same trend. In the serological study in 
non-institutionalised mentally handicapped we showed that males had an almost two times 
higher risk for HBV infection than females.
Degree o f  mental handicap
Some investigators, reviewed in the literature survey, reported a higher prevalence o f HBV- 
markers in severely mentally handicapped. This fact can be associated to the poorer 
hygienic behaviour in severely mentally handicapped, who are (semi)ambulant. Our non­
institutionalised study suggested a higher prevalence in persons who were more mentally 
handicapped than the others.
Country o f  birth
The study in the non-institutionalised population showed that mentally handicapped 
persons, originated from countries where hepatitis B is more prevalent than in the 
Netherlands, had on average a 5.4 times higher risk for HBV infection.
Institutionalisation
In the non-institutionalised mentally handicapped the prevalence o f HBV-markers was 4 
times higher in persons who lived in a general institution before. This could be expected 
because o f the high number o f HBV carriers in most general institutions. In contrast mild 
mentally handicapped young people who were institutionalised before did not show a higher 
HBV prevalence. In institutions for mildly handicapped HBV infections are not common.
Behaviour
Many mentally handicapped are not able to take care o f their own hygiene. They show poor 
hygienic behaviour, which facilitates often horizontal and sometimes sexual viral 
transmission. The chance to be infected increases under circumstances that people are 
grouped together for a long time, such as in residential institutions but also in day-care 
centres.
HBV transmission from mentally handicapped to staff (and vice versa) may occur because 
close contacts are universal between mentally handicapped individuals and care taking staff. 
Most studies concerning the HBV prevalence among caring staff o f institutions for
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mentally handicapped showed that the HBV prevalence in staff was not or slightly elevated 
compared with the local population. Although based on a small number of studies, we found 
in the literature study a median prevalence rate of 11% HBV-markers and 1% HBsAg in 
staff. In case the prevalence was elevated it was never that high as the prevalence in the 
residents. The slightly elevated prevalence was also observed in our institutional study; i.e. 
5.3% HBV-markers in caring staff and 0% markers in not caring employees.
Prevention
Hepatitis B infection can be prevented by hygienic measures or by vaccination. In general it 
is accepted that within a normal population hepatitis B can be controlled reasonably well by 
hygienic measures alone. Most important precautions are avoidance of contacting blood and 
blood products and safe sex. However, very young children and (moderately or severely) 
mentally handicapped persons are unable to take care of their own hygienic behaviour. The 
study performed in the general institution showed that, despite of the hygienic measures, 
taken after a first screening to HBV-markers, the annual attack rate for hepatitis B was still 
high (2,3% vs normally less than 0.05%). Hepatitis B vaccination is available since 1983 
and has proven to be very effective in general populations. In our study, in the general 
institution, hepatitis B vaccination appeared to be very effective for mentally handicapped 
individuals too. After the initiation of the vaccination program, the annual attack rate 
decreased to 0.1% in the total population and to 0.05% in the vaccinees. Young mentally 
handicapped persons, including those with Down’s syndrome respond well to primo­
vaccination. Older persons develop a lower response. We showed that that effect is stronger 
for persons with Down’s syndrome, most likely due to an overexpression of aging genes in 
Down’s syndrome. The long-term immunogenicity and the memory function of the immune 
system of the well responded vaccinees with Down’s syndrome as well as with other forms 
of mental handicap did not differ from those in a normal population.
Policy for hepatitis B prevention in persons with a 
mental handicap in the Netherlands
Based on the studies, presented in this thesis, the following recommendations can be given 
to prevent HBV infection in mentally handicapped people:
To initiate a vaccination programme for people with Down’s syndrome, because they are 
obviously at risk for HBV infection. It is preferable to vaccinate them at young age for two 
reasons. Firstly, it is important to vaccinate all children with Down’s syndrome against
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HBV infection before they have close contacts with other potential HBV carriers in crèches, 
schools, day-care centres, group-homes or institutions. Secondly the immune response to the 
vaccination and the long-term efficacy of the vaccination of people with Down’s syndrome 
are optimal at young age and similar with non-handicapped children. No adapted 
vaccination strategy is needed afterwards. It should be considered to include the hepatitis B 
vaccination for children with Down’s syndrome in the general vaccination programs for 
children in the Netherlands. For children and adults, who did not yet been vaccinated, a 
catch-up program has to be started. The older persons with Down’s syndrome (>40 years) 
have to be vaccinated only if they run a real risk for HBV infection. For instance when they 
live or work together with HBV carriers. The risk to being infected with HBV appears to 
decrease when people get older. In addition the immune response to the vaccination 
decreases strongly with aging.
To vaccinate all residents in the traditional general institutions for the mentally handicapped 
persons. All new admissions should be screened for HBV-markers before vaccination. The 
relevance of this advice is limited, because the policy of the Dutch government is aimed at 
closing down the traditional general institutions and is providing small scale facilities for all 
mentally handicapped people, mostly in the community.
To vaccinate residents in small scale living facilities, group-homes, or special institutions, 
only if one or more of the fellow residents is HBV carrier. This policy is equal to that of the 
general policy in the Netherlands that implies that all members of a family or members of 
any group who live like a family should be vaccinated against hepatitis B if one member of 
the group is HBV carrier {Health Council,1996}. Persons at risk (people with Down’s 
syndrome who are not vaccinated, people who lived before in a general institution for 
mentally handicapped, people, or their parents, originated from countries with a moderate or 
high prevalence of hepatitis B, people with alternating sexual contacts) have to be screened 
for HBV-markers at admission.
To vaccinate attendees of crèches, schools, day-care centres for mentally handicapped only 
if one or more fellow attendees are HBV carriers, provided that people are not able to take 
care of their own hygienic behaviour, such as (young) children or people with a moderate or 
severe mental handicap in day-care centres. It is advised to screen people at risk (see 3) 
before their admission to such a crèche, school or day-care centre.
To vaccinate staff in charge of the daily care for mentally handicapped HBV carriers within 
living facilities as well as in day-time facilities. Caring staff, themselves infected with HBV 
should only be allowed to work if the mentally handicapped, for whom they care, are 
sufficiently protected against HBV either by vaccination or by past infection.
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Furthermore each organisation for mentally handicapped persons has to have a written 
protocol of hygienic regulations. The Werkgroep Infectie Preventie, a national working 
group, that formulates guidelines for infection prevention, has edited a special protocol with 
guidelines for the prevention of infectious diseases in mentally handicapped {WIP,1997}.
When the above mentioned recommendations are implemented in the Dutch health care 
system, mentally handicapped individuals will run a low risk for HBV infection similar to 
everybody else in the Netherlands.
114
References
Andre F . Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine. Am J Med 1989; 87: 14S- 
20S .
Akhter M, Stout C, Twiehaus J . Hepatitis B screening and vaccination in a facility for the mentally retarded . Mo 
Med 1985; 82:345-8.
Arulrajan A, Tyrie C, Phillips K, O'Connell S . Hepatitis B screening and immunization for people with a mental 
handicap in Southampton: costs and benefits . J Intellect Disabil Res 1992; 36: 259-64.
Bakal C, Marr J, Novick L, Millner E, Goldman W, Pitkin O . Deinstitutionalized mentally retarded hepatitis-B 
surface antigen carriers in public school classes: a descriptive study. Am J Public Health 1980; 70: 709-11.
Bakal C, Novick L, Marr J, Millner E, Goldman W, Pitkin O . Mentally retarded hepatitis-B surface antigen 
carriers in NYC public school classes: a public health dilemma. Am J Public Health 1980; 70: 712-6 .
Barnaba V, Franco A, Alberti A, Benvenuto R, Balsano F . Selective killing of hepatitis B enveloppe antigen 
specific B cells by class I-restricted exogenous antigen specific T lymphocytes .Nature 1990; 345: 258-60
Bayer M, Blumberg B, Werner B . Particles associated with Australia antigen in the sera of patients with 
leukaemia, Down's Syndrome andhepatitis . Nature 1968; 218: 1057-9.
Bertoletti A, Sette A, Chisari F, et al . . Natural variants of cytotoxic epitopes are T-cell receptor antagonists for 
antiviral cytotoxuc T cells . Nature 1994; 369: 407-10.
Bertotto A, Crupi S, Fabietti G, Troiani S, Parente C, Mezzetti D . CD3+/CD30+ circulating T Lymphocytes are 
markedly increased in older subjects with Down’s syndrome (Trisomy 21) . Pathology 1999; 67: 108-110.
Blumberg B . Polymorphism of the serum proteins and the development of isopercipitins in transfused patients . 
Bull N Y Acad Med 1964; 40: 377-86.
Blumberg B . An inherited serum isoantigen in leukemia and Down's syndrome . J Clin Invest 1966; 4: 988-97.
Blumberg B, Gersley B, Hungerford A, London W, Sutnick A. A serum antigen (Australia antigen) in Down's 
syndrome, leukemia and hepatitis . Ann Intern Med 1967; 66: 924-31.
Blumberg B, et al. Down's syndrome: two types distinguished by a serum antigen (Australia Antigen) . Ann Intern 
Med 1967; 66: 1040.
Blumberg B, Gerstley B, Sutnick A, et al. Australian antigen hepatitis virus and Down's syndrome. Ann N Y 
Acad Sci 1970; 171:486-99.
Blumberg B, Larouze B, London W et al. The relation of infection with the hepatitis B agent to primary hepatic 
carcinoma. Am J Pathol 1975; 81: 669-82.
Blumberg B . Australia Antigen and the biology of hepatitis B . Science 1977; 17-25 .
Boughton C, Hawkes R. An approach to the management of viral hepatitis in a residential institution. Australian 
Journal of Mental Retardation 1973; 2: 161-4 .
Boughton C, Hawkes R, Schroeter D, Harlor J . The epidemiology of hepatitis B in a residential institution for the 
mentally retarded. Aust NZJ Med 1976; 6: 521-9 .
Boughton C, Hawkes R, Overby L. Viral hepatitis in institutions for the mentally retarded. Australian Journal of 
Mental Retardation 1979; 5: 229-31
Breuer B, Friedman S, Millner E et al. Transmission of hepatitis B virus to classroom contacts of mentally 
retarded carriers . JAMA 1985; 254: 3190-5 .
Broggini M, Maggiolo F, Bianchi E, Torre D . Study on the control of hepatitis B virus infection in an institution 
for the mentally retarded. Boll Ist Sieroter Milan 1983; 62: 495-500.
Bruining M, Koenraads S, Kruyt A, et al. Een onderzoek naar het voorkomen van hepatitis B infecties in een 
tehuis voor geestelijk geretardeeerden en enkele waarnemeningen omtrent de infectiositeit van donorbloed. 
Ned Tijdschr Geneeskd 1974; 118: 1150-3.
Burgio G, Ugazio A, Nespoli L, Maccario R. Down’s syndrome: A model of immunodeficiency. Birth Defects 
1983: 19:325-7
115
Cancio-Bello T, de Medina M, Shorey J, Valledor M, Schiff E . An institutional outbreak of hepatitis B related to 
a human biting carrier. J Infect Dis 1982; 146: 652-6.
Carithers R . Effects of interferon on hepatitis B . Lancet 1998; 351: 157.
Carman W et al. Viral genetic variation: hepatitis B virus as a clinical example . Lancet 1993; 341: 349-53.
Chance E . Prevalence of hepatitis associated antigen (HAA) in an institution for the mentally retarded . Am J Ment 
Defic 1972; 77: 1-5.
Chang M, Chen C, Lai M, Hsu H, Wu T, Kong M. Universal hepatitis B vaccination and the incidence of 
hepatocellular carinoma in children. New Engl J Med. 1997; 336: 1855-9.
Chaudhary R, Perry E, Cleary T. Prevalence of hepatitis B infection among residents of an institution for the 
mentally retarded. Am J Epidemiol 1977; 105: 123-6.
Chaudhary R, Perry E, Hicks F, MacLean C, Morbey M. Hepatitis B and C infection in an institution for the 
developmentally handicapped [letter] . N Engl J Med 1992; 327: 1953.
Clarke S, Caul E, Jancar J, Gordon-Russell J. Hepatitis B in seven hospitals for the mentally handicapped. J Infect 
1984; 8:34-43.
Clemens RF, Hofmaann H, Berthold G, et al. Prävalenz von Hepatitis A,B und C bei bewohnern einer Einrichtung 
fur geistig behinderte. Sozialpädiatirie 1992; 14: 357-63.
Clements M, Miskovsky E, Davidson M et al. Effect of age on the immunogenicity of yeast recombinant 
hepatitis B vaccines containing surface antigen (S) or Pre S2 + S antigens. J Infect Dis 1994: 170: 510-6
Cockayne EA. Catarrhaljaundice, sporadic and epidemic and its relations to yellow atrophy of the liver. Quarterly 
journal of Medicine 1912; 6: 1.
Cooper B, Klimek J, Upadhyaya A, Devine, S. Poor seroconversion rate after hepatitis B vaccination in high-risk 
institutionalized mentally retarded patients. Am J Infect Control 1986; 14: 204-8
Cossart Y. Hepatitis in mental insitutions. In: Cossart YE, editor. Virus hepatitis and its control. London: Bailliere 
Tindall, 1977: 244-54.
Cossart Y, Path M. What ditermines the incidence of serumhepatitis after blood transfusions. Am J Dis Child. 
1972;123:354-6
Coursaget P, Yvonnet B, Chotard et all. Seven-year study of hepatitis B vaccine efficacy in infants from an 
endemic area (Senegal). Lancet 1986; 2: 1143-5.
Coutinho R, Lelie N, Albrecht-van Lent P, Reerink-Brongers E, Stoutjesdijk L, Dees P et al. Efficacy of a heat 
inactivated hepatitis B vaccine in male homosexuals: outcome of a placebo controlled double blind trial. Brit 
Med J 1983; 286: 1305-8
Cramp ME, Grundy HC, Perinpanayagam RM, Barnado DE. Seroprevalence of hepatitis B and C virus in two 
institutions caring for mentally handicapped adults. J R Soc Med 1996; 89: 401-2.
Cuadrado E, Barrena M. Immune dysfunction in Down’syndrome: Primary immune deficiency or early senscence 
of the Immune system? Clin immunology and immunopathatholgy 1996; 78: 209-14.
Cunningham C. Down’s syndrome: an introduction for parents. Trinity Press; Worcester and London 1982.
Cunningham SJ, Cunningham R, Izmeth MG, Baker B, Hart CA. Seroprevalence of hepatitis B and C in a 
Merseyside hospital for the mentally handicapped. Epidemiol Infect. 1994; 112: C195-200.
Dandoy S, Dandoy JR. Status of hepatitis B screening and vaccine use in facilities for mentally retarded persons. 
Am J Ment Defic 1986; 91: 184-9.
Dane VS, Cameron CH, Briggs M. Virus-like particles in serum of patients with Australia-antigen-associated 
hepatitis. Lancet 1970; 1: 695-8.
Dankert J, Zijlstra JB, Kruyt AC, Van Grunsven MF. The occurence of hepatitis B antigen and hepatitis B 
antibody in pupils and employees in an institute for mentally retarded. Bulletin van de coördinatie-commissie 
biochemisch onderzoek van de sectie psychiatrische instituten van de NZR 1973; 6: 54-60.
Davis GL, Weber DJ, Lemon SM. Horizontal transmission of hepatitis B virus. Lancet 1989; i: 889-92. de Meyer 
S, Gong Z, Suwandi W, Van Pelt J, Soumillion A, Yap S. Organ and species specificity of hepatitis B
116
virus(HBV) infection: a review of literature with a special reference to preferential attachment of HBV to 
humanhepatocytes. J Viral Hepat 1997; 4: 145-53. 
de Witte-van der Schoot PPM. Hepatitis B in een internaat voor geestelijk gehandicapten. Scriptie SSG Utrecht; 
1985.
de Witte-van der Schoot PPM. Hepatitis B, vaccinatiebeleid en vaccinatierespons. TVAZ 1987; 1: 22-30 
de Witte-van der Schoot PPM. Hepatitis B vaccination and revaccination policy in institutions for the mentally 
retarded [Abstract]. 1st European congress on mental retardation and medical care. Noordwijkerhout, april 
1991.
de Witte-van der Schoot PPM. Hepatitis B prevention in European centres for mentally handicapped people.
Newsletter MAHM 1994; 5-7 
de Witte-van der Schoot PPM. Hepatitis B bij mensen die gebruik maken van semi- en extramurale voorzieningen 
in Nederland. Gennep: StAugustinusstichting 1995.
Devlin J, Mulcahy M, Corcoran R, Ramsay L, Tyndall P, ShattockA. Hepatitis B in the non-residential mentally 
handicappedpopulation. J Intellect Disabil Res 1993; 37: 553-60.
Devuyst O, Maesen-Collard Y. Hepatitis B in a Belgian institution for mentally retarded patients: an 
epidemiological study. Acta Gastroenterol Belg 1991; 54: 12-8.
Dietzman D, Matthew E, Madden D, et al. The occurrence of epidemic infectious hepatitis in chronic carriers of 
Australia antigen. J Pediatr 1972; 80(4): 577-82.
Di Ciommo V, Ferrario F, Rossi De Gasperi M, De Marchis C, Albertini G. Epidemiology of hepatitis B virus in 
non-institutionalized children and adolescents affected by handicap. J Intellect Disabil Res 1993; 37: 295-9. 
Dicks J, Dennis E. Down's syndrome and hepatitis: an evaluation of carrier status. J Am Dent Assoc 1987; 
114(5): 637-9.
Dyggve H, Clausen J. The serum immunoglobulin level in Down's syndrome. Dev Med Child Neurol 1970; 12(2): 
193-7.
Ellis C, Erb LJ, McKeown DJ, McFarlane GM. Hepatitis B control in Toronto classrooms for the mentally 
retarded: a seroprevalence survey. Can J Public Health 1990; 81: 156-60.
Eskola J, Keski-Oja J, Wilska M, Autio S. Risk of hepatitis B in a ward for mentally retarded HBsAg carriers.
Infection 1986; 14: 170-2.
Ferris A, Pitt D, Gust I, Kaldor J. Australia antigen and Down's syndrome [Letter]. Lancet 1972; 1: 46.
Findlay M, MacCallum F, Murgatroyd F. Observations bearing on the aetiology of infective hepatitis (so-called 
epidemic catarhaljaundice). Trans R Soc Trop Med Hyg 1939; 32: 575-86.
Follett E, Symington I, Cameron M. Experience with hepatitis B vaccination in nurses in a hospital for the 
mentally handicapped. Lancet 1987; 2(8561): 728-31 
Foster G, Ackrill A, Goldin R et al. Expression of the terminal protein region of hepatitis B virus inhibits cellular 
responses to interferons alpa and gamma and double stranded RNA. PNAS 1991;88: 2999-92 
French G, Tinsley H, Tam J, et al. Hepatitis B in mental handicap hospitals [Letter]. Lancet 1989; 1: 841.
Galama J, Daniels-Bosman M. Hepatitis B vaccinatie: toediening in arm of bil? Ned Tijdschr Geneeskd 
1985;129: 1245-6
Ganem D. Hepadnaviridae and their replication. In Fields B, Knipe D, Howley P eds. Lippencot-Raven 
Publishers, Philadelphia,New York.3th edition 1996: 2703-37.
Gannon M, Murphy D. Hepatitis B and mental handicap [letter]. Lancet 1989; 1: 436.
GHIGV/GGZZ. Advies m.b.t. vaccinatie hepatitis B. Rijswijk: Dutch Inspection of Health 1991 
Gitlin N. Hepatitis B: diagnosis, prevention, and treatment. Clin Chem 1997; 43: 1500-6.
Goodman M, Wainright R, Weir H, Gall J Jr. A sex difference in the carrier state of Australia (hepatitis- 
associated) antigen. Pediatrics 1971; 48: 907-13.
Grace N, Ahearn B, Fisher W. Behavioural programme to reduce risk of hepatitis B virus transmission [letter].
Lancet 1994; 343:737.
Green J. Hepatitis B and Down's syndrome [letter] . BMJ 1988; 297: 1336.
117
Green J. Hepatitis B in mental handicapped hospitals [letter]. Lancet 1989; 1: 840.
Grosheide P, Bosman A, van Hattum J, Lumey L, van Loon A. Hepatitis B virus infecties in Nederland: een 
inventariserend onderzoek. Bilthoven: RIVM 1991, publication 119003001
Grosheide P. Prevention of perinatal hepatitis B virus infection [dissertation]. Rotterdam: Erasmus University, 
1993.
Gruyters M. Enquête infectieziekten en vaccinatiebeleid in zwakzinnigenzorg. TVAZ 1990; 1: 3-7.
Gust I, Dimitrakakis M, Sharma D. The prevalence of HBeAg and anti-HBe in an institution for the mentally 
retarded. Aust NZ J Med 1978; 8: 471-3.
Hadler S, Francis D, Maynard J, et al. Longterm immunogenicity and efficacy of hepatitis B vaccine in 
homosexual men. N Engl J Med 1986; 315: 209-14.
Hawkes R, Boughton C, Schroeter D, Decker H, Overby L. Hepatitis B infection in institutionalized Down's 
syndrome inmates: a longitudinal study with five hepatitis B virus markers. Clin Exp Immunol 1980; 40: 
478-86.
Hawkes RA, Boughton CR, Schroeter DR. The antibody response of institutionalized Down's syndrome patients 
to seven microbial antigens. Clin Exp Immunol 1978; 31: 298-304.
Hayashi J, Kashiwagi S, Noguchi A, et al. Hepatitis B virus infection among mentally retarded patients in 
institutions, Okinawa, Japan. FukuokalgakuZasshi. 1989; 80: 436-40.
Hayes C, Johnson Z, Thornton L, Fogarty J, Lyons R, O’Connor et al. Ten-year survival of Down’s syndrome 
births. Int J of Epidem 1997; 26: 822-9.
Health Council of the Netherlands: Committee Hepatitis B. Advice concerning hepatitis B. ‘s-Gravenhage: Health 
Council of the Netherlands 1983.
Health Council of the Netherlands: Committee Hepatitis B. Protection against hepatitis B. Rijswijk: Health 
Council of the Netherlands, 1996; publicationno. 1996/15.
Health Council of the Netherlands: Committee Hepatitis C. Detection and treatment of people with hepatitis C. 
Rijswijk: Health Council of the Netherlands, 1997; publication no 1997/19.
Heide F, Lang D, Soucek M, Van Duyne S, Van Dyke D eds. Clinical perspectives in managment of Down’s 
syndrome. Springer Verlag, New York New York 1990.
Hemmi S, Merlin G, Aguet M. Functional charaterization of a hybrid human mouse interferon gamma receptor: 
eidence for species-specific interaction od the extracellular receptor domain with a putative signal transducer 
PNAS 1992: 89: 2737-41
Heijtink R, de Jong P, Schalm S, Masurel N. Hepatitis B vaccination in Down's syndrome and other mentally 
retarded patients. Hepatology 1984; 4: 611-4.
Heijtink R, van der Velde-Langendijk M, Weber Y et al. Viral hepatitis and liver diseases. In: Zuckermann AJ, 
eds. Hepatitis B vaccination in mentally retarded patiemts: recombinant vaccine versus plasma derived 
vaccine. New York: Alan R Liss, 1988: pp 1068-70.
Higgins G, Parker C, Faust J, Rosenfeld M. Hepatitis-associated (Australia) antigen and Down's syndrome. Am J 
Ment Defic 1974; 78: 426-8.
Hollinger F, Goyal R, Hersh T, Powel H, Schidman R, Melnick J. Immune response to hepatitis virus type B in 
Down's syndrome and other mentally retarded patients. Am J Epidemiol 1972; 95: 356-62.
Holt P, Goodall B, Lees E, Hambling M. Prevalence of hepatitis B markers in patients and staff in a hospital for 
the mentaly handicapped. J Hosp Infect 1986; 7: 26-33.
IsermanH. Haufigkeitvon Hepatitis Bbei geistig behinderten heimbewohneren. DMW 1991; 116: 316.
Jayaratnam R. Hepatitis B vaccination for staff in institutions for the mentally handicapped. Public Health 1988; 
102: 257-62.
Jilg W, Schmidt M, Deinhardt F, Zachoval R. Hepatitis B vaccination: how long does protection last? [letter]. 
Lancet 1984; 2: 458.
Jilg W, Schmidt M, Deinhardt F. Immune response to hepatitis B revaccination. J Med Vir, 1988;24:377-84.
118
Kaplan P, Greenman R, Gerin J, Purcell R, Robinson W. DNA polymerase associated with human hepatitis B 
antigen. J Virol 1973; 12: 995-1005.
Kee F, McGinnity M, Marriott C, et al. Hepatitis B screening in a northern Irish mental handicap institution: 
relevance to hepatitis B vaccination. J Hosp Infect 1989; 14: 227-32.
Kingham J, McGuire M, Paine D, Wright R. Hepatitis B in an hospital for the mentally subnormal in Southern 
England. BMJ 1978; 2: 594-6.
Krugman J, Giles J, Hammond J. Hepatitis virus: effects of heat on the infectivity and antigenecity of the MS-1 
and MS-2 strains. J Infect Dis 1970; 122: 432-6.
Krugman J, Giles JP. Viral hepatitis: new light on an old disease. JAMA 1970; 212: 1019-29.
Krugman S, Giles J, Hammond J. Viral hepatitis type B (MS-2 strain): studies on active immunization. J Am Med 
Assoc 1971; 217: 41-5.
Krugman S, Joan P, Gilles P. Viral hepatitis, type B (MS-2-strain):. further observations on natural history and 
prevention. N Engl J Med 1973; 12: 755-60.
Krugman S, Overby LR, Mushahwar IK, Ling CM, Frosner GG, Deinhardt F. Viral hepatitis, type B. Studies on 
natural history and prevention re-examined. N Engl J Med 1979; 300: 101-6.
Lang D. Susceptibility to infectious diseases in Down’s syndrome. In: Lott I, McCoy E. Down’s syndrome: 
Advances in medical care. Wiley-Liss, San Diego 1991; 83-92 .
Lange B, Kobrinsky N, Barnard D, Arthur D, Buckley J, Howells W et al. Distictive demography, biology, and 
outcome of acute myeloid leukaemia and myelodysplastic syndrome in children with Down’s syndrome: 
children’s cancer group studies 2861-91. Blood 1998; 91: 608-15.
Lau J, Wright T. Molecular virology and pathogenesis of hepatitis B. Lancet 1994; 342: 1335-40.
LCI protocol Hepatitis B. Rijswijk, LCI 1998.
LCI protocol Hepatitis C. Rijswijk, LCI 1999.
Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733-45.
Leentvaer-Kuijpers A, Wiersma S, Van Doornum G, Couthino R. Evaluatie van het hepatitis B 
preventieprogramma bij pasgeborenen. II Amsterdam 1989-1991. Ned Tijdschr Geneeskd 1993; 137: 2594-8.
Lehman NI, Sharma DLB, Gust ID. Prevalence of antibody to the hepatitis A virus in a large institution for the 
mentally retarded. J. Med. Virol. 1978:335
Lemon S, Thomas D. Vaccines to prevent viral hepatitis. N Engl J Med 1997; 336: 196-204.
Livengood J, Miller G, Coulter D, Foster LR. Hepatitis B and workers in institutions for the mentally retarded: 
risk of infection for staff in patient care. Am J Prev Med 1989; 5: 170-4.
Lohiya G, Lohiya S, Caires S, Reesal M. Occupational exposure to hepatitis B virus. Analysis of indications for 
hepatitis B vaccine. J Occup Med 1984; 26: 189-96.
Lohiya G, Lohiya S, Caires S, Nizibian R. Occupational risk of hepatitis B from institutionalized mentally 
retarded HBsAg carriers: a prospective study. J Infect Dis 1986; 154: 990-5.
Lohiya G, Lohiya S, Ngo VT, Crinella R. Epidemiology of hepatitis B e antigen and antibody in mentally retarded 
HBsAg carriers. Hepatology 1986; 6: 163-6.
Lohiya S, Lohiya G, Caires S. Epidemiology of hepatitis B infection in institutionalized mentally retarded clients. 
Am J Public Health 1986; 76: 799-802.
Lurman. Eine ikterusepidemie. Berliner Klinische Wochenschrift 1885; 22: 20.
Madden D, Dietzman D, Matthew E et al. Epidemiology of hepatitis B virus in an institution for mentally retarded 
persons. Am J Ment Defic 1976; 80: 369-75.
Madden D, Matthew E, Dietzman D, et al. Hepatitis and Down's syndrome. Am J Ment Defic 1976; 80: 401-6.
Magnius L, Espmark J. New specificities in Australia antigen positive sera distinct from le Bouvier determinants. 
J Immunol 1972; 109: 1017-21.
Mantel N, Haensel W. Statistical aspects of the analysis of data from retrospective studies of disease. JNCI 1959; 
22:719-48.
119
Matthew E, Dietzman D, Madden D et al.. A major epidemic of infectious hepatitis in an institution for the 
mentally retarded. Am J Ep 1973; 96:199-215.
McCallum F. Early studies of viral hepatitis. Br Med Bull 1972; 28: 105-8.
McQuarrie M, Forghani B, Wolochow D. Hepatitis B transmitted by a human bite. JAMA 1974; 230: 723-4.
McGregor M, Cowie V, Wassef K, Veasey D, Munro J. Hepatitis B in a hospital for the mentally subnormal in 
SouthWales. J Ment Defic Res 1988; 32: 75-7.
McMillan B, Hanson RP, Golubjatnikov R; Sinha SK Hepatitis-B surface antigen and antibody: prevalence and 
persistence in institutionalized and noninstitutionalized persons. Public Health Rep 1979; 94: 262-7.
McPhillips J, Collins J, Spigland I. Hepatitis B virus infections transmitted from retarded children to their families 
during brief home exposure. J Pediatr Gastroenterol Nutr 1984; 3: 69-71.
Melartin L, Panelius M. Occurrence of Australia antigen in Finnish mongolism patients. Ann Med Exp Biol Fenn 
1967; 45: 157-8.
Mölsä P. Hepatitis B carriers in a centre for the mentally retarded in Finland and immunogenicity of hepatitis B 
vaccine. J Ment Defic Res 1990; 34: 379-83.
Moradpour P, Wands J. Understanding hepatitis B virus infection. N Engl J Med 1995; 322: 1092-3.
Mura MS, Lamous F, Scalise . Ricera dell antigene Australia (HBsAG) in una communita’ di retardati psico­
mentali nel personale addetto.Boll Ist sieroter milan 1977; 56: 279-81.
Murphy M, Insoft M, Pike-Nobile L, Epstein L. A hypothesis to explain the immune defects in Down’s syndrome. 
In Epstein C, Hassold T, Lott I, Nadel L, Patterson D: Etiology and pathogenesis of Down’s syndrome. 
Wiley-Liss,New York 1995; 147-67.
Nigro G, Taliani G. Nursery-acquired asymptomatic B hepatitis [letter]. Lancet 1989; 1: 1451-2.
Nordenfelt E, Andren-Sandberg M, Lundquist A, Henrikson H. Persistence of Australia (Au) antigen among 
patients in a hospital for mentally retarded and its relation to chronic liver disease. Scand J Infect Dis 1971; 3: 
103-7.
NVAZ. Overzicht enquetegegevens betreffende hepatitis B in instellingen voor zwakzinnigen. TVAZ 1983, no 2.
Oster J, Mikkelsen M, Nielsen A. Mortality and life tables in Down’s syndrome (Mongolism). Acta Paediatr 
Scand 1975: 64: 322-26.
Pakker N, de Witte-van der Schoot E, van Druten J, Verbeek A. Hepatitis B (re)vaccinatie binnen een instelling 
voor verstandelijk gehandicapten. Tijdschr Sociale Gezondheidsz 1994; 72: katern bij nr 4, 20e WEON- 
congres, 11.2.
Perrillo R, Storch G, Bodicky C, Campbell C, Sanders G. Survey of hepatitis B viral markers at a public day 
school and a residential institution sharing mentally handicapped students. J Infect Dis 1984; 149: 796-800.
Perrillo R, Strang S, Lowry O. Different operating conditions affect risk of hepatitis B virus infection at two 
residential institutions for the mentally disabled. Am J Epidemiol 1986; 123: 690-8.
Perrillo P, Schiff E, Davis G et al. A randomized controlled trial of interferon alfa-2b alone and after prednisone 
withdrawel for the treatment of chronic hepatitis B. The hepatitis interventional therapy group. N Engl J Med 
1990; 323:295-301.
Perry E, Chaudhary R, Cleary T, Roughley F. Hepatitis B surface antigen and its subtypes in an institution for the 
mentally retarded. Can Med Ass J 1975; 112: 46-52
Planz O, Seiler P, Hengartner H, Zinkernagel R. Specific cytotoxic T cells eliminate B cells producing virus- 
neutralizing antibodies.Nature 1996; 382: 726-9
Prince AM. An antigen detected in the blood during the incubation period of serum hepatitis. Proc Nat Acad Sci 
USA 1968; 60:814-21.
Pueschel S, Bodenheimer H Jr, Giesswein P, Dean M. The prevalence of hepatitis B surface antigen and antibody 
in home-reared individuals with Down’s syndrome. Res Dev Disabil 1991; 12: 243-9.
Rehermann B, Ferrari C, Pasquinelli C, Chisari F. The hepatitis B virus persists for decades after patients 
recovery form acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nature 
Med 1996;2:1104-8.
120
Reiniers J, Meheus A. Hepatitis B in institutions for the mentally handicapped. Tijdschr Soc Gezondheidsz 1985; 
63:748-54.
Remis R, Rossignol M, Kane M. Hepatitis B infection in a day school for mentally retarded students: transmission 
from students to staff. Am J Public Health 1987; 77: 1183-6.
Renner F, Andrle M, Horak W, Rett A. Hepatitis A and B in non-institutionalized mentally retarded patients. 
Hepatogastroenterology 1985; 32: 175-7.
Ristinen E, Mamtani R. Ethics of transmission op hepatitis B virus by health care workers. Lancet 
1998;352:1381-3.
Robinson W, Clayton D, Greenman R. DNA of a human hepatitis B virus candidate. J Virol 1974; 14: 384-91.
Robinson L. Down’s syndrome and leukemia. Leukemia 1992;6:5.
Roitt I, Brostoff J, Mal D. Immunology. Mosby, London; 1995.
Roure C. Overview of epidemiology and disease burden of hepatitis B in the European region. Vaccine 1995; 13 
suppl 1S18-21
Scanlon S, Khan S. Hepatitis Bina residential population with a mental handicap. Ir Med J 1989; 82: 80-2.
Schoub B, Johnson S, McAnerney J, Blackburn N. Hepatitis B virus prevalence in two institutions for the 
mentally handicapped. S AfT Med J 1993; 83: 650-3.
Schuckink-Kool F. Onderzoek naar hepatitis B in de leefgemeenschap's Heerenloo-Loozenoord. Ruit 1988; dec: 
7-23.
Scotese I, Gaetaniello L. Matarese G, Lecora M, Racioppi L Pignata C. T cell activation associated with an 
aberrant pattern of protein tyrosine phosphorylation after CD3 pertubation in Down’s syndrome. Pediatric 
Research 1998; 44: 252-8.
Scull D, Coope B. Response to hepatitis B vaccination in a mental handicap hospital [letter]. J Intellect Disabil 
Res 1996; 40: 485-6.
Sherlock S. Hepatitis B: the disease. Vaccine 1990; 8 Suppl: S6-9.
Sherlock S, Doley J. Diseases of the liver and the biliary system.10th ed. Oxford: Blackwell 1997.
Siegel M. Susceptibility of mongoloids to infection. Incidence of pneumonia, influenza A, and Shigella 
dysenteriae (Sonne). Am J Hyg 1948; 48:53.
Skinhoj P, Dietrichson O, Dyggve H, Mikkelsen M, Petersen P, Stene J. Hepatitis and hepatitis associated antigen 
(HAA) in Down's syndrome. J Ment Defic Res 1971; 15: 236-43.
Stehr-Green P, Wilson N, Miller J, Lawther A. Risk factors for hepatitis B at a residential institution for 
intellectually handicapped persons. N Z Med J 1991; 104: 514-6.
Stevens C, Alter J, Taylor P. Hepatitis B vaccine in patients receiving hemodialysis. Immunogenecity and 
efficacy. N Engl J Med 1984;31:496-501.
Stevens C, Toy P, Taylor P, Lee T, Yip H. Prospects for control of hepatitis B virus infection: implications of 
childhood vaccination and long-term protection. Pediatrics 1992; 90: 170-3.
St.Clair D. Chromosome 21, Down’s syndrome and Alzheimer’s disease. Journal of Mental Deficiency Research 
1985; 254:213-4.
Sutnick A, London W, Blumberg B, et al. Australia antigen, Down's syndrome and hepatitis. J Clin Invest 1967; 
46: 1122.
Sutnick A, London W, Gerstley B, Cronlund M, Blumberg B. Anicteric hepatitis associated with Australia 
antigen. Occurrence inpatients with Down's syndrome. JAMA 1968; 205: 670-4.
Szmuness W, Pick R, Prince A. The serum hepatitis virus specific antigen (SH): a preliminary report of 
epidemiologic studies in an institution for the mentally retarded. Am J Epidemiol 1970; 92: 51-61.
Szmuness W, Prince A. The epidemiology of serum hepatitis (SH) infections; a controlled study in two closed 
institutions. Am J Epidemiol 1971; 94: 585-95.
Szmuness W, Prince A, Etling G, Prick R. Development and distribution of hemaglutinating antibody against the 
hepatitis B antigen in institutionalised populations. J Infect Dis 1972; 126: 498-506.
121
Szmuness W, Purcell R, Dienstag J. Antibody to Hepatitis A antigen in institutionalized mentally retarded 
patients J.A.M.A. 1977; 237; 1702.
Szmuness W, Harley E, Ikram H, Stevens C. Sociodemographic aspects of the epidemiology of hepatitis B. In: 
Vyas GN, Cohen S, Schmid R, eds. Viral hepatitis. Philadelphia: Franklin Institute Press, 1978: 297-320. 
Szmuness W, Stevens C, Harley E et al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical 
trial in a high-risk population in the United States. N Engl J Med 1980; 303: 833-41.
Szmuness W, Stevens CE, Harley EJ. A controlled clinical trial of the efficiency of the hepatitis B vaccine 
(Heptavax B): A final report. Heptology 1981; 1: 377-85.
Szmuness W, Stevens C, Harley E et al. Hepatitis B vaccine in medical staf of hemodialysis units: efficacy and 
subtype cross protection N Engl J Med 1982; 307: 1481-6 
Tevaluoto-Aarnio M. Epidemiology of hepatitis b antigenemia in an institution for mentally retarded. Scand J 
Infec Dis 1974; 6:309-13.
Thomson R, Rawlins M, James O, Tyrer S, Codd A. Low prevalence of hepatitis B in mental handicap hospital 
[letter]. Lancet 1989; 1: 44-5.
Tiku M, Beutner K, Carmody P, Sultz H, Kaul B, Ogra P. Hepatitis B infection in health care personnel of an 
institution for mentally handicapped children and adults. J Clin Microbiol 1976; 3(5): 469-73.
Tiku ML, Beutner KR, Ramirez. Distribution and characteristics of hepatitis B surface antigen in body fluids on 
institutionalized children and adults. J Infect Dis 1977; 136: 571-6.
Tiollais P, Pourcel C, Dejean A. The hepatitis B virus. Nature 1987; 317: 489-95.
Torre D, Giola M, Zeroli C, Ferrario G, Broggini M, Agrifoglio L, Botta V. Hepatitis B and C infection in an 
institution for the mentally handicapped [letter]. Infection 1993;21:410-1.
Torre D, Maggiolo F, Broggini M, Botta-V. Age-related response to hepatitis B vaccine in the mentally retarded 
[letter]. Lancet 1984; 2: 866.
Torre D, Broggini M, Botta V, Sampietro C. Duration of immunity to hepatitis B vaccination in institutionalized 
mentally retardedpatients. Vaccine 1989; 7: 102-3.
Troisi C, Heiberg D, Hollinger F. Normal immune respons to hepatitis B vaccine in patients with Down's 
syndrome. JAMA 1985; 254: 3196-9.
Vajro P, Lettera P, Fontanella A, et al. Vaccination against hepatitis B in preschool children with Down's 
syndrome. J Intellect Disabil Res 1992; 36: 77-81. 
van Damme P, Meheus A. Hepatitis B in mental handicap hospitals [letter]. Lancet 1989; 1: 840-1. 
van Damme P, Vranckx R, Safary A, Andre F, Meheus A. Protective efficacy of a recombinant deoxyribonucleic 
acid hepatitis B vaccine in institutionalized mentally handicapped clients. Am J Med 1989; 87: 26S-29S. 
van Damme P, Vranx R, Meheus A. Immunogenicity and efficacy of recombinat DNA hepatitis B vaccine in 
institutionalized patients with Down’s syndrome. Vaccine 1990; 8: 853-4. 
van Damme P, Cramm M, van der Auwera JC, Vranckx R, Meheus A. Horizontal transmission of hepatitis B 
virus. Lancet 1995; 345: 27-9.
Van der Meer J. Defects in host defense mechanisms. In Rubin RH, Young LS, eds. Clinical aproach to infections 
in the compromised host; 3rd ed. New York: Plenum Press, 1994. 
van Ditzhuijsen TJ, de Witte-van der Schoot PPM, van Loon AM, Rijntjes PJ, Yap SH. Hepatitis B virus 
infection in an institution for the mentally retarded. Am J Epidemiol 1988; 128: 629-38. 
van Ditzhuijsen TJ, Kleijnen FM, Rijntjes PJ, van Loon AM, Yap SH. The prevalence of serological markers, 
hepatitis B virus DNA and elevated serum amino transferase values in institutionalized mentally handicapped 
males and females: an epidemiological study of HBV infection in residents with Down's syndrome or other 
forms of mental deficiency. Eur J Epidemiol 1988; 4: 349-56.
Van Ditzhuijsen T. Clinical and epidemiologic aspects of hepatitis B virus DNA detection. Thesis. Nijmegen 
1988.
van Hattum J, de Gast GC. Virale hepatitis. In: Van Furth R, De Geus AA, Hoepelman IM, Van der Meer SWM, 
Verhoef J, eds. Leerboek der infectieziekten. Hattum: Bohn Stafleu Van Lochum, 1992: 269-86.
122
van Schrojenstein Lantman-de-Valk H, Haveman M, Crebolder H. Comorbidity in people with Down's syndrome: 
a criteria-based analysis. J Intellect Disabil Res 1996; 40: 385-99.
Vermeltfoort J. Revaccinatie tegen hepatitis B bij non- en hporesponders in een groep geestelijk gehandicapten. 
Ned Tijdschr Geneeskd 1991; 135: 2173-5.
Vierncci A, Ragazzini F. Australia antigen and antibodies: a study in Italian patients. Folia Allergol Roma 1970; 
17: 524-37.
Vrijmoeth P, Heijtink R, Schreuder H, Kroes A. Vaccinatie tegen hepatitis B mogelijk aangewezen bij 
geinstitutionaliseerde oudere verstandelijk gehandicapten met geisoleerde anti-HBc-positiviteit van het 
prevaccinatieserum. Ned Tijdschr Geneeskd 1997; 141: 1694-7.
Vroom BCM, van Hattum J. Virale Hepatitis. Utrecht :AZU, 1999.
Wagemans A, Zielhuis G. Een gedifferentieerd hepatitis B vaccinatiebeleid in een zwakzinnigeninstituut. Ned 
Tijdschr Geneeskd 1985; 129: 1325-8.
Wahl M, Hermodsson S, Iwarson S. Immune responses to hepatitis B vaccine in the mentally retarded. J Infect 
1983; 7 (Suppl): 47-51.
Wainwright R, McMahon B, Bulkow L et al. Duration of immunogenicity and efficacy of hepatitis B vaccine in a 
Yupik Eskimo population. JAMA 1989; 261: 2362-6.
Ward R, Krugman S, Giles J, et al. Infectious hepatitis: Studies on its natural history and prevention. N Eng J Med 
1958; 258: 407-16.
West D, Snavely D, Zajac A, Brown G, Babb C. Development and persistence of antibody in a high risk 
institionalized population give plasma derived hepatitis B vaccine. Vaccine 1990; 8:111-14.
West D, Watson B, Lichtman J, Hesley T, Hedberg K. Persistence of immunologic memory for twelve years in 
children given hepatitis B vaccine in infancy. Pediatr Infect Dis J.1994:13: 745-7
Whittle H, Maine N, Pilkington J, Mendy M, Fortuin M, Bunn J et al. Long-term efficacy of continuing hepatitis 
B vaccination in infancy in two Gambian villages. Lancet 1995; 345: 1089-92.
WHO. Hepatitis B Vaccine: making global progress..Http://www.who.int/gpv-dvacc/diseases/hepatitis b.htm. 
1998.
Williams C, Weber F, Cullen J, Kane M. Hepatitis B transmission in school contacts of retarded HBsAg students. 
J Pediatr 1983; 103: 192-6.
Williams C. Acquisition of hepatitis B by a mentally retarded community student [letter]. J Infect Dis 1985; 151: 
741.
Williams C, Weber F, McKim M, Steadham C, Kane M. Hepatitis B virus transmission in a public school: effects 
of mentally retarded HBsAG carrier students. Am J Public Health. 1987; 77: 476-8.
Williamson H, Lehmann N, Dimitrakakis M, Sharma D, Gust I. A longitudinal study of hepatitis infection in an 
institution for the mentally retarded. Aust NZ J Med 1982; 12: 30-4.
WIP. Richtlijnen voor infectie preventie ten behoeve van de zorg voor mensen met een verstandelijike handicap. 
W.I.P Leiden; 1997.
Wismans P. The hepatitis B virus. In: The immune response to hepatitis B virus antigens: Studies in vivo and in 
vitro [dissertation]. RijksuniversiteitUtrecht, 1989.
Wismans P, van Hattum J, Mudde GC, Endeman HJ, Poel J, de Gast G. Is booster injection with hepatitis B 
vaccine necessary in healthy responders? A study of the immune response. J Hepatolog 1989; 8: 236-40.
Wisniewski K, Dalton A, Crapper M, Lachlan D, Wen G, Wisniewski H. Alzheimer’s disease in Down’s 
syndrome: clinicopathologic studies. Neurology 1985; 35: 957-61.
Wright T, Lau J. Clinical aspectss of hepatitis B virus infection. Lancet 1993; 342: 1340-4.
Wood R, MacDonald K, White K, Hedberg C, Hanson M, Osterholm M. Risk factors for lack of detectable 
antibody following hepatitis B vaccination of Minnesota health care workers. JAMA 1993; 270: 2935-9.
Yamachi K et all. Suppression of hepatitis B ntibody synthesis by factor made T cells from chronic hepatitis B 
carriers. The Lancet,1988;I:324-6.
123
Zaaijer H. Virale hepatitis In Hoepelman I, van der Noorda J, Sauerwein R, Verburgh H. Microbiologie en 
infectieziekten. Bohn StafleuVan Loghem, Houten; 1999: 197-213.
Zajac BA, West DJ, McAleer WJ, Scolnick EM. Overview of clinical studies with hepatitis B vaccine made by 
recombinant DNA. J Infect 1986;13 Suppl A
Zigman W, Schupf N, Lubin R, Silverman W. Premature regression of adults with Down’s syndrome. American 
Journal of Mental Deiciency 1987; 92: 161-8.
Zinkernagel K, Eke S, Achile P et al. Antigen localization regulates immune responses in a dose- and time- 
dependant fashion: a geographic view of immune reactiviety. Imm Rev 1997; 156:199-09.
Zuckermann AJ. The history of viral hepatitis. In Zuckermann AJ, ed. Human viral hepatitis: hepato-associated 
antigen andvirusses.Amsterdam: North-Hollandpublishers, 1975: 1-18.
Zuckerman AJ. Who should be immunised against hepatitis B? [editorial]. Br Med J Clin Res Ed 1984; 289: 
1243-4.
124
Summary
Based on the historical background - of hepatitis B in general as well as in mentally 
handicapped persons, the present knowledge about the disease, data on prevalence and risk 
factors for hepatitis B in the mentally handicapped from the literature, results from 
empirical research in the Netherlands and a hypothesis about the high risk for hepatitis B 
infection in Down’s syndrome - guidelines have been developed for a Dutch prevention 
policy for persons with a mental handicap in general and for persons having Down’s 
syndrome in particular.
The research in the Netherlands consisted of different phases.
The formerly Sint Augustinus-stichting in Gennep, which is now part of Vizier, used to be a 
general residential institution for about 500, mainly male, mentally handicapped residents. 
Hepatitis B occurred frequently in this institution. Therefore a prevalence study regarding 
hepatitis B virus (HBV) markers was conducted among all residents in 1980. The 
prevalence of HBV infection was considerably higher compared to that of the general Dutch 
population: 60% versus 4.5% positive for HBV-markers. Fifty percent of the residents of 
this institution showed antibodies against HBV, indicating that they were infected in the 
past. Ten percent appeared to be HBV carriers. Furthermore, it appeared that persons with 
Down’s syndrome were chronically infected more frequently compared to other mentally 
handicapped. Also people admitted at young age or people admitted for a long period 
appeared to be more often infected with HBV.
In 1982 a vaccine against hepatitis B virus became available. The Dutch Health Council 
established that mentally handicapped, living in residential institutions, were at high risk for 
hepatitis B infections and the Council strongly advised to vaccinate them all.
Prior to starting a vaccination programme, another study was conducted in the Sint 
Augustinus-stichting in 1983. This survey included 187 persons who were HBV marker­
negative at the screening of 1980 or who were institutionalised after 1980. Only one person 
had suffered from a clinical hepatitis B infection during that last three years. Eleven other 
persons seroconverted to positive hepatitis B marker during that same period, indicating that 
they had suffered from a subclinical hepatitis B infection. Three of these twelve persons 
became chronically infected with hepatitis B. It was calculated that the annual attack rate 
was 40 times higher compared to that in the general Dutch population (2.3% vs. 0.05%). In 
care taking staff the HBV prevalence was slightly higher than that of the general population 
in the same region of the country.
After the results of this study became available it was decided that the seronegative mentally 
handicapped residents should be vaccinated against HBV in the Sint Augustinusstichting. 
Furthermore, all new admissions should be screened for HBV-markers and if seronegative 
receive HBV vaccination ad once. All take caring personnel were offered a hepatitis B 
vaccination.
A survey regarding the effects of vaccination was conducted between 1984 and 1989 in the 
same institution. It appeared that the primo-response to the vaccination of the 194 mentally 
handicapped vaccinees was comparable to HBV vaccination responses in the general 
population. More than 85% had a protective antibody level of more than 10 IU/l, and 75% 
had a level of more than 100 IU/l. At a young age the primo-response did not differ between
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persons with Down’s syndrome and other mentally handicapped persons. The primo- 
response was lower when persons were vaccinated at an older age. This effect was stronger 
for persons having Down’s syndrome. Only 60% of the vaccinees with Down’s syndrome 
had a level of more than 10 IU/l versus 73% in persons without Down’s syndrome when 
older than 30 years after primo-vaccination. Persons with a response of less than 10 IU/l 
were boostered once or twice.
Almost 70% of all vaccinees still had a level of more than 10 IU/l in 1989, 5 years after 
primo-vaccination. Persons with levels lower than 100 IU/l were boostered once more and 
afterwards only 10% of all vaccinees had an unprotective level (10 IU/l). The level 5 years 
after vaccination also depended on age. Persons who were vaccinated when older than 20 
years had more frequently a declining antibody level. The development of the levels was not 
different for persons having Down’s syndrome. Revaccination after 5 years showed 
sufficient mounted antibody responses in those who respond well to the primo-vaccination, 
including those with Down’s syndrome.
After initiation of the vaccination programme the annual attack rate in this institution 
declined from 2.3% to 0.1%, more comparable to the attack rate in the general population. 
The prevalence of HBV carriers decreased gradually the Sint Augustinusstichting from 
10.4% in 1980 to 8.3% in 1995 and the prevalence of HBeAg positive carriers from 39.2% 
to 9.5% during the same period.
In 1993 data on the prevalence of hepatitis B among 50% of all mentally handicapped living 
in Dutch residential institutions came available through a questionnaire based survey. It 
appeared that in these residential institutions for mentally handicapped on average 3.8% of 
the residents had chronic hepatitis B infection and 28.8% was HBV-marker positive. The 
prevalence of hepatitis B infection appeared to be slightly lower in small institutions ( 250 
residents) compared to the larger ones.
Because little was known about the distribution of hepatitis B among mentally handicapped 
who do not live in traditional residential institutions, a nation-wide hepatitis B prevalence 
serological study was conducted in 1994 and 1995 among 1,351 persons using different 
facilities: 30 group-homes, 21 adult day-care centres, one sheltered workshop and one 
institution for mild mentally handicapped young persons. Five percent of the research 
population had HBV-marker and 0.9% were chronically infected with hepatitis B. In only 
two of the investigated facilities, one adult day-care centre and the sheltered workshop, an 
elevated hepatitis B transmission was recorded.
Another purpose of this serological survey was to identify determinants contributing to an 
elevated hepatitis B transmission. Hepatitis B infections appeared to occur more frequently 
in persons having Down’s syndrome, in males, in persons between 30 and 50 years of age, 
in persons who had lived in a general institution at some point in their lives and in persons 
originated from countries with a higher prevalence of hepatitis B than the Netherlands.
From an extensive literature survey, running from 1969 until 1999, including 93 population 
studies and about 10,000 mentally handicapped individuals, it was concluded that the 
prevalence of hepatitis B was usually intermediately high (2-7% HBV carriers) or high (8% 
HBV carriers or more) in residential institutions for mentally handicapped and much lower 
in mentally handicapped individuals living at home. The HBV prevalences within 
institutions incline to decrease during the years. Depending on the presence of HBeAg one
126
could distinguish institutions with active hepatitis B and those where hepatitis B is almost 
eliminated. Transmission of hepatitis B was reported in students and teachers in special 
school for mentally handicapped and in family members and care-taking personal of 
mentally handicapped HBV carriers. It was calculated that persons with Down’s syndrome 
run a 2-fold higher risk for acquisition HBV infection, a 5-fold higher risk for HBsAg 
carriership and a 4-fold higher risk for persisting HBeAg.
Based on the data of this thesis we conclude that persons with Down’s syndrome should be 
vaccinated against hepatitis B at a young age because they run a higher risk for a hepatitis B 
infection in the following way: they contract the infection easily and they develop 
asymptomatic and chronic hepatitis B easily. In addition they show a lower response to 
hepatitis B vaccination when they get older. We hypothesised that the high susceptibility for 
hepatitis B in Down’s syndrome may be caused by overexpression of 21 chromosome 
genes, resulting in minor primary immune defects and early senescence of the immune 
system.
Environmental conditions mainly influence the risk for other mentally handicapped to acquit 
HBV infection. Therefore all residents of the traditional general institutions should be 
vaccinated against hepatitis B, because they live in large communities in which the 
prevalence of HBV infections is mostly increased and optimal hygienic conditions are hard 
to achieve. Under these circumstances hepatitis B infections are transferred easily and 
without detection. Institutional staff in charge of the daily care of the HBV carriers has to be 
vaccinated too. HBV carrying staff is only allowed to work in these institutions if the 
mentally handicapped for whom they take care are sufficiently protected against hepatitis B. 
In small scale housings the best policy is to vaccinate family-members, housemates and 
caring staff only if there are persons with chronic hepatitis B infections involved. It is 
advised to screen people at risk before entering a special facility for mentally handicapped 
The same policy has to be implanted in day-care centres, schools or sheltered workshops in 
case good hygienic conditions are impossible to achieve.
These recommendations have been adapted by the National Health Council and recently 
also by Mrs. Borst, minister of Health and the Health Insurance Executive Board of the 
Netherlands.
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Samenvatting
Dit proefschrift geeft een onderbouwing voor een Nederlands hepatitis B preventiebeleid 
voor mensen met een verstandelijke handicap en in het bijzonder voor mensen met het 
syndroom van Down. Daarbij is onder meer gebruik gemaakt van de geschiedenis van 
hepatitis bij mensen met een verstandelijke handicap, van literatuurgegevens over 
prevalentie en risicofactoren, van empirische onderzoeksgegevens uit Nederland en van een 
hypothese over de oorzaak van het verhoogd risico op hepatitis B bij mensen met het 
syndroom van Down.
Het onderzoek in Nederland heeft een aantal fases doorlopen.
In de vroegere Sint Augustinusstichting (nu onderdeel van Vizier in Gennep), een 
Algemeen Zwakzinnigen Instituut (AZI), woonden voorheen hoofdzakelijk mannen. Omdat 
aldaar klinische hepatitis B regelmatig voorkwam werd in 1980 een prevalentiestudie 
uitgevoerd naar de merkstoffen van hepatitis B virus (HBV-markers). De HBV 
besmettingsgraad bleek in dit instituut vele malen hoger te zijn dan die van de Nederlandse 
bevolking: 60% tegenover 4.5%. Bij 50% van de bewoners werden antistoffen tegen HBV 
aangetoond. De aanwezigheid van antistoffen wijst op een infectie in het verleden. Tien 
procent van de bewoners was HBV drager. Verder bleken personen met het syndroom van 
Down vaker drager te zijn. Van de personen met het syndroom van Down was 18,8% HBV 
drager tegenover 7,0% van de personen met een andere oorzaak van de verstandelijke 
handicap. Mensen die op jonge leeftijd waren opgenomen en mensen die al lange tijd op het 
instituut verbleven hadden vaker een HBV besmetting doorgemaakt.
In 1982 kwam een vaccin tegen hepatitis B beschikbaar. De Nederlandse Gezondheidsraad 
stelde op dat moment vast dat verstandelijk gehandicapten die in instellingen verblijven, tot 
de risicogroepen behoren en adviseerde hen te vaccineren. Alvorens dit advies ten uitvoer te 
brengen vond in 1983 in de Sint Augustinusstichting opnieuw een onderzoek naar HBV- 
markers plaats. Dit onderzoek betrof alle verstandelijk gehandicapte bewoners, in totaal 
187, bij wie in 1980 geen of onvoldoende HBV-markers waren aangetroffen. Voorts alle 
bewoners die na 1980 in het instituut waren opgenomen. Ook het personeel werd deze keer 
onderzocht. Het was bekend dat slechts één bewoner in de drie tussenliggende jaren een 
klinische hepatitis B had doorgemaakt. Bij nog 11 andere personen, die in 1980 ook al op 
het instituut woonden, werden HBV-markers aangetoond. Dit betekende dat deze 11 een 
subklinische infectie hadden doorgemaakt. Drie personen waren chronisch drager 
geworden. Wij rekenden uit dat de “annual attack rate” voor hepatitis B in de Sint 
Augustinusstichting beduidend hoger was dan die in de normale populatie (2.3% versus
0.05%). Bij het verzorgend personeel werd, in vergelijking met het niet verzorgend 
personeel en met de normale populatie in de regio, een licht verhoogde prevalentie van 
HBV-markers aangetroffen. Nadat de resultaten van het onderzoek bekend waren geworden 
werd besloten alle seronegatieve bewoners te vaccineren, alsmede het verzorgend personeel. 
Alle nieuw bewoners zouden in het vervolg bij binnenkomst gescreend worden op HBV- 
markers. Bij een seronegatieve testuitslag zou vaccinatie volgen.
Een onderzoek naar de korte en lange termijn effecten van hepatitis B vaccinatie bij mensen 
met een verstandelijke handicap werd uitgevoerd tussen 1984 en 1989, wederom
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op de Sint Augustinusstichting. De primo-respons op vaccinatie was over het algemeen 
goed en vergelijkbaar met die bij niet verstandelijk gehandicapten. Ruim 85% van de 
gevaccineerden toonde een beschermende antilichaamspiegel van meer dan 10 IU/l anti- 
HBs en 75% zelfs een spiegel van meer dan 100 IU/l. Een spiegel van meer dan 100 IU/l 
wordt tegenwoordig bij iedere vaccinatie nagestreefd. Op jonge leeftijd was de primo- 
respons van personen met het syndroom van Down identiek aan die van personen zonder 
het syndroom van Down. De primo-respons bleek lager te zijn bij vaccinatie op oudere 
leeftijd. Dit effect was sterker voor mensen met het syndroom van Down. Na het dertigste 
levensjaar had slechts 60% een beschermende spiegel van meer dan 10 IU/l anti-HBs in 
tegenstelling tot 73% van de personen zonder het syndroom van Down. Personen met een 
anti-HBs spiegel van minder dan 10 IU/l kregen een of twee keer een booster in mei en 
oktober 1985. De helft ontwikkelde alsnog een beschermende antilichaamspiegel.
V ijfjaar na de primo-vaccinatie (juli 1989) bleek nog bijna 70% van alle gevaccineerden 
een antilichaamspiegel van meer dan 10 IU/l te hebben en 50% procent een spiegel van 
meer dan 100 IU/l. De hoogte van de anti-HBs spiegel 5 jaar na vaccinatie bleek af te 
hangen van de leeftijd. Bij personen die ten tijde van de eerste vaccinatie ouder waren dan 
20 jaar daalden de antilichaamspiegels meer. Dit effect was sterker bij personen met het 
syndroom van Down. De mensen met een spiegel van minder dan 100 IU/l anti-HBs kregen 
een booster. Na deze booster toonde 90% van alle gevaccineerden een spiegel van meer dan 
100 IU/l anti-HBs. De respons op de booster was voor mensen met het syndroom van Down 
gelijk aan die van mensen zonder het syndroom Down. Deze goede respons betekent dat het 
immunologisch geheugen van de gevaccineerde personen uitstekend was. Uiteindelijk had 
in oktober 1989 nog 10% van de gevaccineerde bewoners een onvoldoende beschermende 
antilichaamspiegel (< 10 IU/l anti-HBs).
Door de hepatitis B vaccinaties daalde de “annual attack rate” voor HBV infecties binnen 
het instituut van 2,3% naar 0,1%. Voorts nam het percentage HBV dragers in de Sint 
Augustinusstichting geleidelijk af van 10,4 in 1980 naar 8,3 % in 1995. Het percentage 
HBeAg positieve dragers daalde van 39,2 naar 9,5% gedurende dezelfde periode.
In 1993 zijn met behulp van een schriftelijke enquête de prevalentiegegevens van 50% van 
alle bewoners in Nederlandse AZI’s beschikbaar gekomen. Binnen de responderende AZI’s 
(32) was gemiddeld 3,8% van de bewoners HBV drager. Gemiddeld 28,8% van de 
bewoners had antistoffen tegen HBV. De prevalentie van HBV infecties was in de kleinere 
instituten (< 250 bewoners) een fractie lager dan die in de grotere instituten. Binnen 75% 
(28) van de instituten was de prevalentie van HBV dragerschap groter dan 1%. In instituten 
voor meervoudig gehandicapten was de HBV prevalentie vergelijkbaar met die van de 
Nederlandse bevolking.
Omdat weinig bekend was over de verspreiding van hepatitis B bij mensen met een 
verstandelijke handicap, die niet in de traditionele instituten wonen, werd op verzoek van de 
toenmalige Geneeskundige Hoofdinspecties, van de Geestelijke Volksgezondheid en van de 
Volksgezondheid, afdeling infectieziekten, in 1994 en 1995 een landelijk serologisch 
hepatitis B prevalentieonderzoek uitgevoerd bij 1351 personen die gebruik maken van 
andersoortige voorzieningen: 30 Gezins Vervangende Tehuizen (GVT’s), 21 Centra Voor 
Dagbesteding (CVD’s), een sociale werkvoorziening en een instituut voor jonge mensen 
met een licht verstandelijke handicap. Van de onderzochte groep bleek 5 % HBV-markers 
te hebben Het percentage HBV dragers was 0,9%. Slechts in 2 van de onderzochte 
voorzieningen, een CVD en de sociale werkvoorziening kon een verhoogde HBV
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transmissie worden aangetoond. In hetzelfde onderzoek is gezocht naar de factoren die 
bijdragen aan de verhoogde kans op een besmetting met HBV. Het bleek dat HBV- 
besmettingen significant vaker voorkwamen bij mensen tussen de 30 en 50 jaar, mensen met 
het syndroom van Down, mannen, personen die eerder in een AZI verbleven en personen 
afkomstig uit landen met een verhoogde HBV prevalentie.
Een uitgebreide literatuurstudie, die 93 onderzoekspopulaties uit voornamelijk westerse 
landen omvatte en in totaal ongeveer 10.000 verstandelijk gehandicapten, leidde tot de 
conclusie dat de prevalentie van hepatitis B in het merendeel van de residentiële instituten 
middelmatig hoog (2-7% HBV dragers) dan wel hoog (> 8% HBV dragers) is. Bij 
thuiswonende verstandelijk gehandicapten bleek deze prevalentie over het algemeen lager 
en vergelijkbaar met die van de plaatselijke bevolking. De prevalenties van HBV infecties 
binnen de instituten nemen geleidelijk af. Men kon instituten onderscheiden waar de 
transmissie van hepatitis B aanzienlijk was en instituten waar de infectie onder controle is 
gekomen. Hepatitis B transmissie werd ook aangetoond bij leerlingen en leerkrachten van 
speciale scholen voor kinderen met een verstandelijke handicap alsmede bij gezinsleden en 
verzorgend personeel van verstandelijk gehandicapte HBV dragers. Dezelfde studie toonde 
aan dat mensen met het syndroom van Down twee keer zo vaak als anderen besmet werden 
met HBV, vijf keer zo vaak chronisch drager werden en vier keer zo lang infectieus bleven.
Op basis van de resultaten van de in dit proefschrift beschreven studies adviseren wij om 
alle mensen met het syndroom van Down tegen hepatitis B te vaccineren, bij voorkeur op 
heel jonge leeftijd. Mensen met het syndroom van Down lopen een duidelijk verhoogd 
risico met betrekking tot hepatitis B. Zij worden gemakkelijker geïnfecteerd met HBV; bij 
hen verloopt de infectie vaker ongemerkt en zij worden vaker chronisch drager. Daarnaast 
neemt bij het ouder worden de vaccinatie-respons af. De verhoogde gevoeligheid van 
mensen met het syndroom van Down voor hepatitis B infectie wordt naar onze mening 
veroorzaakt door een te veel aan genproducten van het extra chromosoom 21 met als gevolg 
partiële immuundefecten en vroegtijdige veroudering van het immuunsysteem.
Voor andere verstandelijk gehandicapten spelen met name omgevingsfactoren een grote rol 
bij de kans op besmetting met hepatitis B. Wij adviseren om alle bewoners van traditionele 
algemene zwakzinnigen inrichtingen tegen hepatitis B te vaccineren. In deze instituten is de 
prevalentie van hepatitis B doorgaans verhoogd en optimale hygiëne mag niet worden 
verwacht van ernstig en matig verstandelijk gehandicapte personen. Personeel dat belast is 
met de dagelijks zorg van HBV dragers dient eveneens gevaccineerd te worden. Personeel 
dat HBV drager is mag alleen die verstandelijk gehandicapte bewoners verzorgen die 
voldoende beschermd zijn tegen hepatitis B besmetting.
In kleinschalige woonvoorzieningen, gezinsvervangende tehuizen, logeerhuizen en kort 
verblijfhuizen dienen alle huisgenoten alsook het verzorgend personeel van HBV dragers te 
worden gevaccineerd. Dit advies sluit aan bij dat van de Gezondheidsraad die adviseert om 
contacten binnen het gezin of woongemeenschappen van HBV dragers te vaccineren. Wij 
bevelen voorts aan om toekomstige bewoners afkomstig uit risicogroepen (mensen met het 
syndroom van Down, mensen die eerder in een instituut woonden, mensen afkomstig uit 
middelhoge of hoog endemische gebieden en mensen met wisselende seksuele contacten) 
bij binnenkomst onmiddellijk te screenen op HBV-markers.
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In dagvoorzieningen zoals scholen en dagverblijven dient tot vaccinatie te worden 
overgegaan als dragers onvoldoende in staat worden geacht de normaal geldende hygiëne in 
acht te nemen.
Alle voorzieningen voor verstandelijk gehandicapten dienen te beschikken over een 
hygiëne-protocol.
Bovengenoemde aanbevelingen zijn door de Gezondheidsraad overgenomen en dit jaar 
door mevrouw Borst, minister van Volksgezondheid, Welzijn en Sport en de 
Ziekenfondsraad geëffectueerd.
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'ankwoord
Zonder hulp van velen had dit proefschrift nooit tot stand kunnen komen.
Allereerst wil ik noemen al degenen bij wie we bloed mochten prikken. Voor velen van hen 
was dit een spannende gebeurtenis. Sommigen moesten grote angsten overwinnen vooraleer 
een buisje bloed kon worden afgenomen.
De directie van de Sint Augustinusstichting, later die van Saamvliet en momenteel de Raad 
van Bestuur van Vizier ondersteunde mij, niet alleen materieel maar ook immaterieel en 
moreel.
Mijn collega’s van de Sint Augustinusstichting waren immer nauw betrokken bij de 
onderzoeken en de consequenties die daaruit voortkwamen.
Mijn collega's van de deelnemende semi- en extramurale voorzieningen: WODAGG in 
Uden (onderdeel van Vizier), INTOS in Gennep, NOVO in Groningen, AGO in Amsterdam 
en Groot Emaus in Ermelo, overtuigden de directies van het belang van het onderzoek. Zij 
zochten uit welke personen voor deelname in aanmerking kwamen en vroegen vervolgens 
toestemming voor het onderzoek. Zij beantwoorden vele vragen van familieleden en 
groepsleiding. Zij hielpen mij bij het afnemen van de bloedmonsters.
Veel van mijn collega’s AVG uit het gehele land vulden enquête formulieren in.
Mijn medeleden van de commissie infectieziekten van de NVAZ dachten steeds actief en 
constructief mee over het gewenste beleid en de gevolgen die dat met zich mee kon 
brengen.
Velen waren betrokken bij het daadwerkelijke bloedonderzoek. Zonder iemand te kort te 
doen wil ik speciaal vermelden de medewerkers van de polikliniek van de Sint 
Augustinusstichting. Zij prikten, gingen met mij op stap en verzorgden vele secretariële en 
administratieve werkzaamheden.
Groepsleiding, intra- en semimuraal begeleidde vele mensen bij het bloed prikken, hetgeen 
vaak inspannend was. Ook vulden velen van hen vragenformulieren in, voor zover dat 
tenminste mogelijk was.
De medewerkers van het Virologisch Laboratorium van het Academisch Ziekenhuis 
Nijmegen (AZN) verrichtten het laboratoriumonderzoek. Op de meest mogelijke en 
onmogelijke tijden kregen zij veel bloed te verwerken.
Nadine Pakker en Judith van de Akker, studentes Biomedische Gezondheids-weten- 
schappen Katholieke Universiteit Nijmegen (KUN), hebben in het kader van hun 
afstudeerstages Epidemiologie vele statistische analyses uitgevoerd en wisten belangrijke 
epidemiologische conclusies te trekken. Een en ander hebben zij neergeschreven in 
afstudeerscripties. Zij werden daarbij begeleid door Hans van Druten, vakgroep Medische 
Informatiekunde, Epidemiologie en Statistiek KUN.
Charlotte Moret en Moniek de Witte deden veel voorbereidend werk voor het proefschrift. 
Lesley de Witte corrigeerde de uiteindelijke versie op overtredingen tegen de Engelse taal. 
De medewerkers van de afdeling Informatisering en Automatisering van Saamvliet losten 
vele conversieproblemen op.
Het Landelijk Informatiecentrum Hepatitis B (LIH) gaf mij toestemming gebruik te maken 
van hun huisstijl.
Monique Eijgenberger, Moniek de Witte en Katrien de Witte hielpen bij de afwerking. Hun 
eindeloze geduld en grote nauwkeurigheid zijn het uiterlijk van het proefschrift zeer ten 
goede gekomen.
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Mijn promotoren Andre Verbeek en Jos van der Meer en copromotor Joep Galama waren 
degenen die mij inspireerden tot en begeleidden bij het schrijven van het uiteindelijke 
proefschrift. Zij waren immer zéér behulpzaam, zéér kritisch en zéér stimulerend. Heel 
speciaal wil ik Andre Verbeek noemen, die de gang er in hield en steeds oplossingen 
bedacht en aanreikte om het mij mogelijk te maken het proefschrift tot een goede einde te 
kunnen brengen.
De grootste steun kreeg ik van het thuisfront. Gedurende vele jaren was hepatitis B een 
terugkomend gespreksonderwerp binnen ons gezin. Moniek, Katrien en Lot, onze dochters, 
vonden het stoer dat hun moeder zou gaan promoveren en zouden het een afgang gevonden 
hebben als de zaak niet zou zijn doorgegaan. Dit ondanks de geregelde spanningen en 
ongemakken die het onderzoek en het schrijven van het proefschrift met zich meebrachten. 
Verschillende werkstukken zijn inmiddels aan het onderwerp gewijd. Ook vergezelden en 
hielpen zij mij als ik weer eens voor het onderzoek op stap moest. Dat deed overigens ook 
mijn moeder, die daarnaast steeds veel begrip kon opbrengen voor het feit dat ik niet zo 
veel tijd voor haar had.
Theo heeft er bij voortduring op aangedrongen mijn onderzoeksresultaten op te schrijven. 
Hij heeft mij daar op velerlei manieren en onder velerlei omstandigheden bij geholpen.
Ik dankjullie allen heel hartelijk.
134
Curriculum Vitae
Els van der Schoot werd geboren op 29 mei 1947 te Breda. Op het Sint Janslyceum in 
’s Hertogenbosch behaalde zij in 1966 het HBS B diploma. Zij studeerde geneeskunde aan 
de Katholieke Universiteit van Nijmegen. Na haar artsexamen in 1974 ging zij werken als 
arts voor mensen met een verstandelijke handicap. De eerste jaren op Maria Roepaan te 
Ottersum en in 1979 op de Sint Augustinusstichting te Gennep (beiden onderdeel van het 
huidige Vizier te Gennep). Na opgeleid te zijn bij de Stichting Sociale Gezondheidszorg 
(SSG) te Utrecht, nu Netherlands School of Public Health, werd zij in 1985 geregistreerd 
als Arts voor Verstandelijk Gehandicapten. Haar eindscriptie was getiteld: “Hepatitis B in 
een internaat voor geestelijk gehandicapten”. Zij was lid van de commissie Hepatitis B van 
de Gezondheidsraad die in 1996 het rapport “Bescherming tegen Hepatitis B “ heeft 
uitgebracht. Gedurende vele jaren was zij voorzitter van de commissie infectieziekten van 
de NVAZ (Nederlandse Vereniging voor Artsen werkzaam in de Zorg voor mensen met een 
verstandelijke handicap).
Vanaf 1995 bekleedt zij een managementfunctie binnen de zorg voor mensen met een 
verstandelijke handicap. In 1998 en 1999 volgde zij de Stolte Leergang voor 
Leidinggevenden in de Zorgsector bij TIAS (Tilburg Institute for Advanced Studies in 
Management). Momenteel is zij manager van het expertisecentrum van Vizier.
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STELLINGEN
bij het proefschrift Hepatitis B and Mental Handicap
1. In een omgeving zonder goede hygiëne verspreidt hepatitis B zich gemakkelijk en 
ongemerkt.
2. De ernstige hepatitis B epidemieën in grote instituten voor verstandelijk gehandicapten 
ontstonden in de jaren zestig en zeventig door een gebrek aan inzicht in de verspreiding 
van het hepatitis B virus (dit proefschrift).
3. Het syndroom van Down geeft een verhoogd risico voor hepatitis B. Het syndroom van 
Down leidt tweemaal zo vaak tot infectie met het hepatitis B virus, vijfmaal zo vaak tot 
een chronische hepatitis B en viermaal zo vaak tot hoge besmettelijkheid (dit 
proefschrift).
4. Een onevenwichtige aanmaak van genproducten van het chromosoom 21 leidt bij het 
syndroom van Down tot primaire immuundefecten en vroegtijdige veroudering van het 
immuunsysteem met als gevolg partiële afweerstoomissen (dit proefschrift).
5. De verhoogde kans op chronisch dragerschap bij mensen met het syndroom van Down 
wordt veroorzaakt door partiële afweerstoomissen die het hepatitis B virus de tijd 
gunnen zich om te vormen en te ontsnappen aan normale immuunresponsen (dit 
proefschrift).
6. De primaire respons op hepatitis B vaccinatie is lager bij ouderen. Bij mensen met het 
syndroom van Down is dit effect nog sterker (dit proefschrift).
7. Een voldoende primaire respons op hepatitis B vaccinatie genereert, ook bij mensen 
met het syndroom van Down, langdurige bescherming tegen hepatitis B en maakt 
aanvullende boosters overbodig (dit proefschrift).
8. Ontmanteling van grote instituten en vaccinatie van alle mensen met het syndroom van 
Down zullen het risico op besmetting met het hepatitis B virus voor mensen met een 
verstandelijke handicap sterk verminderen. De overheid heeft beide adviezen inmiddels 
overgenomen.
9. Algemene hepatitis B vaccinatie is de enige effectieve manier om de verspreiding van 
hepatitis B en het ontstaan van levercirrose en levercarcinoom in de bevolking tegen te 
gaan. Het is daarom beter te onderhandelen over de prijs van het vaccin dan over de 
risicogroepen.
10. Hepatitis B seropositief personeel moet verboden worden mensen met een verstandelijk 
handicap, die onvoldoende beschermd zijn tegen hepatitis B, te verzorgen.
11. Verplichte vaccinatie van alle studenten in de gezondheidszorg garandeert op termijn de 
grootst mogelijke bescherming van ieder individu in de gezondheidszorg.
12. Bijzondere expertise bevordert dat mensen met een handicap blijven wonen, werken en 
recreëren in een niet bijzondere omgeving.
13. Mutor ergo sum (vrij naar Descartes).
14. Men zou niet mogen klagen als men geen oplossing aan kan dragen.
15. It is more important to do the right things than to do things right (Peter Drucker).
16. Plegers van seksueel misbruik jegens gehandicapten dienen opgenomen te worden in 
een centraal register.
17. Het schrijven van een proefschrift is absurde vrijetijdsbesteding.
Els de Witte-van der Schoot 
16 december 1999
